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PREGNANCY
Reproductive function in the female is cyclic. A series of functional interrelationships 
between the hypothalamus, the anterior pituitary, and the ovaries leads to the 
monthly rupture of an ovarian follicle and extrusion of an egg (“ovulation”), which is 
then transported to the fallopian tubes to be fertilized. Should fertilization fail to occur, 
menstruation ensues within 14 days and the hormonal and morphological events that 
led to ovulation are repeated. 
Ovulation occurs around day 14 of the menstrual cycle, followed by fertilization 
as egg and sperm unite within 24 hours. The first three days of development occur 
within the fallopian tube. Upon arrival within the uterus the conceptus develops into 
a blastocyst (Figure 1) and begins to make mRNA for human chorionic gonadotropin 
(hCG), the first hormone signal from the early embryo. By day 6 after fertilization 
the blastocyst initiates implantation into the maternal endometrium or uterine lining. 
Within a few days of fertilization the blastocyst becomes a spherical structure composed 
of two layers. The outside layer of cells become trophoblasts and the inside of a group 
of cells called the inner cell mass (Figure 2A) will develop into the fetus and ultimately 
the baby. In addition to making hCG, the trophoblasts mediate the implantation process 
by attaching to, and eventually invading into the endometrium (Figure 2B). Once firmly 
attached to the endometrium the developing conceptus grows and continues to expand 
into the endometrium. One of the basic paradigms which is established even within 
the first week of gestation is that the embryonic/fetal cells are always separated from 
maternal tissues and blood by a layer of cytotrophoblasts (mononuclear trophoblasts) 
and syncytiotrophoblasts (multinucleated trophoblasts) (Figure 2C-F). This is critical 
not only for nutrient exchange, but also to protect the developing fetus from maternal 
immunologic attack (1).
Implantation is regulated by a complex interplay between trophoblasts and 
endometrium. On the one hand trophoblasts have a potent invasive capacity and if 
allowed to invade unchecked, spread throughout the uterus. The endometrium, on the 
other hand, controls trophoblast invasion by secreting locally acting factors (i.e. cytokines 
and protease inhibitors), which modulate trophoblast invasion. Within the placenta the 
syncytiotrophoblasts generate high levels of hCG which modulates cytotrophoblast 
differentiation towards a non-invasive hormone secreting villous-type trophoblast. 
The closer the trophoblasts are to the endometrium the less hCG is made, allowing 
the trophoblasts to differentiate into anchoring type cells (2). Trophoblasts that leave 
the placenta and migrate within the endo and myometrium are induced to make 
proteases and protease inhibitors, to further facilitate trophoblast invasion into the 
maternal tissues (2). Ultimately, normal implantation and placentation is a balance 
between regulatory gradients created by both the trophoblasts and the endometrium.
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Interestingly, studies have shown that the endometrium of women during the 
menstrual cyclic secretory phase (progesterone dominant phase) also express, produce 
and secrete hCG hormone in the glandular and luminal epithelium (3,4). This modest 
local epithelial hCG synthesis by healthy secretory endometrium in connection with 
intensive subepithelial vascularization and stromal natural killer (NK) cell accumulation 
Figure 1.
(A) Blastocyst. By 4-5 days after fertilization the embryo has differentiated into two distinct cell types: 
inner cell mass (lighter cells) and trophoblast (darker cells). (B) Implantation. The blastocyst becomes 
attached to the uterine lining (endometrium) and trophoblasts begin to invade into the endometrium, 
beginning the process of placentation. (C) Implantation site. By day 9 the embryo is surrounded by 
two layers of trophoblasts: the inner mononuclear cytotrophoblasts and the outer multinucleated 
syncytiotrophoblast layer. (D) Implantation site: The invading trophoblasts penetrate the maternal 
vessels, forming pools of maternal blood which surround the growing trophoblasts. (E) Implantation. 
The embryo has begun to make an early circulatory system. The embryonic tissue and maternal blood 
are separated by a layer of cytotrophoblasts and syncytiotrophoblasts. (F). Implantation. The basic 
structure of the placenta has been formed with maternal blood cells being delivered to the forming 
placenta via spiral arteries while being drained away via uterine veins. Like the roots of a tree, the 
developing chorionic villi remain immersed in a space filled with nutrient rich maternal blood (Modified 
from Sadler TW, Langman’s medical Embryology, 5th edition, Williams & Wilkins, 1985).
Pregnancy and immunomodulation
13
lasts until the late secretory phase (3,4). The physiological role of this hCG secretion is 
to suppress cellular apoptosis in endometrial gland epithelial and stroma cells, which 
also explains the absence of apoptosis in the decidual epithelium during early gestation 
with high hCG concentrations (5). In addition, hCG can directly trigger the angiogenic 
activities of the endometrium for increased capillary function (6,7). Different in vivo and in 
vitro methods confirm the initiation of angiogenesis in response to hCG (8,9). Therefore, 
the modest endogenous endometrial hCG release from the gland epithelium can play 
a direct or indirect role in the regulation of angiogenic factors and can contribute to the 
initiation of microvascularization to prepare for a receptive endometrium during healthy 
menstrual cycle. 
Another glycoprotein produced by the syncytiotrophoblast and made throughout 
gestation is human placental lactogen (hPL). hPL appears to regulate the lipid and 
carbohydrate metabolism of the mother. In addition to the hPL the syncytiotrophoblasts 
produce prolactin, relaxin and chorionic adrenocorticotropin. The physiological role of 
these hormones represents a shift from maternal to placental control. The trophoblasts 
also appear to produce a number of hypothalamic-pituitary hormones, including 
gonadotropin releasing hormone (GnRH) and corticotropin releasing hormone (CRH). 
In addition to the hypothalamic factors GnRH and CRH, pituitary hormones, including 
hCG, growth hormone (GH) and adrenocorticotropic hormone (ACTH) are also 
synthesized and secreted by cultured trophoblasts (10). It appears that the placenta, 
in addition to replacing much of the women’s pituitary function during pregnancy, 
also replaces critical hypothalamic functions so as to maintain control and feedback 
loop mechanisms close to the conceptus. Table 1 outlines the various hormones and 
hormone-like molecules associated with human pregnancy. These hormones are 
produced by three different compartments (maternal, placental and fetal).
EFFECTS OF PREGNANCY ON THE IMMUNE SYSTEM
Pregnancy is a unique physiological event in which mother and child are exposed 
to each others human leukocyte antigens (HLA) and other molecules. How the HLA-
mismatched fetus escapes rejection remains a biological enigma. Medawar was the first 
who discussed this problem in immunological terms. He proposed five main theories 
for the survival of the fetal allograft. Medawar’s theories were, that the conceptus 
was antigenically immature; the intrauterine site was immunologically privileged; the 
placenta was a barrier; the pregnant mother became immunologically incompetent; or a 
serum blocking factor was present (11). Each theory was disproven.
To maintain a successful pregnancy, the maternal host must somehow bypass or 
compensate for the usual immunological processes developed to ensure recognition 
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and elimination of non-self molecules (11). Therefore, the maternal immune system as 
a whole is to be modulated in several ways during pregnancy. A successful pregnancy is 
thus dependent on maternal tolerance or immune-nonreactivity to the paternal antigens 
inherited by the fetus. The protection begins with the trophoblast cells that define the 
boundary between the mother and fetus (12). These cells are derived from the outer 
layer of the blastocyst and, if female, have an inactivated paternal X chromosme (13). 
The trophoblast cell membrane is restricted in expressing the cell surface antigens 
that normally stimulate T-cell-dependent graft rejection responses, i.e. HLA-A, -B (class 
I antigens), and –D (class II antigens). Instead, trophoblast cells express a unique 
combination of HLA-C, HLA-E and HLA-G, which interact with uterine NK cells and 
decidual macrophages (14,15) to prevent NK cytotoxicity towards the trophoblast cells 
and to suppress CD8+ and CD4+ T cells (14,16). 
Table 1. Pregnancy specific protein hormones by compartment. 
GnRH, gonadotropin releasing hormone; CRH, corticotropin releasing hormone; TRH, thyrotropin 
releasing hormone; GHRH, growth hormone releasing hormone; hCG, human choriogonadotropin 
hormone; hGH, human growth hormone; ACTH, adrenocorticotropic hormone; hPL, human placental 
lactogen; hCT, human calcitonin; IGF-I/II, insulin-like growth factor I/II; PAPP-A, pregnancy associated 
plasma protein A; IGFBP-1, insulin-like growth factor binding protein 1; PP14, placental protein 14.
Maternal Placental Fetal
Decidual derived
- Prolactin
- IGFBP-1
- PP14
Corpus luteum derived
- Relaxin
Hypothalamic-like (cytotrophoblast)
- GnRH
- CRH
- TRH
- GHRH
- Somatostatin 
Pituitary like (syncytiotrophoblast)
- hCG
- hGH
- ACTH
- hPL
- hCT
- Oxytocin
Growth Factors
- Inhibine
- Activin
- IGF-I/IGF-II
Other Proteins
- Pregnancy specific β1-glycoprotein
- PAPP-A
Alpha-fetoprotein
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Wegmann has proposed that there is a bi-directional interaction between the 
maternal immune system and the reproductive system (“feto-placental unit”) which may 
result in the redirection of maternal immunity away from cell-mediated immunity and 
toward enhanced humoral responsiveness (17). In this model the conceptus protects 
itself by secreting T-helper-2 (TH2) cytokines (humoral immunity) such as interleukin-4 
(IL-4), IL-5, IL-10, IL-13 and granulocyte macrophage colony stimulating factor (GM-
CSF) that down-regulate T-helper-1 (TH1) cytokines (cell mediated immunity) such as 
IL-1, IL-2, IL-6, IL-12, IL-15, IL-18, interferon-γ (IFN-γ), and tumor necrosis factor-alpha 
(TNF-α) (18), which are generally harmful to the maintenance of pregnancy (19,20). 
Local T cells produce such cytokines, but major sites of TH2 cytokine production appear 
to be nonlymphoid tissues including the placental/decidual tissues, particularly the 
trophoblast (21). During the normal pregnancy, the TH1/TH2 activity balance is strongly 
shifted toward TH2 activity (so called “TH2 phenomenon”), and this has been said to play 
a protective role in the feto-maternal relationship. In normal pregnancy peripheral and 
local T cells are increased. However, peripheral T cells express TH1 cytokines, whereas 
T cells located in the decidua primarily express TH2 cytokines (22). Since progesterone 
can induce T cell differentiation towards the TH2 pathway, this has been associated with 
the induction of a TH2 cytokine profile in utero (23). Since non-haematopoietic cells such 
as trophoblasts and epithelial cells can also produce cytokines, it is unclear how such 
a TH2 bias may be induced (24,25). Progesterone may act on progesterone receptor-
positive cells such as macrophages and glandular epithelial cells and/or may affect 
other cell types as well. Inflammation and infection can alter the balance of TH1 and 
TH2 cytokines causing a shift toward a TH1 predominance, that initiates and intensifies 
the cascade of inflammatory cytokine production involved in spontaneous abortion, 
preterm delivery and/or preeclampsia. The bias of immune responses to TH1 or TH2 
is not limited to T-helper-cells and their responses, but also includes cells of the innate 
immune system such as natural killer T (NKT) cells (26). NKT cells are characterized 
by a fixed repertoire of T cell receptors as well as having clear NK cell attributes. 
There is evidence that the bias that TH cells adapt depends on the cytokine milieu 
created by NKT cells, which appear to play a dominant role in immunoregulation (27). 
Rather than discussing a TH1 or TH2 bias, which implies a key role for T-helper-cells, 
it is better to refer to the type 1 or type 2 bias to include the innate as well as adaptive 
immune responses which acknowledges the potential role of NKT cells.
Other subsets of cells involved in successful pregnancy are NK cells and 
macrophages. NK cells are a key component of innate immunity, particularly crucial 
during the early phase of immune responses against certain viruses, parasites and 
microbial pathogens. During early pregnancy, transformation of the non-pregnant 
endometrium into decidua is characterized by a dominant mature, granulated NK cell 
population. These uterine NK (uNK) cells in the pregnant uterus appear to retain cytolytic 
Chapter 1
16
activity but also strongly produce cytokines, especially IFN-γ. The interaction of NK cell 
receptors with HLA-A, -B and C, HLA-E and HLA-G on extravillous cytotrophoblasts 
is suggested to inhibit the cytotoxic activity of these cells (17,28). Moreover, uNK 
interactions with extravillous trophoblasts are clearly important in the precise control 
of decidual trophoblast invasion which, when impaired, may lead to shallow invasion 
and pre-eclampsia (28). In addition, the interactions of uNK cells with activated 
macrophages may induce NK cell cytokine production (IFN-γ and TNF-α) that leads to 
fetal loss (29). In a normal pregnancy resident decidual macrophages tend to produce 
prostaglandin E2 (PGE2), which acts to suppress cell-mediated immune responses 
by inhibiting antigen presenting cells (APC) production of IL-12 (27). Therefore, there 
must be an alternative interaction in the decidua with macrophages being replaced by 
trophoblasts. Indeed, trophoblasts activated by infection, potentially through Toll-like 
receptors (TLR) (30,31), release neutrophil chemoattractants, leading to a localized 
accumulation of neutrophils, which then act as antimicrobial effectors and probably also 
abortion effectors (32). Thus, trophoblasts are postulated to be part of the pregnancy-
specific innate immune defence system (33,34). 
EFFECTS OF PREGNANCY ON AUTOIMMUNE DISEASES
Since 1990, the central dogma of immunology has been that the immune system 
does not normally react to self. It has also become apparent that autoimmune responses 
are not as rare as once thought and that not all autoimmune responses are harmful. 
Some responses play a distinct role in mediating the immune responses in general. 
For example, certain forms of autoimmune response such as recognition of cell surface 
antigens encoded by the major histocompatibility complex (MHC) and anti-idiotypic 
responses against self idiotypes are considered to be essential for the diversification 
and normal functioning of the intact immune system (35). Apparently, an intricate 
system of checks and balances is maintained between the various subsets of cells of 
the immune system, thereby providing the individual with an immune system capable 
of coping with foreign invaders. In that sense, autoimmunity plays a regulating role in 
the immune system.
It has now also been recognized that an abnormal autoimmune response is 
sometimes a primary cause and at other times a secondary contributor to many human 
and animal diseases. Types of autoimmune disease frequently overlap, and more than 
one autoimmune disorder tends to occur in the same individual, especially in those 
with autoimmune endocrinopathies (36). Autoimmune diseases, such as systemic 
lupus erythematosus (SLE), diabetes, rheumatoid arthritis (RA), post-partum thyroid 
dysfunction and autoimmune thrombocytopenia (ATP) are characterized by autoimmune 
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responses directed against widely distributed self-antigenic determinants, or directed 
against organ- or tissue specific antigens (37). Such disease may follow an abnormal 
immune responses against only one antigenic target, or against many self antigens. 
In many instances, it is not clear whether autoimmune responses are directed against 
unmodified self-antigens or self-antigens that have been modified by (or resemble) any 
of numerous agents such as viruses, bacterial antigens and haptenic groups (36,37).
Autoimmune diseases are a heterogeneous group of disorders whose expression 
is influenced by multiple genes and environmental factors. Disease expression is also 
affected by age, gender, and reproductive status (38). For example, onset of autoimmune 
thyroid disease (ATD) and RA is most common in women around menopause. Both ATD 
and RA tend to improve during pregnancy but commonly flare up or develop initially in the 
postpartum period (39). In contrast to RA and ATD, the age of onset of SLE in women is 
highest during the reproductive years and declines markedly around the menopause. In 
addition, SLE, particularly the immune-complex-mediated glomerulonephritis, tends to 
worsen during pregnancy but may improve in the postpartum period (38,40). Similarly, 
antibody-mediated diseases such as ATP and autoimmune hemolytic anemia (AHA), 
which may be initial manifestations of SLE, frequently develop during pregnancy and 
may improve in the postpartum period (41,42). 
Although no autoimmune disease can be considered exclusively TH1 or TH2 cytokine-
driven, it is generally agreed that the clinical manifestations ATD and RA primarily reflect 
nonspecific macrophage and specific cell-mediated immunopathological mechanisms. 
TH1 cytokines, such as TNF-α and IL-1α, are most characteristically expressed at 
high levels in these diseases (43). In contrast, SLE, ATP, and AHA, in large part, are 
considered to be antibody-mediated diseases dependent on TH2 cytokines such as 
IL-10 (38). Thus, it can be proposed that diseases such as RA improve during pregnancy 
because of the suppression of non-specific and cell-mediated immunity. Moreover, 
RA may flare in the postpartum period because of the restoration of the capacity to 
produce normal, or more likely supranormal, levels of TH1 cytokines. Conversely, 
the development of antibody-mediated autoimmune diseases during pregnancy such 
as SLE and their tendency to improve in the postpartum period may represent the 
antithesis of the regulatory mechanisms operative in RA. 
Thus, these autoimmune conditions show striking differences in the ages that 
are most commonly associated with their onset and their expression during pregnancy 
and the postpartum period. Each of these illnesses is much more common in 
women than men; that is, female-to-male ratios are about 19:1 in ATD, 3-4:1 in RA, 
and 9:1 in SLE (38). These contrasting clinical observations clearly suggest that 
hormones are involved in the pathogenesis of these various autoimmune diseases, 
although mechanisms are undoubtedly complex. The changing expression of human 
autoimmune diseases during pregnancy and the postpartum period is regulated, in 
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part, by hormonal modulation of the proinflammatory TH1 to the antiinflammatory TH2 
cytokines balance (38). Further investigations are required to increase our insight into 
the relationship between pregnancy and autoimmune diseases expression.
REFERENCES 
1. Sadler TW. Langman’s medical embryology, sixth edition, Williams & Wilkins, Baltimore, 1990.
2. Kliman H. Trophoblast infiltration. Reproductive medicine review 3:137-157, 1994.
3. Odell WD, Griffin J, Sawitzke A. Chorionic gonadotropin secretion in normal, nonpregnant humans. 
Trends Endocrinol Metab 1:418-421, 1990.
4. Zimmermann G, Ackermann W, Alexander H. Epithelial human chorionic gonadotropin is expressed 
and produced in human secretory endometrium during the normal menstrual cycle. Biol Redprod 
80:1053-1065, 2009.
5. von Rango U, Krusche CA, Kertschanska S, Alfer J, Kaufmann P, Beier HM. Apoptosis of extravillous 
trophoblast cells limits the trophoblast invasion in uterine but not in tubal pregnancy during first 
trimester. Placenta 24:929-940, 2003.
6. Gargett CE, Lederman F, Heryonta B, Gambino LS, Rogers PAW. Focal vascular endothelial growth 
factor correlates with angiogensis in human endometrium. Role of intravascular neutrophiles. Hum 
Reprod 16:1065-1075, 2001.
7. Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D, Bowen JM, Gardner L, King 
A, Loke YW, Smith SK. Angiogenic growth factor messenger ribonucleic acid in uterine natural killer 
cells. J Clin Endocrinol Metab 86:1823-1834, 2001.
8. Zygmunt M, Herr F, Keller-Schönwetter S, Kunzi-Rapp K, Münstedt K, Rao CV, Lang U, Preissner 
KT. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol 
Metab 87:5290-5296, 2002.
9 . Berndt S, d’Hauterive SP, Blacher S, Pequeux C, Lorquet S, Munaut C, Applanat M, Herve MA, 
Lamande N, Corvol P, van den Brule F, Frankenne F, Poutanen M, Huhtaniemi I, Geenen V, Noel 
A, Foidart J-M. Angienic activity of human chorionic gonadotropin through LH receptor activation on 
endothelial and epithelial cells of the endometrium. FASEB J 20:E2189-E2198, 2006.
10. Reece EA, Hobbins JC, Gant Jr NF. Handbook of clinical obstetrics: The fetus & mother. Third 
edition, Blackwell Publishing Ltd, 2008.
11. Medawar PB. Some immunological and endocrinological problems raised by the evolution of 
viviparity in vertebrates. Symp Soc Exp Biol 7:320–338, 1953.
12. Johnson M. Origins of pluriblast and trophoblast.in the eutherian conceptus. Reprod Fertil Dev 
8:699-709, 1996.
13. Moffett A, Loke YW, McLaren A. The biology and pathology of trophoblast. Cambridge University 
Press, Cambridge, 2006.
14. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J 
19:681-693, 2005.
15. Hiby SE et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia 
and reproductive success. J Exp Med 200:957–965, 2004.
16. Ishitani et al. The involvement of HLA-E and F in pregnancy. J Reprod Immunol 69:101–113, 2006.
17. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-
fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14:353-356, 1993.
18. Orsi NM, Tribe RM. Cytokine networks and the regulation of uterine function in pregnancy and 
parturition. J Neuroendocrinol 20:462-469, 2008.
Pregnancy and immunomodulation
19
19. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E (1999) Maternal Th1-
and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent 
spontaneous abortions. Cell Immunol 196:122–130, 1999.
20. Jenkins C, Roberts J, Wilson R, MacLean MA, Shilito J, Walker JJ. Evidence of a T(H) 1 type 
response associated with recurrent miscarriage. Fertil Steril 73:1206–1208, 2000.
21. Chaouat G. Regulation of T-cell activities at the fetoplacental interface-by placenta? Am J Reprod 
Immunol 42:199-204, 1999.
22. Szekeres-Bartho J, Barakonyi A, Miko E, Polgar B, Palkovics T. The role of gamma/delta T cells in 
the feto-maternal relationship. Semin Immunol 13:229-33, 2001.
23. Piccinni MP. T cells in normal pregnancy and recurrent pregnancy loss. Reproductive Biomedicine 
Online 13:840–844, 2006.
24. Lea RG. 2001 Proliferation, differentiation and apoptosis in pregnancy and cancer. In Cancer and 
Pregnancy, pp 216–228. Eds ER Barnea, E Jauniaux & PE Schwartz. London: Springer Verlag.
25. Hauguel-de Mouzon S, Guerre-Millo M. The placenta cytokine network and inflammatory signals. 
Placenta 27:794–798, 2006.
26. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural 
killer T cells. J Exp Med 4:637-641, 2002.
27. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of 
preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113:1631-
1640, 2004.
28. Bulla R, Fischetti F, Bossi F, Tedesco F. Feto-maternal immune interaction at the placental level. 
Lupus 13:625-629, 2004.
29. Parham P. NK cells and trophoblasts: partners in pregnancy. J Exp Med 18:951-955, 2004.
30. Arck P, Dietl J, Clark D. From the decidual cell internet: trophoblast-recognizing T cells. Biol Reprod 
60:227-233, 1999.
31. Elovitz MA, Wang Z, Chien EK, Rychlik DF, Phillippe M. A new model for inflammation-induced 
preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am J Pathol 163:2103-
2111, 2003.
32. Abrahams VM, Bole-Aldo P, Kim YM, Straszewski-Chavez SL, Chaiworapongsa T, Romero R, Mor 
G. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 173:4286-
4296, 2004.
33. Clark DA, Chaouat G, Arck PC, Mittruecker HW, Levy GA. Cytokine-dependent abortion in CBA x 
DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase (correction of prothombinase). 
J Immunol 160:545-549, 1998. Erratum in: J Immunol 162:3105, 1999.
34. Guleria I, Pollard JW. The trophoblast is a component of the innate immune system during pregnancy. 
Nat Med 6:589-593, 2000.
35. Guilbert L, Robertson SA, Wegmann TG. The trophoblast as an integral component of a macrophage-
cytokine network. Immunol Cell Biol 71:49-57, 1993.
36. Jefferis R. Idiotypy and idiotypic netwerks: a time to redefine concepts. Clin Exp Immunol 91:193-
195, 1993.
37. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 
1069:322-345, 2006.
38. Hawa M, Beyan H, Leslie RDG. Principles of autoantibodies are disease-specific markers. 
Autoimmunity 37:253-256, 2004.
39. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 
13:307-338, 1995.
40. Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. 
Clin Rheumatol 11:189-194, 1992.
41. Lahita RG. The effects of sex hormones on the immune system in pregnancy. Am J Reprod Immunol 
28:136-137, 1992.
42. Varner MW. Autoimmune disorders and pregnancy. Semin Perinatol 15:238-250, 1991.
Chapter 1
20
43. Jones WR. Autoimmune disease and pregnancy. Aust N Z J Obstet Gynaecol 34:251-258, 1994.
44. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human 
T-helper cell differentiation revisited. Immunol Rev 226:132-146, 2008.
2HETEROGENEITY IN THE BIOLOGICAL FUNCTION AND STRUCTURE OF hCG 

Heterogeneity of hCG
23
BACKGROUND
In 1920 human chorionic gonadotropin (hCG) was the first protein hormone 
described and isolated from the placenta. The sole function of hCG has been then 
assumed to be the promotion of progesterone production by corpus luteal cells. The 
first pregnancy test, the rabbit test, was formulated in the 1920s and for four decades 
bioassays such as the rabbit test were the only practical way to measure hCG or detect 
pregnancy. In 1960s the first polyclonal antibodies against hCG and subsequently the 
competitive immunoassay was developed. This was the first rapid and sensitive test for 
hCG and led to the development of commercial hCG tests as seen today. In the past four 
decades a revolution has occurred in knowledge about this molecule through the finding 
that hCG is not just one biologically active molecule. Instead, hCG consists of a group 
of biologically important molecules having different physiological functions. Recently, 
several investigators such as De Medeiros, Cole and Birken extensively reviewed the 
function of the various biologically active forms of hCG (1-5) that we have summarized 
in this chapter.
CHEMISTRY AND STRUCTURE OF hCG 
hCG is a member of a family of four closely related glycoprotein hormones (6). 
Three of the hormones, luteinizing hormone (LH), follicle-stimulating hormone (FSH) 
and hCG control aspects of reproduction, while thyroid-stimulating hormone (TSH) 
regulates metabolism. These four hormones are produced within the pituitary gland. 
hCG, however, is produced primarily by the trophoblasts that are destined to become 
placental tissue. It has been demonstrated that next to the pituitary, endometrial epithelial 
cells and certain trophoblastic and nontrophoblastic tumors produce hCG (7,8).
hCG has a molecular weight of approximately 38,000 Dalton with 237 amino acids 
organized in two dissimilar noncovalently linked subunits designated alpha (α) and 
beta (β) (9,10). Both subunits consist of a single polypeptide chain. The α-subunit, 
consisting of 92 amino acids and encoded by a single gene, is common to all four 
glycoprotein hormones (11,12). The ß-subunit of the four glycoprotein hormones arises 
from separate genes and defines hormone specificity (13,14). The β-subunit of the 
glycoprotein hormones displays various degrees of homology, which between hCG and 
LH is ~80% (6). The ß-subunit of LH contains 121 amino acids whereas β-subunit of 
hCG (β-hCG) contains 145 amino acids, the difference being due to a 24-amino-acid 
extension, the so-called C-terminal peptide (CTP) (6). Seventy percent of hCG consists 
of the protein chains and 30% of carbohydrate units. 
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The sugar branches, covalently bound to the peptide chains, are of two types: 
O-linked oligosaccharide containing an N-acetylgalactosamine residue linked to 
either a serine or a threonine residue and an N-linked oligosaccharide containing an 
N-acetylgalactosamine residue linked to an asparagine residue (15-17). 
Six carbohydrate moieties are attached to β-hCG and two to α-hCG (Figure 1). 
The N-linked carbohydrate chains on α-hCG are attached to Asn52 and Asn78 and 
those on β-hCG to Asn13 and Asn30. Four O-linked oligosaccharides are attached to 
Ser121, Ser127, Ser132 and Ser138 in the CTP of β-hCG (15-17). Owing to variation 
in the content of terminal sialic acid, hCG displays extensive charge heterogeneity with 
isoelectric point (pI) values ranging from 3 to 7. β-hCG is more acidic (pI range 3–5) 
than α-hCG (pI range 5–8) (18,19).
Figure 1. Amino acid sequence of hCG α-subunit and β-subunit. 
Digits indicate amino acid residue positions and N and O indicate the positions of N- and 
O-linked oligosaccharides. Gray area indicates the residues belonging to signal peptide.
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α-hCG is structured in three loops stabilized by disulfide bonds. These bonds, 
initially assigned between residues 7–31, 10–32, 28–60, 59–87 and 82–84 (20), were 
reassigned at positions 7–31, 59–87, 10–60, 28–82 and 32–84 (21,22) (Figure 2A). 
The last three bonds comprise the cystine knot which is a characteristic signature of 
polypeptide growth factors controlling cell survival, proliferation and differentiation. 
The two N-linked complex-type carbohydrate moieties are attached to asparagine 
Figure 2.
(A) α-hCG protein core (thick red line) and assigned disulfide bonds (thin yellow and 
light pink line) forming three hairpin loops (α1, α2, α3). (B) β-hCG subunit polypeptide 
chain (thick green line) with its seatbelt region (thick black line) and assigned disulfide 
bonds. Numbers represent amino acid numbers; yellow bars, cystine knots; thick blue 
lines, seatbelt disulfide bonds; thin blue line, small loop disulfide bond; b1, b2, b3 loops of 
β-hCG (modified from Xing et al. Protein Sci 2001;10:226-235).
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residues in the second and third loops. The β-hCG has a highly glycosylated CTP 
extension, rich in serine and proline, which confers the immunological and biological 
specificity to the whole hCG (Figure 1). The β-hCG disulfide bonds initially assigned at 
positions 9–90, 26–110, 34–88, 32–72, 38–57 and 93–100 (20) were further reassigned 
at positions 23–72, 26–110, 34–88, 38–90, 9–57 and 93–100 (21) (Figure 2B). The 
β-hCG molecule has two beta hairpin loops, stabilized by the disulfide bond 23–72 on 
one side of a central cystine knot and a long loop on the other side (22). The cystine 
knot is formed by a ring (residues β34–88 and β38–90 bridged by disulfide bonds) 
through which the β9–57 disulfide bridge penetrates. In its carbohydrate branches, hCG 
has asparagine units on both the α and β subunit and unique O-glycosydically linked 
oligosaccharide moieties on β-hCG.
BIOSYNTHESIS OF hCG
Both biosynthesis and processing of the hCG molecule resemble that of other 
glycoprotein hormones. Although the cell type determines the sort of oligosaccharide 
processing on alpha and beta subunits, the alpha–beta combination modulates the 
extension of this processing (23). The set of enzymes contained in the secretory cell 
determines the nature of the processing and composition of the oligosaccharides added 
to both subunits. Initially, each subunit is synthesized separately, in a non-balanced 
ratio, as a result of mRNA transcription of the two separate genes. The alpha subunit 
is usually synthesized in excess. In pregnant women, the ratio α:β subunits increase 
from 1.7:1.0 in the first trimester to 12.0:1.0 at term (24). The metabolic sequence, 
cleavage of signal peptides, assembly of the native hCG, sequential post-translational 
glycosylation and formation of the disulfide bonds happen at the same time that the 
hCG molecules are translocated from the place of synthesis in the rough endoplasmatic 
reticulum (RER) up to the cell surface (25). 
While the α-subunit is encoded by a single gene (26), the β-subunit is encoded by 
a family of at least six genes arranged in tandem in a cluster on chromosome 19 (27). 
Initially, it was believed that only three β-hCG genes are functional genes encoding the 
correct β-hCG amino acid sequence. Currently it is suggested that the total amount 
of β-hCG gene expression rather than the expression of individual genes is important 
for the maintenance of normal pregnancy (28). The α and β genes expression may be 
regulated by many factors, but a key role in the control of their expression is not clear 
yet.
Also hCG secretion is under the control of a large number of factors which may act 
by both autocrine and paracrine mechanisms (29). On placental trophoblastic cells, 
these modulators interact with specific surface receptors. Upon stimulation by these 
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factors, α-hCG and β-hCG genes are activated by phosphorylation of a cAMP response 
element binding protein (CREBP) through the protein kinase C (PKC) pathway. It has 
been shown that α-hCG and β-hCG promoters also have binding sites for the activator 
protein 2 (AP-2), which suggests that this transcription factor provides a mechanism 
for coordinating the induction of these genes during placental cell differentiation. AP-2 
might be the ultimate regulator of hCG gene expression at the promoter region (30). 
After transcription of the genetic message, the translation of the mRNA into the nascent 
α and β subunits takes place in the membrane-bound ribosomes of the RER. Each 
translated product is synthesized as a slightly immature peptide, named pre-α and 
pre-β forms, containing the specific sequences and the signal peptide extension with 
24 and 20 amino acids, respectively (Figure 1). The processing of immature subunits 
to the mature state involves co-translational signal peptide cleavage and removal by 
microsomal signal peptidases while the peptide chains still reside upon the ribosomes. 
Just before the oligosaccharide moieties are attached to the polypeptide chain, 
the newly synthesized protein is released into RER channels and transported to the 
Golgi (31).
The association of α-hCG and β-hCG subunits form the complete dimer. Both 
subunits than still contain a high content of mannose. The two subunits are intimately 
associated with each other along much of their surfaces, each subunit having similar 
folds with two hairpin loops at one end and a single loop at the other (32). The assembly 
of hCG in the RER is made by threading the glycosylated end of α-hCG loop 2 beneath 
a hole formed in a disulfide latched strand of the β-subunit named seatbelt (33). 
The CTP of β-hCG is in contact with α-hCG in the native dimer and forms the seatbelt 
around the α-hCG (residues β93–110) that stabilizes the heterodimer. The final 
closing of the β26–110 bridge locks the seatbelt and secures the αβ dimer, preventing 
disassembly (34).
SECRETION OF hCG
After fertilization, the embryo produces hCG early in development. hCG is already 
detected at the 4- to 8-cell stage and is secreted from blastocysts by 7 days after 
fertilization. hCG can be detected in maternal serum near the time of implantation and 
it is routinely used to detect pregnancy. Serum concentrations of hCG rise rapidly after 
implantation with an average doubling time of about 31 h. After the first trimester, hCG 
levels decline before reaching a low plateau that persists throughout the remainder 
of pregnancy. Although the cellular mechanisms that lead to the onset of hCG gene 
transcription are not understood yet, it is likely that the α-hCG and β-hCG-genes are 
among the first embryo-specific genes to be transcribed. The mechanisms that result in 
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deactivation of hCG gene expression after the first trimester are also unknown.
The secretion of hCG shows spontaneous pulse-like bursts with irregular amplitudes 
and frequencies. The finely tuned and dynamic pattern of hCG secretion may involve an 
up- and down-regulation of the gonadotropin-releasing hormone (GRH) receptor (36). 
The process involves a serial of steps in which cells make up and release hCG, and 
α-hCG and β-hCG free subunits. There is no releasing factor known specific to hCG, 
although cAMP activates the genetic transcription of DNA sequences for synthesis of 
the polypeptide chains. The processing of the carbohydrate chains, their transport to 
the Golgi for attachment to the α and β chains, αβ combination and the release of hCG 
from the cell surface into the circulation are not completely clear. The primary signal 
for the relevant enzyme expression can be stimulated by cAMP analogs, epidermal 
growth factor, TNF-α, GRH, estradiol, insulin, and glucocorticoids (36,37). The principal 
modulators with inhibitory activity are progestational steroids and prolactin (38,39). 
Table 1 shows several regulating factors that seem to be involved in the hCG 
secretion.
hCG predominates in all normal and abnormal pregnancies. It is present at reduced 
levels during spontaneous abortion and ectopic pregnancy (64) and at double regular 
levels in Down syndrome pregnancy (65,66). hCG is also the principal molecule 
produced in individuals with hydatidiform moles or pregnancies comprising solely 
trophoblast tissue (17,67). Regular hCG, which is normal glycosylated heterodimeric 
hCG, is also normally produced by the pituitary gland at the time that LH peaks and in 
menopausal women (7,67).
Multiple variants of hCG have been detected in serum and urine samples 
(Figure 3). Free α-subunits of hCG and free β-subunits of hCG have been demonstrated 
in pregnancy serum, cancer patient serum and urine, and cancer cell line culture fluids 
(68,69). A β-subunit core fragment, which comprises two fragments of β-subunit, 
β6–40 and β55–92, held together by disulfide bonds, is found in pregnancy urine 
samples (70). Urine β-core fragment is used as a general tumor marker for all non-
gestational malignancies (71-75). A large form of hCG dimer is synthesized by 
choriocarcinoma cells (17,76,77). This is hyperglycosylated hCG with 1.5 fold larger 
N-linked and double size O-linked oligosaccharides (17,78,79). Similar large N- 
and O-linked oligosaccharides have been demonstrated on the free β-hCG named 
hyperglycosylated free β-hCG which is produced by non-gestational cancer cells (77,80). 
Similar large oligosaccharides are found on the α-subunit secreted in pregnancy, free 
α-subunit (81). While hCG is hyperglycosylated in choriocarcinoma and gets larger 
oligosaccharide side chains, free α-subunit is also glycosylated in malignancy, gaining 
an additional O-linked oligosaccharide and called O-glycosylated free α-subunit (82).
The regular hCG and hyperglycosylated hCG degradation process involve elastase 
and other proteases secreted by macrophages associated with tumor tissue or present in 
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the circulation (83). These proteases cleave or nick hCG at β-subunit 44-45, 47-48 or 53-
54 (17,83), generating a nicked hCG and a nicked hyperglycosylated hCG, a nicked free 
β-hCG and nicked hyperglycosylated free β-hCG (Figure 3). These enzymes progress 
further to cleave and release the C-terminal peptide on the nicked molecules (βCTP, 
β residues 93–145) generating nicked hCG missing βCTP, nicked hyperglycosylated 
hCG missing βCTP, nicked free β-hCG missing βCTP and nicked hyperglycosylated 
free β-hCG missing βCTP (17,67,83). These are 15 variants, all found in serum and 
urine samples in normal or abnormal pregnancies, gestational trophoblastic diseases 
or non-gestational malignancies (Figure 3). Of these 15 variants, only 5 are natural 
products made by the placenta in pregnancy or by non-trophoblastic malignancies, 
Table 1. Endocrine and paracrine/autocrine regulators of trophoblast hCG secretion in vitro, 
according to the pregnancy time (38-63). 
EGF, epidermal growth factor; LIF, leukemia inhibiting factor; TNF, tumor necrosis factor; M-CSF, 
macrophage-colony-stimulating factor; TGF, transforming growth factor; GABA, gamma amino butyric 
acid; PTH, parathyroid hormone; hGH, human growth hormone.
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Figure 3. 15 common hCG variants present in serum and urine samples in either pregnancy, 
gestational trophoblastic disease or malignancy. 
Numbers refer to subunit polypeptide amino acid numbers (1 and 145 in the 145 amino acid long 
β-subunit), O refers to O-linked and N to N-linked oligosaccharides. OO and NN refer to large or 
hyperglycosylated oligosaccharides. α is α-subunit and β is β-subunit. βCTP is the C-terminal segment 
(residues 93–145) of the regular or hyperglycosylated hCG β-subunit (from Cole LA. Reprod Biol 
Endocrinol. 7:1-37, 2009).
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regular hCG, hyperglycosylated hCG, hyperglycosylated free β-hCG and free α-subunit 
and O-glycosylated free α-subunit. The other 10 variants are degradational products 
originating from macrophage cleavage and cleavage by proteases in the circulation and 
the kidney. It is also noteworthy that free α-subunit has no known biological function. 
Free α-subunit is considered a biological waste product (82). 
In the kidney, the hCG is internalized by proximal renal tubule cells and degraded 
to small fragments (84), but a significant part is excreted unaltered by passage through 
the tubule to the collecting duct. The molecules more rich in sialic acid are eliminated 
more quickly (85). Desialylated hCG passes through the glomerules to the urine, or 
alternatively, the tubule cells take them up more quickly (86). Owing to proteolytic 
processing of hCG as it passes through the kidney, the urine contains a much greater 
variety of forms of hCG than does the blood.
The liver accumulates hCG molecules as soon as 2 h after injection of this 
gonadotropin. The concentration of hCG in the liver is about 5-fold lower than in the 
kidney (84). Removal of sialic acid increases the clearance of hCG up to 200 times (87). 
A large proportion of hCG does not contain the sialic acid, and these desialylated forms 
exposing galactose residues bind to high affinity hepatocyte receptors for galactose-
terminated oligosaccharides, being further distributed in the interior of the hepatocytes (88). 
Native hCG is taken up primarily by Kuppfer cells in liver tissue and distributed along 
the sinusoides (86). 
In the ovary, variable amounts of hCG molecules are internalized by granulosa/
theca lutein cells (89). These cells may degrade it to small fragments (90). Initially, it 
was thought that the uptake of hCG was limited to the availability of specific receptors, 
but further studies have found that in ovarian tissue hCG can be degraded either after 
binding to its specific receptor or following an alternative mechanism of uptake (91). 
The intracellular fate of hCG in granulosa cells is not completely clear; it is probably 
transported to lysosomes and degraded to small molecules or fragments there (92). 
Human granulosa cells incorporate and degrade intact hCG to β-core fragment, even after 
being previously exposed to hCG in vivo (93). In addition, after injection of hCG, β-core 
fragment can be detected in follicular fluid 34–36 hours later. This suggests that either 
the β-core fragment accumulates in this biological compartment or represents a pool of 
fragments of the different gonadotropins cross-reacting with the β-core assays (94).
BIOLOGICAL ACTIvITY OF hCG
hCG and LH bind to the same specific receptor on the target cell (115). For a 
long time, it was believed that hCG receptors were localized and had an effect on 
gonadal tissues only. Many studies have characterized functional hCG/LH receptors in 
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several nongonadal tissues including placenta and fetal membranes, sperm, prostate, 
myometrium, fallopian tube, breast, skin, adrenals, thyroid, vessels, lymphocytes and 
the central nervous system (35,95-100). 
The hCG/LH receptor is encoded by a single gene, located on human chromosome 
2p21. This receptor belongs to the superfamily of G-protein-coupled seven 
transmembrane (TM) domain receptors (101). The gene codes for a protein receptor 
containing 701 amino acids structured in three distinct domains: a large N-terminal 
extracellular domain which binds hCG, a serpentine TM containing seven TM repeats 
connected by three extra- and intracellular loops (TM region) and a C-terminal tail under 
the cellular membrane (102). 
The early secretion of hCG by the developing trophoblasts prevents its own receptor 
down-regulation. The extracellular domains of hCG and other gonadotropin receptors 
are members of the leucine-rich repeat (LRR) protein superfamily and are responsible 
for the high-affinity binding. α-hCG and β-hCG subunits share a receptor-binding region 
and an agonist activity to adjacent areas of the molecule (103). The tertiary model 
shows that the contact between hCG and its receptor is made by interacting residues 
in the curved portion of the extracellular domain of the receptor and the groove in the 
hormone formed by the apposition of the α-loop 2 and β-loops 1 and 3 (104). 
The biological activity of hCG is dependent on the structure, proper conformational 
modifications in one or both subunits, and on specific regions of the protein chain and 
certain carbohydrate residues. Even though the ligand-binding portion of the molecule 
to the receptor is located on the surface of β-hCG, the amino acid residues Tyr-Tyr-
His-Ly-Ser of the CTP portion of α-hCG also are important for receptor binding (105). 
Alpha His-94 is more involved with receptor binding and α-His-82 may be involved in 
the biological activation of the target cell. Proteinaceous protease inhibitors neutralize 
the agonist activity of hCG and reduce the binding of hCG to its receptor. Primary 
sequence analogies between hCG and the serine protease chymotrypsin implicate an 
enzymatic cascade in the hCG activation of the cell (103). The α-15–17 and α-73–
75 sequences contact the second extracellular loop of the hCG receptor and promote 
signal transduction (101). The α-39–41 sequence in the long loop 2, which interfaces 
with loops 1 and 3 of the β-hCG subunit, is involved in the recognition by its receptor (107). 
The CTP residues α-87–92 are involved in receptor binding and biological expression 
(108). 
There are three major biological roles for the β-hCG subunit in hCG: to carry 
some sites necessary for receptor binding, to induce active conformation of β-hCG, 
and to stabilize the hormone-receptor complex (109). There are at least two receptor-
determined loops located between cysteine residues β38–57 and β93–100 in β-hCG 
which confer receptor specificity (105). The surface able to activate the hCG receptor 
include the majority of the α-hCG and the Asp-99 residue contained in loop β93–100 (111). 
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Although the CTP region of β-hCG is not involved in receptor binding or in vitro signal 
transduction, it is critical for the in vivo biological response (105). The N-terminal region 
of β-hCG and the C-terminal region of α-hCG also appear to be involved in receptor 
binding (112).
There is no general agreement regarding which receptor regions are in contact 
with hCG. N-terminal peptides 7–40, central peptide 102–121 and CTP 259–273 of the 
ectodomain seem to bind the hCG surface (104). Sequences Arg21-Pro38, Arg102-
Thr115, Try253-Phe272 and Lys513-Lys583 of the extracellular domain may also be 
involved in receptor binding (113). 
The binding of hCG to its receptor induces a conformational change in the 
cytoplasmic domain and generates a conventional signal transduction through the 
activation of the associated heterotrimeric G-protein. This leads to an increase in cAMP 
and the consequent activation of protein kinase A (PKA) upon activation of the adenylyl 
cyclase (AC) pathway (Figure 4). It also leads to an increase in intracellular calcium 
through the inositol triphosphate/phospholipase A2 pathway (114). Alternatively, in the 
endometrium, hCG induces phosphorylation of the extracellular signal-regulated kinase 
(ERK 1/2) in a PKA-independent manner and is involved in processes of proliferation, 
growth and differentiation (50). hCG receptor selectivity is given by the N-terminal three-
fifth of the exodomain, which includes a specific cysteine-rich cluster (NCR), flanked by 
an LRR6 sequence on the surface of the hCG receptor molecule. This sequence is able 
to distinguish the positively-charged seatbelt loop of β-hCG, between cys10 and cys11, 
from other gonadotropins (115). This is why the hCG receptor is not activated by other 
glycoprotein hormones. The antagonist effect of trypsin, chymotrypsin and of the serum 
protease inhibitor protinin suggests that these inhibitors bind to the binding site of the 
hCG receptor or to the hCG-binding site (116).
The carbohydrate moieties of hCG have relevant roles in the biological activity of 
hCG. The N-linked carbohydrates on alpha, beta or both subunits have little effect on 
receptor binding. The removal of certain sugar residues even increases the affinity 
of hCG for its receptor (117). The N-linked oligosaccharides αN78, and βN30 do 
not play a significant role in the function of hCG, but the αN52 is crucial for signal 
transduction (118). The Asn13 oligosaccharide of β-hCG seems to play an important 
role in steroidogenesis. The mannose moieties also are essential in stimulating cAMP 
accumulation and steroidogenesis (119). The Asn52 on α-hCG is critical for both the 
cAMP response and the steroidogenesis by maintaining the stability of the dimer, for 
proper conformation of hCG and assuring dimer secretion (120). In addition, αAsn52 
helps to position hCG in a favorable orientation for signal transduction (118). 
The sialic acid content of hCG is of major significance in the receptor-binding ability 
and biological activity. Although the biological activity of hCG diminishes with the gradual 
desialylation or partial or complete removal of carbohydrate units internal to the sialic 
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Figure 4. Model of hCG signal transduction showing the signaling specificity domain (SSD) on 
the extracellular surface of the transmembrane domain (TMD) and the leucine-rich domain (LRD) 
near the SSD–TMD complex.
The NH2- and COOH-terminal portions of the LRD contact the ends of the SSD and TMD helices. hCG 
binding increases the distance between the top of the SSD and the top of LRD, promotes the rotation 
of LRD and a gate-like movement of the LRD and creates a binding pocket for TMD rearrangement 
and signaling. After binding, hCG activates its receptor. Consequently, the heterotrimeric G-protein-
coupled receptor is formed. GDP is released from the G-protein and is replaced by GTP. This leads to 
dissociation of the G-protein subunits into an α-subunit and a βγ dimer. Gα activates adenylate cyclase, 
which leads to an increase in intracellular cAMP levels, stimulation of PKA expression of steroidogenic 
acute regulatory protein (StAR), cholesterol uptake, and steroidogenic enzyme activation (P450scc, 3β-
HSD, P450c17). From Moyle et al. J Biol Chem 279:44442-44459, 2004).
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acid, the removal of certain carbohydrate residues increases the affinity of hCG for its 
receptor (121). The βO-linked branches, not involved in bioactivity, contribute to the 
longer half-life (122). Regular hCG promotes progesterone production via the corpus 
luteum hCG receptor. Hyperglycosylated hCG on the other had, has an autocrine rather 
than an endocrine function. This autocrine function is apparent in growth, invasion and 
tumor formation (17) via inhibition of apoptosis in cancer cells, seemingly through the 
transforming growth factor TGFβ-RII receptor (123). The hypothesis that some variant 
forms could act on other receptors as well, such as TGFβ-IIR, could explain the role of 
these molecules in certain abnormal pregnancy conditions and in particular cancer. 
In addition to the maintenance of the corpus luteum function, hCG is involved 
in autocrine and paracrine regulation of EGF, TGF, and LIF for increasing placental 
syncytium formation (124) and in blastocyst implantation (125). It also mediates 
glycogenolysis in human placental villi (126), stimulates prostaglandin synthesis 
by placental tissue and inhibits myometrium contractility (127-132). hCG maintains 
maternal blood supply to support hemochorial placentation and the nutrition of the fetus 
(95,127-131). hCG maintains angiogenesis in the myometrial spiral arteries throughout 
the pregnancy (127-131). It has been shown that hCG promotes the fusion of villous 
cytotrophoblast cells to syncytiotrophoblast (133). The presence of hCG receptors 
on a variety of non-gonadal tissues suggests other functions as well. In cord blood 
and amniotic fluid, hCG may regulate the vascular tone (134), and attenuates the 
vascular response to angiotensin II (130). In its free form, β-hCG seems to inhibit or 
stimulate cellular growth (135). The free α-hCG is linked with prolactin secretion and 
control of endometrial cell differentiation (81). In addition, free α-hCG potentiates 
progesterone-mediated decidualization of endometrial stromal cells during normal 
menstrual cycles (137).
Research by multiple groups in the past few decades has dramatically changed the 
view on the function of hCG. The function of hCG as solely promoting progesterone 
production was a dogma for almost 80 years, even though hCG was only biologically 
active for 3 weeks of its 37 weeks of production. This made little biological sense. The 
view has now changed from hCG as a hormone produced by trophoblast cells that 
promotes progesterone production by luteal cells to hCG as a collection of a variety 
of molecules each with different functions. With all the new doors opening in the hCG 
story, everything is still far from complete. 
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BIOLOGICAL EFFECTS OF OLIGOPEPTIDES DERIvED FROM β-hCG LOOP-2
There are at least 15 variants of hCG that have been detected in serum and urine of 
normal or abnormal pregnancies, gestational trophoblastic diseases or non-gestational 
malignancies (1-13). Of these 15 variants, β-subunit core fragment (β-core) and nicked 
β-hCG are in the context of this thesis of particular interest. As discussed in chapter 2, 
a β-core comprises two fragments of the β-subunit, β6–40 and β55–92, held together 
by disulfide bonds. This form of β-subunit completely misses β-loop-2 residues 41-54 
(Figure 1). In nicked β-hCG these residues are cleaved at various positions, e.g. at 43-
44, 47-48, 53-54 (Figure 1). Both forms of β-hCG lose their biological function and are 
unable to bind to the hCG/LH receptor. 
Several investigators have studied the biological effects of heterodimeric hCG and 
its multiple variants on gonadal tissues and/or their role in immune modulation (14-18). 
The smaller fragments that may liberate from the breakdown of hCG or its variants are 
generally considered as biological waste products. Their possible biological role has 
not been studied. We hypothesized that smaller fragments may liberate from β-loop-2 
residues 41-54. These residues are missing in β-core, and might be further nicked as 
these same residues are cleaved at various positions in nicked β-hCG.
We did not restrict our analyses of β-hCG-loop-2 fragments to the fragments that are 
liberated from residues 40-54 according to the known cleavage sites in nicked β-hCG, 
but also analyzed all other possible peptides that theoretically might exist based on the 
primary sequence of β-loop-2. All these possible peptide-sequences were analyzed by 
several proteomics tools for a number of characteristics that we hypothesized might be 
crucial for functional activity in inflammatory processes (19). These characteristics are:
MHC class I and class II binding, as we supposed the involvement of the • 
antigen processing and degradation machinery in the generation of regulatory 
oligopeptides.
Hydrophobicity, as we supposed the necessity of the regulatory peptides to • 
easily traverse intracellular membranes.
Proteolytic sites other than the ones known from nicked β-hCG.• 
Homology to other putative regulatory oligopeptide sequences in endogenous • 
proteins.
To this end the following proteomics tools were used:
BIMAS (20) database to predict the HLA peptide binding sites.• 
SYFPEITHI (20) database to predict the MHC I and II peptide binding sites.• 
ExPASy ProtScale (22, 23) tools to determine the hydrophobicity.• 
ExPASy Peptide Cutter (23) database to predict proteolytic sites.• 
ExPASy Blasts (23) tools to determine the occurrence of oligopeptides in • 
endogenous (host or pathogen) proteins.
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Figure 1. 
A, β-hCG subunit polypeptide chain (thick green line) with its seatbelt region (thick black line) and 
assigned disulfide bonds. Numbers, amino acid numbers; yellow bars, cystine knots; thick blue lines, 
seatbelt disulfide bonds; thin blue line, small loop disulfide bond; β1, β2, β3 loops of β-hCG. B, shows 
β-hCG-loop-2 residues that are missing (residues in the gray area; MTRVLQGVLPALPQ) in β−core and 
shows potentially cleaved sites (43-44, 44-45, 47-48, 53-54) within this region that have been found in 
nicked β-hCG (modified from Xing et al. Protein Sci 2001;10:226-235). 
Figure 2 (right). The effect of in vitro exposure of a plancental derived trophoblast cell line (ATCC; 
CRL 7548) to the oligopeptides LQG, LQGv, vLPALP, vLPALPQ.
MTR, MTRV and commercial hCG (Pregnyl) on proliferation. The assay was performed in triplicate by 
co-culturing 2 x 105 trophoblast cells per well in 48-well flat-bottom plates (Nalge Nunc Int., Naperville, 
IL, USA) either with oligopeptide (0.1 µg/ml, 1 µg/ml or 10 µg/ml) or with Pregnyl (3 IU/ml, 30 IU/ml 
or 300 IU/ml) in a total volume of 500 µl. Cells were incubated at 37oC in 5% CO2 for 12, 24, 36 or 48 
hours. During the final 8 hours of culture 0.5 µCi of (3H) thymidine ((3H)TdR) per well was added and the 
incorporation of (3H)TdR was measured on beta-plate counter. Open symbols are data points that are 
significantly (p < 0.05) different as compared to the PBS treatment (unpaired Student’s t-test). Data are 
given as mean ± SD and are from one representative experiment out of three.
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Based upon these analyses we synthesized a number of overlapping oligopeptides 
from b-loop-2 residues 41-54 and from the external C-terminal flanking region namely, 
MTR, MTRV, LQG, LQGV, VLPALP, VLPALPQ, VVC and QVVC and tested these 
oligopeptides for their possible biological activity. 
The effect of oligopeptides MTR, MTRV, LQG, LQGV, VLPALP, VLPALPQ and 
a commercial hCG preparation (Pregnyl) were tested on the proliferation of human 
placental-derived trophoblast cells (ATCC, CRL-7548) isolated from 5 months of 
gestation. The results from these experiments showed that oligopeptide LQGV 
significantly decreased proliferation of trophoblastic cells as did commercial hCG 
preparation, while oligopeptide VLPALP significantly increased the proliferation of 
such cells (Figure 2). The oligopeptides MTR, LQG and VLPALPQ did not affect the 
proliferation of trophoblastic cells (Figure 2), whereas MTRV decreased the proliferation 
only in the early phase of the cultures. Apparently, the oligopeptides LQGV, VLPALP 
and MTRV from β-loop-2 residues 41-54 affect trophoblast proliferation and thus 
are biologically active. Furthermore, these oliopeptides differently affect trophoblast 
proliferation. 
It is well known that hCG maintains maternal blood flow (24) to support 
placentation. hCG maintains angiogenesis in the myometerial spiral arteries throughout 
pregnancy (25-30). It has a direct role in regulating human implantation and 
placentation through stimulation of vascular endothelial growth factor (VEGF) and 
immunomodulaton (31,32). We investigated the possible effects of the designed 
oligopeptides on angiogenesis in a chicken egg chorioallantoic membrane (CAM) 
assay. Fertilized, domestic chick eggs were incubated for 8 days and then windowed as 
described previously (33). 
Briefly, two small holes were drilled into the eggshell. One hole was used to open the 
air cell and the other for injection. The oligopeptide (1mg/egg) with or without vascular 
endothelial growth factor (VEGF) (100 ng/egg) was injected into the egg. After 48 hours 
of incubation at 37oC with 32% relative humidity, the shell membrane was carefully 
dissected ad removed. The embryo and the blood vessels were photographed in vivo 
with the use of a microscope and the number of blood vessel branches was counted. 
These experiments revealed that LQG and VLPALP significantly reduced basal as well 
as VEGF-induced angiogenesis in the CAM assay, while LQGV significantly increased 
basal as well as VEGF induced angiogenesis (Figure 3). Oligopeptide VLPALPQ 
significantly reduced VEGF-induced angiogenesis only, whereas MTRV significantly 
increased basal angiogenesis (Figure 3). The oligopeptides MTR, VVC and QVVC did 
not affect the proliferation in the CAM assay (data not shown). These angiogenesis 
experiments confirmed biological activity of the several designed oligopeptides.
Pregnancy confers a transient altered immune status in the maternal host as 
responses are biased toward type 2 (humoral) and away from type 1 (inflammatory 
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Figure 3. Effects of several hCG-related oligopeptides on basal (A) and vEGF-stimulated (B) 
angiogenesis in the chick chorioallantoic membrane (CAM) assay. 
Results are expressed as average number of vessel branches per 10 mm2 in high power (10 X) field 
of view ± SEM. For each treatment ten eggs were used and the vessel branches from four different 
fields per egg were counted under a dissection microscope. Light gray dotted bars show data that are 
significantly different from the PBS (graph A) and VEGF (graph B) controls. Data given are from one 
representative experiment out of three.
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and cell-mediated) phenotype (34, 35). This shift in the immune state during pregnancy 
is more pronounced at the maternal-fetal interface (34,35). Uncontrolled shifts in the 
immune state during pregnancy can have deleterious effects on the outcome of the 
pregnancy, and can lead to abortion. Maternal rejection of the fetus can be triggered by 
pro-inflammatory Th1 cytokines, such as IFN-g and TNF-α (36). Because hCG-related 
oligopeptides were biologically active as shown in the trophoblast proliferation assay 
and in the CAM angiogenesis assay, we further tested these oligopeptides in a poly I:C-
induced embryo resorption mouse model. Poly I:C, a synthetic double stranded-RNA, 
is known to increase the production of pro-abortive Th1 cytokines such as IFN-g and 
TNF-α (37). These experiments showed that the increased poly I:C-induced embryo 
resorption could be significantly inhibited by multiple injection of either MTRV, LQGV or 
Figure 4. Influence of hCG-related oligopeptides on the cumulative poly I:C induced embryo 
resorption rate on day 14 of gestation in female BALB/c mice. 
Ten to twelve weeks old female BALB/c mice were intraperitoneally (i.p.) injected with pregnant mare’s 
serum gonadotropin (PMSG, Sigma-Aldrich) at a dosage of 10 IU/mouse. After 48h mice were i.p. 
injected with hCG at 10 IU/mouse. Each female was co-caged with a 10 to 12 weeks old male C57BL/6 
mouse. The females were checked twice a day for vaginal plug and separated from the male after 
detection of a plug. The day of the vaginal plug was designated day 0 of pregnancy. MTRV, LQGV or 
VLPALPQ was i.p. injected at gestational days 3, 5, 7, 9, 11 and 13 at a dosage of 0.1 mg in 0.1 ml of 
PBS, whereas 0.2 mg of poly I:C in 0.5 ml PBS was i.p. injected at day 7 of gestation. Other female 
BALB/c mice were i.p. injected either with an equal volume of PBS instead of oligopeptide, or with poly 
I:C only. Poly I:C increased the cumulative embryo resorption (dark gray bars). This was significantly 
inhibited by each of the three hCG-related oligopeptides tested (light gray dotted bars). Data are given 
as mean ± SD. 
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VLPALPQ (Figure 4).
Together these studies showed that several of the designed oligopeptides that might 
be liberated in vivo from β-loop-2 residues 41-54 are biologically active in vitro and 
in vivo. Together these studies showed that the designed oligopeptides that might be 
liberated in vivo from β-loop-2 residues 41-54 are biologically active in vitro and in 
vivo. 
SPECIFIC QUESTIONS TO THIS THESIS
The aim of the studies of this thesis was to increase our understanding of the 
biological abilities of the degradation products of the β-hCG-loop-2 peptide chain. 
In these studies several models were employed:
Th1 mediated autoimmune disease in non-obese diabetic (NOD) mice.1.  
The influence of commercial hCG, its lower molecular weight fractions and the 
effects of β-loop-2 related oligopeptides were studied on the development of 
type 1 diabetes and the associated Th1 response (chapter 4).
LPS induced shock in BALB/c mice.2.  The influence of commercial hCG, its lower 
molecular weight fractions and the effects of β-loop-2 related oligopeptides 
were studied on the disease outcome. In addition, the effect of the peptides was 
studied on the production of macrophage migration inhibitory factor (MIF) by 
spleen cells, on the plasma level of liver aminotransferase, on the expression 
of several splenic lymphocyte and macrophage surface markers, and on the 
proliferative response of splenic lymphocytes (chapters 5 and 6).
E.coli induced septic shock in rhesus monkeys.3.  We investigated whether the 
beneficial effect of β-loop-2 related oligopeptides on LPS induced shock in mice 
could be confirmed in a preclinical non-human primate model challenged with 
live E. coli bacteria. In this model the pathological features and haemodynamic 
parameters were studied (chapter 6).
Hemorrhagic shock and resuscitation induced inflammation.4.  Several hCG related 
oligopeptides were studied for their ability to improve the disease outcome, and 
to modulate the proinflammatory cytokine and adhesion molecule expression in 
a rat model for hemorrhagic shock and resuscitation (chapter 7).
Innate immune response to Listeria monocytogenes.5.  In this chapter the effect of 
the hCG-related oligopeptides was studied with regard to the immune response 
to and the clearance of Listeria monocytogenes infection in mice (chapter 
8). This infection model is relevant to pregnancy since pregnant women and 
their babies are more vulnerable to infection with Listeria than non-pregnant 
women.
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Renal ischemia reperfusion injury.6.  We also studied the effect of hCG-related 
oligopeptides on renal ischemia-reperfusion injury in mice with regard to the influx 
and apoptosis of neutrophils, epithelial cell proliferation, serum proinflammatory 
cytokines and adhesion molecules (chapter 9).
Solid tumor growth.7.  Finally we studied the influence of, especially LQGV, 
on tumor growth and vessel integrity in a transplantable lung tumor in mice 
(chapter 10).
These studies revealed a broad spectrum of activities of the hCG-related 
oligopeptides tested on physiological and pathophysiological processes, and suggest 
potential therapeutic value of these oligopeptides.
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ABSTRACT
Clinical symptoms of Th1 mediated autoimmune diseases regress in many patients 
during pregnancy. A prominent feature of pregnancy is the presence of human chorionic 
gonadotropin hormone (hCG) in blood and urine. In this report we tested the effect 
of clinical grade hCG (c-hCG) on the development of diabetes, a Th1 mediated 
autoimmune disease, in non-obese diabetic (NOD) mice. We show that treatment of 
NOD mice with c-hCG before the onset of clinical symptoms lowered the increased 
blood glucose levels, reversed the established inflammatory infiltrate of pancreatic 
tissue and profoundly inhibited the development of diabetes for prolonged time. c-hCG 
also induced profound inhibition of the functional activity (i.e. production of IFN-g) of Th1 
cells. Transfer of spleen cells from c-hCG-treated NOD mice into immuno-compromised 
NOD.SCID mice inhibited the development of diabetes in these otherwise non-treated 
mice. This shows that the treatment of the donor NOD mice with c-hCG changes the 
balance in the immune system. The anti-diabetic activity of c-hCG was not caused by 
heterodimeric hCG or its subunits. Instead, this anti-diabetic activity appeared to reside 
in a 100-2000 Dalton fraction of c-hCG. We called this 400-2000 Dalton fraction natural 
(immuno) modulatory pregnancy factor (NMPF). Although the precise nature of NMPF 
is not elucidated yet, we show that small peptides from loop 2 of beta hCG may account 
for this anti-diabetic activity. 
INTRODUCTION
T cell-mediated autoimmune diseases belong to the commonest chronic diseases 
in industrialized countries and increase worldwide. It imposes a burden on Western 
economies. These diseases, including type I diabetes, Graves’ disease, rheumatoid 
arthritis (RA) and multiple sclerosis (MS) generally have a dominant Th1 immune 
response in common (1,2). An adjustment of the innate and adaptive immune system 
during pregnancy, characterized amongst other by a Th2 cytokine profile, could maintain 
normal immune competence against microorganisms and also account for the clinical 
improvement of Th1 autoimmune disease (3-6). A better understanding of the immune 
modulation during pregnancy and the identification of the natural factor(s) responsible 
for this, could help to develop new strategies for the prevention and treatment of Th1 
autoimmune diseases with less detrimental effect to the treated individual than currently 
used broad range immunosuppressive drugs. Since hormonal changes in pregnant 
women preceed and accompany immune changes, we hypothesized that hCG, an early 
pregnancy hormone, might account for the regression of Th1 mediated autoimmune 
diseases during pregnancy.
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Therefore, we tested a commercial clinical grade hCG (c-hCG) preparation derived 
from first trimester pregnancy urine on the development of diabetes in the NOD mouse 
model (7). Female NOD mice spontaneously develop type I diabetes with remarkable 
similarity to human type I diabetes (insulin-dependent diabetes mellitus (IDDM) (8,9). 
The main clinical feature of this model is the elevated blood glucose level, which is 
caused by Th1 cell-mediated autoimmune destruction of insulin-producing b cells in 
the islets of Langerhans of the pancreas (10). The disease severity in NOD mice is 
correlated with high levels of interferon-gamma (IFN-g), a signature cytokine for Th1 
cells. 
Human CG exhibits a variety of forms in serum and urine (11). Only intact hCG 
stimulates the LH/hCG receptor. Peptide bond cleavages result in biologically inactive 
hCG. Beside heterodimeric hCG, b core fragment and nicked hCG are two other major 
forms that are found in pregnancy serum and urine samples. Both of these forms of hCG 
either have peptide bond cleavages in residues 44-52 (loop 2) of b hCG or completely 
miss loop 2 (residues 41-54). 
Several investigators have studied the biological effects of heterodimeric hCG 
and its variants on gonadal tissues and/or their role in immune modulation (12-14), 
but ignored the possible biological activity of fragments liberated from the breakdown 
of hCG into different variants. Loop 2 is known to be especially prone to proteases. 
The hCG dimer and b core fragment, uncombined α- and b hCG (free b) and nicked 
hCG and free b molecules (cleaved at 44-45 or 47-48) can be detected in the 
circulation (11). We postulate that the loop 2 region, consisting of residues 41-54 with 
amino acid sequence MTRVLQGVLPALPQ, which is absent in b core, can also be nicked 
in vivo and can liberate smaller fragments (oligopeptides) with biological activity. In this 
report we have also tested possible biological activities of two such oligopepeptides, 
namely LQGV and VLPALP on the development of diabetes in the NOD mouse model.
MATERIAL AND METHODS
NOD mice and BALB/c mice 
All mice used in these studies were maintained in a pathogen-free facility at the 
Department of Immunology, Erasmus University Rotterdam, The Netherlands. NOD 
and NOD.SCID mice were bred in our facility. Female BALB/c mice were purchased 
from Harlan (Horst, The Netherlands) and were also maintained in a pathogen-free 
facility at the Department of Immunology. All mice were given free access to food and 
water. The experiments were approved by the Animal Experiments Committee of the 
Erasmus University Rotterdam.
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Diabetes
Diabetes was assessed by measurement of the venous blood glucose level using 
an Abbott Medisense Precision glucometer. Mice were considered diabetic after two 
consecutive glucose measurements ≥11 mmol/l (200 mg/dl). Onset of diabetes was 
dated from the first consecutive reading. 
In vivo treatment 
14 weeks-old female NOD mice (n=12) were treated with c-hCG (Pregnyl Organon, 
Oss, The Netherlands). Treatment was done by injecting 300 IU c-hCG diluted in PBS 
three times per week intraperitoneally ( i.p.). Control mice were treated with PBS only. 
The treatment was discontinued when all PBS treated NOD mice in the experiment 
had developed diabetes. This was at the age of 19 weeks. Thus, the c-hCG and PBS 
treatments were done for five weeks. In instances of sustained hyperglycaemia of 
20 mmol/l the mice were killed to avoid prolonged discomfort. The remainder mice were 
kept alive up to the age of 35 weeks without any further treatment. For Th polarization 
assessment, mice (n=6) were treated i.p. with 300 IU c-hCG, 10 mg lyophilized material 
obtained from first trimester pregnancy urine (u-hCG) or their fractions for 4 days. 
The u-hCG was prepared according to the procedures described below. Control mice 
were treated with PBS only. Spleen cells were pooled from each group and were used 
for CD4+ T-cells preparation (see below) or were stimulated with anti-CD3 and IL-2. 
RPMI 1640 medium was used supplemented with 25 mM HEPES, 100 IU/ml penicillin, 
50 mg/ml streptomycin, 1 mM pyruvate, 50 mM 2-ME and 10% heat inactivated FCS. All 
cultures were performed in triplicate or quadruplicate. 
Glucose tolerance test
Glucose tolerance test (GTT) test was performed at 17 (during treatment, n=6) and 
35 weeks of age (after treatment, n=6) by injecting 0.5 g/kg D-glucose intravenously 
(i.v.). At 3, 5, 10 and 15 minutes blood samples were collected from the tail and tested 
for glucose content.
Immunohistochemistry
At the age of 21 weeks 6 NOD females from the two experimental groups (PBS 
vs c-hCG) were killed. For detailed immunohistochemistry pancreases were removed, 
embedded in Tissue-tek and frozen in liquid nitrogen. Tissues were stored at –80oC 
until immunohistochemistry was performed. Before sectioning, microscopic slides 
were coated with 0.1% gelatin/0.01% chromium-alum. Thereafter, at least ten 5-mm 
cryosections at four non-contiguous levels (around 50 mm apart) of the stored tissue 
specimens were cut, dried in air overnight, and fixed with the appropriate fixatives 
depending on the monoclonal or polyclonal antibody used (15).
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Immunohistochemistry was performed essentially as described previously (15). 
Pancreas cryostat sections were prepared, coded and fixed for 2 min in 2% pararosaniline. 
After a wash with phosphate buffered saline with 0.1% Tween-20 (Merck-Schuchardt, 
Hohenbrunn bei Munchen, Germany) (PBS/Tween), slides were incubated with first 
step antibodies for 30 min at room temperature. The antibodies used were rat RA3.6B2 
for B cells, rat KT3 for T cells, rat MOMA-1 and rat BM8+ for macrophages and rat ER-
MP23+ for dendritic-like cells. Pig anti-insulin (DAKO, Glostrup, Denmark) was used 
diluted 1:100 in PBS/Tween. All other monoclonal antibodies used in this study were 
supernatants from hamster hybridoma cultured at our department and used undiluted. 
Subsequently, slides were washed with PBS/Tween and incubated with peroxidase-
conjugated rabbit-α-guinea pig-Ig (to detect α-insulin) or rabbit-α-rat-Ig (to detect all 
others) second step antibodies in the presence of 2% normal mouse serum for 30 min 
at room temperature. After an additional wash with PBS/Tween, slides were incubated 
with 0.05% (w/v) Ni-di-amino-benzidine (Ni-DAB) with 0.02% H2O2 and washed in water 
after 3 min. Finally, slides were counter stained for 3 min in nuclear fast red, dehydrated 
in a graded ethanol series, and mounted. For each staining run, one slide was stained 
with second antibody only as a control for endogenous peroxidase activity and non-
specific binding of the second step, and a section of spleen was included as positive 
control. 
Spleen cell transfer
Spleens of PBS and c-hCG treated mice were removed under aseptic conditions 
and single-cell suspensions were made. Erythrocytes were removed by incubating with 
Gey’s medium for 5 minutes on melting ice. Isolated pooled spleen cells (20 x 106 in 
0.3 ml PBS) from c-hCG treated mice (n=6) and control mice (n=6) were injected i.v. into 
the tail vein of 8 weeks-old female NOD.SCID mice (n=6). 
In other experiments spleen cells were recovered from diabetic female NOD mice 
and stimulated in vitro with IL-2 (50 U/ml) along with 300 IU/ml c-hCG (Pregnyl, Organon; 
Profasi, Serono; APL, Wyeth Ayerst), or 10 mg/ml from HPLC purified fractions of 
c-hCG or hCG directly purified from pregnancy urine (u-hCG, see below), recombinant 
hCG (10 mg/ml) (r-hCG, Sigma, St. Louis, MO, USA), its subunits (r-α-hCG or r-b-hCG) 
or purified hCG (from pregnancy urine; 10 mg/ml). After 48hrs of culture, cells were 
collected and evaluated for their viability by trypan blue staining. Cells were washed 
twice with PBS and 20 x 106 cells were i.v. transferred into 8-wk-old female NOD.SCID 
mice. 
In vitro stimulation of splenocytes
Splenic cell suspensions (2 x 105 cells/well) were cultured in 96-well flat-bottom 
plates (0.2 ml) and stimulated with plate bound anti-CD3 (145-2C11, 25 mg/ml) and 
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IL-2 (50 U/ml) along with c-hCG or u-hCG or fractions derived from it. After incubation 
for 48hrs, supernatants were collected for cytokine analyses. RPMI 1640 medium was 
used supplemented with 25 mM HEPES, 100 IU/ml penicillin, 50 mg/ml streptomycin, 
1 mM pyruvate, 50 mM 2-ME and 10% heat inactivated FCS. All cultures were performed 
in triplicate or quadruplicate.
Preparation and stimulation of purified CD4+ T cells
Purified CD4+ T cells from the spleen were obtained by complement depletion with 
antibodies to heat stable antigen (HSA), CD16/32, MHC class II (BALB/c, M5/114; NOD, 
M10/216) and GR-1. Cells were further purified using magnetic activated cell sorting 
with a cocktail of biotinylated mAbs against CD11b (M1/70), B220 (RA3 6B2), CD8 
(YTS-169) and CD40 (FGK-45.5), followed by incubation with streptavidin-conjugated 
microbeads (Milteny Biotech, Bergisch Gladbach, Germany). CD4+ T-cells used for 
experiments were always 90-95% purified as determined by flow cytometry.
Th polarization assay
For Th polarization assay, primary stimulation of purified CD4+ cells was done by 
culturing 1 x 105 cells/well in 96-well flat-bottom plates (Nalge Nunc Int., Naperville, 
IL., USA). The cells were stimulated with plate-bound anti-CD3 mAb (145-2C11; 
25 mg/ml) in the presence of soluble anti-CD28 mAb (37-51; 10 mg/ml) and IL-2 (50 U/
ml). For differentiation of Th1 cells (Th1 polarizing condition), anti-IL-4 mAb (11B11; 
10 mg/ml) and IL-12 (10 ng/ml) were added to the cultures. For differentiation of Th2 
cells (Th2 polarizing condition) IL-4 (35 ng/ml) and anti-IFN-g mAb (XMG 1.2, 5 mg/
ml) were employed. Neutral (non-polarized) condition cultures contained only anti-
CD3, anti-CD28 and IL-2. All doses were optimised in preliminary experiments. After 
4 days of culture, the cells were washed 3 times and transferred to new anti-CD3-
coated 96-well plates and restimulated in the presence of IL-2 (50 U/ml) and anti-CD28 
(10 mg/ml). All cultures were performed in triplicate or quadruplicate. Forty-eight hours 
later, supernatants were collected and assayed for IL-4, IFN-g, IL-10 and (total) TGF-b 
production by ELISA as a read-out for Th1 versus Th2 polarization.
Cytokine ELISA
Flat bottom microplates (96-wells, Falcon 3912, Microtest II Flexible Assay Plate, 
Becton Dickinson, Oxnard, CA, USA) were coated with capture antibody diluted in PBS 
(SXC-1; 1 mg/ml, 11B11 and XMG 1.2; 5 mg/ml) at 4oC for 18h. After coating, plates were 
washed (PBS, 0.1% BSA, 0.05% Tween-20) and blocked with PBS supplemented with 
1% BSA at room temperature for 1h. After washing, samples and standards were added 
and incubation was continued for at least 4 hours at room temperature. Thereafter, 
plates were washed and biotinylated detection antibodies were added (2A5.1 for IL-10 
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and BVD624G for IL-4, 0.1 mg/ml; R46A2 for IFN-g, 1 mg/ml) and incubated overnight at 
4oC. After washing, streptavidin-peroxidase (1/1500 diluted, Jackson Immunoresearch, 
West Grove, PA, USA) was added. After 1h, plates were washed and the reaction was 
visualized using 2,2’-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS, 1 mg/ml, 
Sigma, St. Louis, MO, USA). Optical density was measured at 414 nm, using a Titertek 
Multiscan (Flow Labs, Redwood City, CA, USA).
The amount of TGF-b was measured with commercially available ELISA kit (Genzyme 
Corp, Cambridge, MA, USA) according to the protocol provided by the manufacturer.
The detection limits of the various ELISA were: IL-4: 80 pg/ml, IFN-g: 800 pg/ml, 
IL-10: 80 pg/ml and TGF-b: 32 pg/ml.
Purification of u-hCG from first trimester pregnancy urine
First trimester pregnancy urine (2 litres) was collected in a bottle from a healthy 
volunteer and was refrigerated until delivered at the laboratory within 2 days. 
Upon delivery, the pH was adjusted to 7.2-7.4 with sodium hydroxide and allowed to 
sediment for 1h at room temperature (RT). Approximately, 75% of the supernatant 
was decanted and the remainder close to the precipitate was centrifuged (10 min 
at 25000 rpm at 4oC) to remove sediment and added to the rest of the supernatant. 
The supernatant was filtered through 0.45 mm in a Minitan (Millipore) transversal filtration 
set-up. Subsequently, the filtrate (2 litres) was concentrated in an Amicon ultrafiltration 
set-up equipped with a YM Diapore membrane with a 10 kilo Dalton (kDa) cut-off. 
The final volume (250 ml) was dialysed against 2 changes of 10 litres of Milli Q water. 
Next the sample was further concentrated by 10 kDa cut-off in an Amicon ultrafiltration 
to a final volume of 3 ml. The material was further lyophilized for purification and for 
other experiments.
Gel permeation
c-hCG or u-hCG was fractionated by gel filtration using a fast-protein liquid 
chromatography (FPLC) system (Pharmacia, Uppsala, Sweden) equipped with 
Superdex 75 (10mm ID x 300 mm L) gel permeation column. Superdex columns have 
superb resolution and reproducibility for separating monomeric and dimeric forms of 
proteins and peptides. The separation range of this column was 70,000 - 3000 Dalton. 
50 mM of ammonium bicarbonate in combination with 4% methanol was used as a 
running buffer and the selectivity profile of the column was determined. FPLC fractions 
of c/u-hCG in 50 mM of ammonium bicarbonate in combination with 4% methanol were 
further analyzed by gel filtration using a high performance liquid chromatography (HPLC) 
system (Shimadzu Co., Japan) equipped with a macrosphere size exclusion (GPC) 
60Å (7.5mm ID x 300mm L) column (Alltech, Illinois, USA). This is an appropriate column 
for separation of not only proteins, but also peptides. The separation range for this 
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column was 28,000 – 250 Dalton and the flow rate was 0.5 ml/min. External molecular 
weight standards were employed to calibrate the column elution positions. The eluted 
fractions from FPLC and HPLC columns were lyophilized for the use in experiments.
In vivo treatment with oligopeptides
Fourteen weeks-old or 6 weeks-old female NOD mice (n=5-6) were treated i.p. with 
10 mg or 100 mg of oligopeptide LQGV or VLPALP three times per week for three weeks. 
Control mice were treated with PBS only. Up till the age of 30 weeks once in a week 
diabetes was assessed by measurement of the venous blood glucose level using an 
Abbott Medisense Precision glucometer.
In another experiment 14 weeks-old female NOD mice (n=5) were treated i.p. three 
times a week with 100 mg of oligopeptide LQGV or VLPALP for three weeks. After 
the treatment splenic dendritic cells (DC) were isolated and assessed for NF-kappa B 
activation.
Isolation of splenic DC
Splenic DC were isolated using MACS CD11c (N418) MicroBeads (Miltenyi 
Biotec), following the manufacturer’s protocol. In short, single cell suspensions were 
obtained by incubating the spleens with Collagenase D (GibcoBRL, Life technologies). 
The obtained cell suspension was incubated with CD11c MicroBeads, and labelled cells 
were separated from the suspension using an autoMACS (Miltenyi Biotech).
Nuclear extracts
Three million cells/ml were plated in a 12 well plate (Nalge Nunc International) 
2 hours before treatment with LPS (100 ng/ml). After stimulating the cells for 30 minutes, 
cells were collected in a tube and centrifuged for 5 minutes at 2000 rpm (rounds per 
minute) at 4ºC (Universal 30 RF, Hettich Zentrifuges). The pellet was washed with ice-
cold TBS pH 7.4 (Tris buffered saline) once and then the pellet was resuspended in 
400 ml of a hypotonic buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA, 1 mM DTT, protease inhibitor cocktail (CompleteTM Mini, Roche)) and 
left on ice for 15 minutes. 25 ml 10% NP-40 was added, and the sample was centrifuged 
(2 minutes, 4000 rpm, 4ºC). The supernatant (cytoplasmic fraction) was discarded. 
The pellet, which contains the nuclei, was washed with 50 ml buffer A and then the pellet 
was resuspended in 50 ml buffer C (20 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM EDTA, 
1 mM EGTA, 10% (v/v) glycerol, 1 mM DTT, protease inhibitor cocktail). The samples 
were left to shake at 4 °C for at least 60 minutes. Finally, the samples were centrifuged 
and the supernatant (nucleic fraction) was stored at –70ºC.
Bradford reagent (Sigma) was used to determine the final protein concentration in 
the extracts.
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Dection of p65 subunit of NF-kappa B
In nucleic extracts of splenic DC p65 subunit of NFkB was detected using 
TransFactorTM NFκB kit (Clontech, BD) which is an ELISA based method to detect 
NFκB in nuclear extracts. Wells provided in the kit were coated with DNA containing 
the κB site and then the binding of NFκB to the coated well was detected with a specific 
antibody against p65 according to the manufacturer’s protocol.
Statistics
Data was analyzed by Student’s T test and differences were considered significant 
at p<0.05.
RESULTS
In order to determine whether hCG treatment affects the diabetes development in 
NOD mice, we tested c-hCG on pre-diabetic female NOD mice. In our female NOD 
colony the majority of b cells (>80%) are histologically and functionally destroyed 
between 15 and 21 weeks of age and clinical symptoms appear between 15-21 weeks 
of age. c-hCG treatment of 14 weeks-old female NOD mice was done with a titrated 
dose of 300 IU i.p. three times per week. In the experiments reported, all PBS treated 
NOD control mice had developed diabetes and showed blood glucose levels over 20 
mmol/l at 20 weeks of age. In contrast, c-hCG treated mice remained non-diabetic as 
evidenced by blood glucose levels not higher than 7 mmol/l (Figure 1A). This remained 
so up to the termination of the experiment at the age of 35 weeks. 
Figure 1 (right). Effect of 5 weeks of c-hCG treatment (3 times a week, 300 IU c-hCG starting at 
the age of 14 weeks) in female NOD mice on blood glucose levels (n=12). 
(A), Blood glucose levels of c-hCG (-◊-) and PBS (-♦-) treated NOD mice. From 17 weeks and onwards 
the values between the groups were significantly different. After treatment the c-hCG treated mice (n=6) 
were kept alive for an additional 16 weeks without any further treatment. (B), GTT in c-hCG and PBS 
treated NOD mice (n=6) at 17 (during treatment) and 35 weeks of age (after treatment). Blood glucose 
levels of PBS (-♦-) and c-hCG (-◊-) treated NOD mice after glucose challenge at 17 weeks of age, and of 
c-hCG (-n-) treated NOD mice at 35 weeks of age are shown. The values of PBS and c-hCG groups are 
significantly different for all data points. (C), Transfer of diabetes resistance from c-hCG treated NOD 
mice to NOD.SCID mice. Spleen cells were isolated two weeks after termination of the 5-week c-hCG 
or PBS treatment (n=6). Viable pooled cells were infused i.v. into 8-weeks-old NOD.SCID mice (n=6) 
in a dose of 20 x 106 cells/mouse. Transfer of splenocytes from PBS-treated NOD mice to 8 weeks-old 
female NOD.SCID mice consistently induced diabetes after 22 days. Blood glucose levels of NOD.SCID 
mice receiving splenocytes from PBS-treated NOD mice (-♦-) and c-hCG treated NOD mice (-◊-) are 
shown here. Data points from 4 weeks and onwards are significant by different. The results shown here 
are from a single experiment and representative of three independent sets of experiments.
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Histological examinations of the pancreatic tissue of the c-hCG treated mice at 21 
weeks of age showed large insulin-producing islets and virtually no insulitis (Figure 2A-D, 
upper panel). Control-treated mice showed no insulin producing cells except one PBS 
treated mouse where only few weakly positive insulin producing cells and a massive 
infiltrate was found containing large numbers of T and B lymphocytes, macrophages 
(MOMA-1+ and BM8+ cells) and dendritic-like (ER-MP23+) cells (partly shown in Figure 
2A-D, lower panel) in the islets. 
Impairment of the glucose tolerance test (GTT) is positively correlated to insulitis, 
but negatively correlated to the number of functional b cells (16,17). This test showed 
that NOD mice during the 5 weeks of c-hCG treatment and during the follow-up period 
till 35 weeks of age were tolerant for glucose (Figure 1B).
Splenocytes of diabetic NOD mice contain CD4+ and CD8+ diabetogenic T cells, 
which can effectively transfer the disease into immuno-compromised NOD.SCID 
mice (18,19). We transferred splenocytes from 21-weeks-old PBS and c-hCG treated 
NOD mice into NOD.SCID mice. Four weeks after transfer, all NOD.SCID mice which 
had received splenocytes from control (PBS) NOD mice were diabetic (Figure 1C), but 
mice which had received splenocytes from c-hCG treated NOD mice remained non-
diabetic.
The effect of consecutively 4 days of in vivo c-hCG treatment on the Th1 and 
Th2 cell populations of NOD mice was studied in an in vitro Th polarization assay. 
For comparison BALB/c mice were similarly tested. Under Th1 polarizing conditions (thus 
in the presence of IL-12 and anti-IL-4), purified CD4+ T-cells from c-hCG treated NOD 
mice showed a lower capacity to produce IFN-γ producing cells than PBS treated mice 
(19±2 vs 28±3 ng IFN-γ/ml). Under neutral conditions purified CD4+ T-cells from c-hCG 
treated NOD mice also showed a significantly lower IFN-γ production as compared to 
PBS treated mice (Figure 3A), while no significant differences were observed between 
the groups in IL-4 production under neutral conditions (Figure 3B). The same was true 
for the effect of c-hCG treatment of NOD mice on the in vitro IL-4 production by purified 
CD4+ T-cells under Th2 polarizing conditions (2 ng IL-4/ml). The IL-10 (Figure 3C) and 
TGF-β (Figure 3D) production by purified CD4+ T-cells from c-hCG treated NOD mice in 
vitro under neutral conditions was significantly increased as compared to PBS treated 
NOD control mice. 
Figure 2 (right). Immunohistochemistry of the pancreas of NOD mice after five weeks of c-hCG 
treatment. 
Representative islets of PBS and c-hCG treated mice are shown. Staining of pancreatic tissue for 
insulin (A), B cells (B), T cells (C) and macrophages (D) of c-hCG (magn. 320x, upper panel) and PBS 
(magn. 128x, lower panel) treated NOD mice is shown. At least ten independent microscopic fields were 
examined from at least three animals per group. At least 50 islet sections were examined per mouse. 
Inhibition of diabetes by hCG-peptides
67
Chapter 4
68
In contrast to NOD mice, PBS and c-hCG treated BALB/c mice did not show 
differences in IFN-γ production under neutral conditions (Figure 3A) as well as Th1 
polarizing (18±3 vs 17±3 ng IFN-γ/ml) conditions, while a significant upregulation of 
IL-4 production was observed under neutral conditions (Figure 3B). No significant 
differences in IL-4 production were observed under Th2 polarizing conditions between 
PBS and c-hCG treated BALB/c mice (21±4 vs 26±2 ng IL-4/ml).
hCG is a heterodimeric glycoprotein hormone composed of two non-covalently 
bound glycosylated α and β subunits. During pregnancy it is produced by the placenta 
Figure 3. Effect of c/u-hCG treatment on Th polarization in NOD and BALB/c mice under neutral 
(non-polarizing conditions). 
CD4+ T-cells were purified from spleens of mice (n=6) treated with c/u-hCG or its 400-2000 Dalton 
fraction. Cells were stimulated with anti-CD3/anti-CD28 and cultured for 4 days with IL-2. Subsequently, 
the cells were washed and restimulated for 2 days with anti-CD3, anti-CD28 and IL-2 only. Supernatant 
levels of IFN-g (A) and IL-4 (B) were measured by ELISA. Black bars correspond to CD4+ T-cell cultures 
of NOD mice and white bars of BALB/c mice. The supernatant levels of IL-10 (C) and TGF-b (D) in these 
cultures are also shown. These results are from one experiment and are representative of at least three 
independent sets of experiments (* p<0.05).
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and occurs in high concentration in circulation and urine in many different molecular 
forms such as heterodimer, free subunits, β core fragment, proteolytically cleaved 
forms and fragments (11,12,20,21). Commercial hCG preparations are derived from 
first trimester pregnancy urine and vary in their content of hCG and related molecules. 
To define better the active moiety in first trimester pregnancy urine (u-hCG) and in 
the heterodimeric hCG itself, we fractionated c-hCG and u-hCG by gel filtration using 
an FPLC system. Neither c/u-hCG fractions greater than 25,000 Dalton, nor r-hCG, 
highly purified urinary hCG, r-α-hCG and r-β-hCG inhibited the anti-CD3 stimulated 
IFN-γ production in vitro by spleen cells from diabetic NOD mice. Also the transfer of 
diabetes to NOD.SCID mice by such treated spleen cells from diabetic NOD mice was 
not inhibited (data not shown). We further fractionated c/u-hCG on a HPLC system and 
these fractions were also tested for their anti-diabetic effect. These experiments showed 
that the active moiety eluted at molecular range 400-2000 Dalton when assayed for 
IFN-γ inhibiting capacity and transfer of diabetes to NOD.SCID mice, employing spleen 
cells from diabetic NOD mice (Figure 4). This 400-2000 Dalton fraction from c/u-hCG 
also inhibited the development of diabetes in NOD mice, while no such inhibitory effect 
was observed with 400-2000 Dalton fraction from the urine of non-pregnant women 
(data not shown). Similar to c-hCG treatment in vivo, under Th1 polarizing conditions 
the c-hCG and u-hCG 400-2000 Dalton fractions inhibited the IFN-γ production (16±3 
vs 28±3 ng IFN-γ/ml and 17±3 vs 28±3 ng IFN-γ/ml, respectively) as well as under 
neutral conditions by NOD CD4+ T-cells (Figure 3A). The IL-4 production, however, was 
not affected under neutral (Figure 3B) as well as Th2 polarizing conditions (data not 
shown). 
The effect of the 400-2000 Dalton c/u-hCG fractions on the in vitro IL-10 (Figure 3C) 
and TGF-β production (Figure 3D) was similarly enhanced when compared to PBS as 
found after culture with c-hCG and u-hCG. 
We also tested two other c-hCG preparations from Profasi and APL for their anti-
diabetic activity. Profasi and APL showed differential and only partial dose-dependent 
inhibitory effects (data not shown). 
Beside heterodimeric hCG, b core fragment and nicked hCG are two other major 
forms of hCG that are found in the pregnancy serum and urine samples. Both of these 
forms of hCG either have peptide bond cleavages in residues 44-52 (loop 2) of b hCG or 
completely miss loop 2 (residues 41-54). This loop 2 region with amino acid sequence 
MTRVLQGVLPALPQ may liberate smaller fragments (oligopeptides) with biological 
activity. We designed and tested two oligopeptides from the loop 2 of b hCG, namely 
LQGV and VLPALP on the development of diabetes in the NOD mouse model. LQGV 
and VLPALP treatment of 14 weeks-old female NOD mice was done with a dose of 100 
mg (total treatment dose of 900 mg per mouse) or 10 mg (total treatment dose of 90 mg 
per mouse) i.p. three times per week for three weeks. These experiments revealed that 
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both LQGV and VLPALP treatment significantly reduce the diabetes development after 
the age of 17 weeks (Figure 5). 
Several studies have demonstrated that DC from NOD mice exhibit elevated levels 
of NF-kappa B activation upon stimulation due a hyperactive I kappa B kinase (22-
24). These studies have shown that elevated NF-kappa B activation and consequently 
enhanced APC function are specific for the NOD genotype and correlate with the 
progression of insulin-dependent diabetes mellitus (25-27). These results also provided 
evidence for a role for NF-kappa B in regulating the APC function of DC. Therefore, we 
determined whether treatment of 14 weeks-old female NOD mice with either LQGV 
or VLPALP was associated with a decrease in NF-kappa B activity in the nuclear 
extracts of splenic DC by measuring the amount of in vitro LPS stimulated NK-kappa 
B p65 subunit, which is the transactivitor of numerous genes activated by NF-kappa B. 
Figure 4. Analysis of c-hCG by gel filtration using an HPLC system. GPC 60Å column was run at 
a flow rate of 0.5 ml/ml and 1 ml fractions were collected. 
Each fraction was lyophilized and assayed for IFN-g inhibiting capacity and transfer of diabetes to NOD.
SCID mice, employing spleen cells from diabetic NOD mice. This figure shows that the IFN-g inhibitory 
and anti-diabetic activity elutes in fractions that correspond to a molecular weight between 400 to 2000 
Dalton.
Inhibition of diabetes by hCG-peptides
71
Figure 6 shows that in vitro stimulation of splenic DC from either LQGV or VLPALP 
treated NOD mice with LPS leads to a significantly (p<0.045) lower amount of p65 
subunit of NF-kappa B in the nucleus as compared to LPS stimulated splenic DC from 
PBS treated female NOD mice. 
 
DISCUSSION
The study presented here demonstrates that short-term (5 weeks) treatment of female 
NOD mice starting prior to the onset of the symptoms, with hCG preparations derived 
from first trimester pregnancy urine, inhibits the development of diabetes. This was 
supported by GTT testing, showing that the treated NOD mice were tolerant for glucose 
during 5 weeks of c-hCG treatment and during the follow-up period till 35 weeks of age. 
This and histochemical analysis indicated the presence of sufficient numbers of insulin-
producing β-cells. The treatment even reversed established inflammatory infiltrates of 
the pancreas as evidenced by histology. Previous studies of our department have shown 
(15) that in our NOD colony at the age of 14 weeks the mice have abundant infiltrates 
Figure 5. 
Effect of 3 weeks of oligopeptide treatment of female NOD mice (10 or 100 mg oligopeptide, three times 
a week) with either a total treatment dose of 90 mg per mouse (A) or 900 mg per mouse (B) on diabetes 
incidence. Data are from three independent experiments (5-6 animals per group). Open square (□) and 
triangle (∆) show age at which the difference in diabetes incidence is highly significant (p<0.0001, two-
tailed Fisher’s exact test) compared to the PBS group.
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and severe insulitis (stage 4/5) in their pancreas correlating with the start of clinical 
symptoms of diabetes. These infiltrates consist of T and B lymphocytes, macrophages 
and dendritic-like cells. Others have demonstrated that short-term low-dose anti-CD3 
treatment can also induce a complete remission of the diabetes when applied to adult 
NOD females within 7 days of full-blown diabetes (28). However, in the latter studies the 
remission was not associated with the disappearance of the insulitis.
Splenocytes of diabetic NOD mice contain diabetogenic T cells, which can transfer 
the disease into immuno-compromised NOD.SCID mice (18,19). Splenocytes from 
NOD mice treated with c-hCG for five weeks and from c-hCG-treated NOD mice 16 
weeks after termination of the c-hCG treatment were not able to induce diabetes in 
NOD.SCID mice. This shows the fast and prolonged inhibitory effect of c-hCG-treatment 
on diabetogenic NOD cells. In vivo and in vitro c-hCG treated diabetogenic NOD 
Figure 6. 
Effect of 5 weeks of oligopeptide treatment (three times a week, 100 mg oligopeptide) starting at the age 
of 14 weeks on NFκB activation measured in vitro as amount of LPS (100 ng/ml) stimulated p65 subunit 
present in the nucleic extract of isolated splenic DC from female NOD mice (5 mice per group).
Inhibition of diabetes by hCG-peptides
73
splenocytes produced low levels of IFN-γ, which correlated with the inability of these 
cells to transfer the disease to NOD.SCID mice. 
Further investigation also revealed the direct or indirect effect of c/u-hCG treatment 
on CD4+ T-cells of NOD mice. Such in vivo treated purified CD4+ T cells showed lower 
IFN-γ production levels under Th1 polarizing and neutral conditions. This not just 
implicates intrinsic changes in T cells to develop into Th1 cells, but also suggests a 
smaller pool of IFN-γ producing Th1 cells in vivo due to the c/u-hCG treatment. No 
significant differences were observed between the groups in IL-4 production under Th2 
polarizing and neutral conditions. Instead, upregulation of IL-10 and TGF-β production 
was observed under neutral conditions, showing that in vivo c/u-hCG treatment inhibited 
the IFN-γ production and the preferential outgrowth of Th1 cells by inducing increased 
levels of anti-inflammatory cytokines. 
Splenocytes from c/u-hCG treated BALB/c mice did not show differences in IFN-γ 
production in the Th polarization assay as compared to control mice, but did show a 
significant upregulation of IL-4 production under neutral conditions. This excludes the 
possibility of a general inhibitory effect of c/u-hCG treatment on cytokine production and 
substantiates the immunomodulatory effect of the treatment.
Several groups have reported anti-Kaposi’s Sarcoma (KS) and anti-HIV activity 
of some hCG preparations (29). This was not due to the native hCG heterodimer. In 
these studies the active moiety was thought to be β-core or an as yet unidentified hCG 
associated factor. The mechanism of action was proposed to be the selective induction 
of apoptosis or direct cytotoxic effects on the tumor cells (30). No infiltration of the tumor 
with mononuclear cells was observed, leading to the conclusion that the anti-KS activity 
could not be due to an immune-mediated response (31).
As evident by HPLC, our 400-2000 Dalton bioactivity from pregnancy urine and 
thereof derived hCG preparations eluted at a position which is far removed from the 
elution positions of hCG (38 kDa), β-hCG free subunit (>15 kDa) and β-core (> 10 
kDa). In addition, neither c/u-hCG fractions greater than 2000 Dalton, nor r-hCG, highly 
purified urinary hCG, r-α-hCG and r-β-hCG showed inhibition of IFN-γ production and 
anti-diabetic activity. This argues against the possibility that functional heterodimeric 
hCG, its subunits or β-core could be responsible for the immunomodulatory and anti-
diabetic effects. We named this 400-2000 Dalton bioactivity Natural (immuno)Modulatory 
Pregnancy Factor(s) (NMPF). Heat (30 minutes at 56oC) and protease enzyme (elastase, 
pronase) treatment abrogated the immunomodulatory effect of NMPF suggesting a 
peptide nature of the factor(s). Our data excludes that the mechanism through which 
NMPF, with a proven molecular weight between 400 and 2000 Dalton, exerts its anti-
diabetic effect and the c-hCG associated component that exerts the anti-KS/anti-HIV 
effect (30) are the same. 
We are not yet able to define the exact structure of peptide nature component(s) in 
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NMPF that is responsible for immunoregulatory effect. We designed various peptides 
from the primary structure of β hCG loop 2 since this structure is known to be especially 
prone to proteases. We postulate that the loop 2 region consisting of residues 
41-54 with amino acid sequence MTRVLQGVLPALPQ, which is absent in β core and 
is cleaved at various positions in nicked hCG, can liberate in vivo smaller fragments with 
biological activity. We synthesized several partly overlapping oligopeptides from the 
amino acid 41-54 sequence. In this report we show the effect of LQGV and VLPALP on 
the development of diabetes in NOD mice. Both oligopeptides were able to reduce the 
incidence of diabetes in NOD mice at a dose of 10 µg oligopeptide per treatment (total 
dose: 90 µg). A dose of 100 µg oligopeptide per treatment (total dose: 900 µg) did not 
significantly increase the proportion of NOD mice that did become diabetic. In contrast 
to these oligopeptides, NMPF fully inhibited the development of diabetes suggestive 
of the presence of multiple oligopeptides in NMPF. This might imply that a cocktail of 
oligopeptides from loop 2 might be able to fully inhibit the development of diabetes in 
NOD mice as NMPF did. 
Various studies have described a defective NF kappa B regulation in NOD 
DC (22-27). DC derived from NOD mice are more sensitive to various stimuli. This 
might be consistent with a role of DC in the development of diabetes in NOD mice. 
In this study we have shown that the reduction of diabetes incidence in NOD mice 
due to the treatment with LQGV and VLPALP is associated with lower in vitro LPS 
induced NF-kappa B activity in splenic DC. Whether there is a direct or indirect effect 
of these oligopeptides on NF-kappa B activation remains unknown and will be center 
of focus in future studies. Various investigators have demonstrated that DC are able 
to transfer experimental autoimmune diseases such as thyroiditis, encephalomyelitis 
and type 1 diabetes with great efficiency and play an important role in the regulation 
of the autoimmune response early in the disease pathogenesis (32,33). Treatment of 
female NOD mice with LQGV and VLPALP at 6 weeks of age did not affect the diabetes 
incidence (data not shown). Interestingly, histological examinations of the pancreatic 
tissue of the NMPF and oligopeptide (LQGV and VLPALP) treated mice at 23 weeks 
of age showed small insulin-producing islets with virtually no insulitis (data not shown) 
suggesting the induction of a regenerative process due to the treatment.
Recently, several studies have reported the reversal of type 1 diabetes in NOD 
mice by the recovered host beta cells (34-36). In these studies the beta cells recovered 
from the immune attack and proliferated to restore the beta-cell mass, showing that 
the dampening of the autoimmune attack, coupled with the recovery of residual host 
islets, underlies the cure in mice. Beta-cell mass has also been shown to increase 
under several other circumstances, including pregnancy. Mice in which the insulin 
receptor in the liver cells has been knocked out respond by increasing beta-cell mass by 
factor 10 (37). Therefore, it is possible that NMPF and loop 2 oligopeptide have effect 
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on beta-cell proliferation and regeneration in addition to the effect on immune system. 
Consequently, if we can harness the endogenous capacity of beta cells to proliferate 
and can combine this ability with a more effective blunting of the autoimmune attack in 
humans, it may well be possible to devise new treatments for type 1 diabetes. In this 
respect the oligopeptides from loop 2 of beta hCG are interesting candidates. 
In summary, our data shows that a low molecular weight fraction from first trimester 
human pregnancy urine, commercial hCG preparations and particular oligopeptides 
from loop 2 of beta hCG can prevent diabetes development in NOD mice and possibly 
other Th1 mediated autoimmune diseases. Further studies into the mechanism(s) of 
action through which these small factors exert their actions are in progress. 
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SUMMARY
Human chorionic gonadotropin (hCG) is a heterodimeric placental glycoprotein 
hormone required in pregnancy. In human pregnancy urine and in commercial hCG 
preparations (c-hCG) it occurs in a variety of forms including breakdown products. 
Several reports have suggested modulation of the immune system by intact hormone, 
but such effects of breakdown products have not been reported. In the accompanying 
paper in this issue we report that a 400-2000Da fraction from c-hCG and from human 
pregnancy urine inhibits Th1 mediated diabetes in NOD mice. The active component(s) 
were called natural (immuno)modulatory pregnancy factor(s) (NMPF). In this report we 
show that a single treatment with the same low molecular weight NMPF-fraction up to 
24 hours after high dose lipopolysaccharide (LPS) injection inhibited septic shock in 
mice. This counteracting effect of NMPF paralleled the down regulation of the effects of 
LPS on the production of macrophage migration inhibitory factor (MIF) by spleen cells, 
on the plasma level of liver aminotransferase, and on the expression of several splenic 
lymphocyte and macrophage surface markers.
Based on the primary structure of the b-chain of hCG we designed a synthetic 
hexapeptide Valine-Leucin-Proline-Alanine-Leucine-Proline (VLPALP) and showed it 
to have the same protective effects as the 400-2000Da NMPF-fraction. These results 
indicate a new strategy for the treatment of septic shock and the potential of therapeutic 
use of this synthetic oligopeptide.
INTRODUCTION
hCG is heterodimeric glycoprotein hormone produced in pregnancy by the 
placental trophoblast. It maintains the steroid secretions of the corpus luteum and 
thereby maintains the lining of the uterus for development of the embryo after its 
implantation (1). Clinical symptoms of Th1 mediated autoimmune diseases regress 
in many patients during pregnancy (2,3). In the accompanying paper (4) we showed 
for the first time the inhibition of Th1 mediated autoimmune diabetes in NOD mice by 
a fraction from hCG preparation that contains one or more 400-2000 Dalton natural 
(immuno) modulatory pregnancy factors (NMPF). It is postulated that this NMPF, 
possibly in concert with other immunomodulatory factors, accounts for an adjustment 
of the immune system during pregnancy. This adjustment is not only leading to clinical 
improvement of Th1 autoimmune diseases, but also to the maintenance of normal 
immune competence against microorganisms and suppression of the Th1-mediated 
immune response to the paternal antigens of the developing fetus.
In the present paper we investigated whether the 400-2000Da NMPF was not only 
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able to suppress the ongoing insulitis and to reverse the development of diabetes 
in NOD mice (4), but also septic shock in mice. We used high-dose endotoxin 
shock in BALB/c mice as a model of acute inflammation and human septic shock 
syndrome (5,6). In this model intraperitoneal (i.p.) injection of a high dosis of 
lipopolysaccharde (LPS) triggers an acute inflammatory response characterized by the 
rapid increase of the plasma level of liver aminotransferase and the serum level of 
proinflammtory cytokines such as macrophage migration inhibitory factor (MIF) (7). We 
show that the 400-2000Da NMPF-fraction from hCG is able to prevent and even to 
suppress mortality in mice due to LPS-induced septic shock.
hCG occurs in various forms in blood and urine during pregnancy (1,8). Apart from 
its heterogeneity of carbohydrate content, nicks at various regions of hCG, particularly 
in the b-chain, are responsible for these different forms. We designed a synthetic 
oligopeptide (i.e. VLPALP, corresponding to residues 48-53) from the primary structure 
of the b-chain of hCG with similar anti-shock activity in the endotoxin shock model as 
the 400-2000Da NMPF-fraction. 
MATERIAL AND METHODS
Mice, endotoxin shock model, and hCG-treatment
BALB/c mice were purchased from Harlan (Horst, The Netherlands) and maintained 
as described in the accompanying paper (4). For the induction of sepsis, 8-12 weeks 
old female BALB/c mice (n=10) were injected i.p. with 8 mg/kg LPS (E. coli 026:B6; 
Difco Laboratories, Detroit, MI, USA). The experiments were approved by the Animal 
Experiments Committee of the Erasmus University Rotterdam.
To test the effect of NMPF on LPS-induced septic shock, hCG-preparations from 
several sources were used: commercial hCG preparation (c-hCG; Pregnyl Organon, 
Oss, The Netherlands, Lot numbers 209893, 235863, 248455), hCG purified from 
first trimester pregnancy urine (u-hCG), the 400-2000Dalton fractions of c-hCG and 
u-hCG, recombinant hCG (r-hCG; Sigma, St. Louis, MO, USA), its subunits (r-α-hCG 
and r-b-hCG; Sigma, St. Louis, MO, USA), highly purified urinary hCG and the synthetic 
oligopeptide VLPALP designed from b-chain of hCG. BALB/c mice were treated with 
either a dose of 300 IU c-hCG, 5 mg/kg u-hCG, 0.5 mg/kg 400-2000Dalton NMPF-
fraction from c-hCG or u-hCG, 5 or 15 mg/kg NMPF peptide (VLPALP) or 5 mg/kg 
r-hCG or its subunits (r-α-hCG or r-b-hCG). This treatment was done either two hours or 
24 hours after the LPS injection. Control groups were treated with PBS instead of LPS, 
and/or PBS instead of hCG/NMPF.
Purification and dose titration of preparation of u-hCG from first trimester human 
pregnancy urine and of the 400-2000Da NMPF-fractions was done according to the 
method described in the accompanying paper (4). 
Inhibition of LPS-induced shock by hCG-peptides
83
Semi-quantitative sickness measurements 
Mice were scored for sickness severity using the following criteria. Score 1: 
percolated fur, but no detectable behaviour differences compared to untreated control 
mice; score 2: percolated fur, huddle reflex, responds to stimuli (such as tap on cage), 
just as active during handling as untreated control mice; score 3: slower response to 
tap on cage, passive or docile when handled, but still curious when alone in a new 
setting; score 4: lack of curiosity, little or no response to stimuli, quite immobile; score 5: 
laboured breathing, inable or slow to self-right after being rolled onto back (moribund); 
score 6: dead. 
Cytokine assay
Spleen cells were isolated from treated BALB/c mice 24 hours after the LPS shock 
induction as described previously (4). Splenic cell suspensions were cultured (2 x 105 
cells/well) in 96-well flat-bottom plates (0.2 ml) and stimulated with LPS (10 mg/ml). 
RPMI 1640 medium was used supplemented with 25 mM HEPES, 100 IU/ml penicillin, 
50 mg/ml streptomycin, 1 mM pyruvate, 50 mM 2-ME and 10% heat inactivated fetal calf 
serum. All cultures were performed in triplicate or quadruplicate. After incubation for 
12hrs, supernatants were collected for MIF analysis. 
The amount of MIF was measured with commercially available ELISA kit (Chemicon 
International, Temecula, CA, USA) according to the protocol provided by the 
manufacturer. The detection limit was 800 pg/ml.
Analysis of liver enzymes 
Hepatocyte damage was assessed 24 hours after LPS administration by 
measuring plasma enzyme activities of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) using commercial kits (Merck, Darmstadt, Germany) on an 
automated analyzer (ELAN-Analyzer; Eppendorf, Hamburg, Germany). 
Flow-cytometric analysis
Spleen cells were isolated from treated BALB/c mice 24 hours after the LPS shock 
induction and used for the analysis of cell surface markers. Splenic cells (2 x 105) were 
resuspended in PBS containing 1% BSA and 0.1% sodium azide (PBS-BSA-azide). For 
the staining of surface antigens, spleen cells were incubated with FITC or PE-conjugated 
mAb against CD3, B220, NK1.1, MHC-II and F4/80 (all obtained from PharMingen, San 
Diego, CA, USA). After washing twice with PBS-BSA-azide, the cells were resuspended 
and analyzed on FACScan (Becton Dickinson, San Jose, CA, USA). 10 ml propidium 
iodide (0.2 mg/ml) was added to evaluate the viability of the cells. In all samples the 
viability was higher than 94%. 104 events were collected and the expression of the 
markers analyzed using CellQuest software (Becton Dickinson).
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Statistics
Data was analyzed by Student’s T test and differences were considered significant 
at p<0.05.
RESULTS
The model for LPS-induced septic shock syndrome in BALB/c mice was standardized 
by testing various doses of E. coli 026:B6 LPS i.p. Every 12 hours the survival and 
sickness scores were assessed. For the experiments reported here, we used a treatment 
of 8 mg LPS per kg body weight (BW), which was lethal for all BALB/c mice by 60 
hours. The signs of sickness were apparent in all LPS-treated mice, but the kinetics and 
severity were different between the mice. In order to quantitate the observed differences, 
we used a semi-quantitative sickness scoring system that was standardized in several 
shock experiments using large numbers of BALB/c mice (n=30). In these experiments, 
mice i.p. injected with 8 mg LPS/kg BW achieved a sickness score (see section Material 
and Methods) of about 2 within 12 hours. At the time point of 24 hours most of the 
BALB/c mice had reached the sickness score of 3 or 4. Thereafter the mice gradually 
reached a sickness score of 5 or died (score 6). At the 60 hours time point all LPS-
injected mice were dead (score 6).
Treatment of BALB/c mice with c-hCG (300 IU) or u-hCG (5 mg/kg) 2 hours after 
LPS (8 mg/kg BW) injection increased the survival rate to 80% as compared to 0% of 
the PBS treated mice, while the 400-2000Da fraction purified from c-hCG or u-hCG (0.5 
mg/kg) prevented mortality and reduced the sickness score in all mice (Figure 1A). The 
maximum sickness scores observed in c/u-hCG and the 400-2000Da fraction treated 
groups during the experiment were 3 and 2, respectively. The score 3 was observed 
in all (10/10) c-hCG treated mice at 24 hours after LPS-injection, and the score 2 was 
observed in all (10/10) 400-2000Da NMPF-fraction treated mice at 24 hours after LPS-
injection. In the hours thereafter the mice steadily recovered, so that at 84 hours after 
the shock induction all treated mice had a sickness score not higher than 1. Two days 
later all mice had completely recovered. Similar hCG treatments using highly purified 
urinary hCG, r-hCG, r-α-hCG and r-b-hCG were ineffective (data not shown). 
HCG occurs in various forms during pregnancy. It is known that hCG and its 
uncombined subunits, especially b-hCG, are prone to proteolytic cleavage resulting in 
different forms of “nicked” hCG (8). In order to determine whether such fragments or 
other breakdown products of hCG could be responsible for the above described anti-
shock activity, we designed a synthetic oligopeptide with the amino acid sequence of 
valine-leucine-proline-alanine-leucine-proline (VLPALP) from the primary structure of 
b-hCG and tested it for its anti-shock activity in the same model. Similar to the c/u-hCG 
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Figure 1. Effect of commercial hCG preparation (c-hCG), hCG from first trimester pregnancy 
urine (u-hCG), 400-2000Da c-hCG (c-hCG fraction), 400-2000Da u-hCG (u-hCG fraction) and 
vLPALP on the survival of BALB/c mice subjected to LPS-induced septic shock. 
(A), Survival percentages and sickness scores (at 84 hours) of PBS (◊), c-hCG (□), u-hCG (٭), c-hCG 
fraction (x), and u-hCG fraction (o) treated mice. Treatment was performed 2 hours (arrow) after the 
LPS injecton. (B), Survival percentages and sickness scores (at 84 hours) of PBS (◊), c-hCG fraction 
(x), u-hCG fraction (o) and VLPALP (∆) treated mice. Treatment was performed 2 hours (arrow) after the 
LPS injection. (C), Survival percentages and sickness scores (at 84 hours) of PBS (◊), c-hCG fraction 
(x), u-hCG fraction (o) and VLPALP (∆) treated mice. Treatment was performed 24 hours (arrow) after 
the LPS injection. The results shown are from a single experiment and representative of at least three 
independent sets of experiments (each group: n=10).
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fractions, treatment of BALB/c mice with VLPALP (5 mg/kg BW) two hours after LPS (8 
mg/kg BW) injection completely inhibited mortality due to septic shock. The maximum 
sickness score observed in the VLPALP-treated mice was 2 (at 24 hours) decreasing 
to score 1 (at 60 hours), with complete recovery of the majority of the mice at 84 hours 
(Figure 1B).
Since different pathophysiological processes are involved in septic shock syndrome 
we determined whether the NMPF fractions and VLPALP have the ability to inhibit the 
septic shock in the later stages of the disease as well. Therefore, we postponed the 
400-2000Da NMPF-fraction and the VLPALP-treatment till 24 hours after the septic 
shock induction by LPS. In these experiments the same dose of NMPF fraction 
(5mg/kg) was also effective in reducing the mortality, although this delayed treatment 
was not equally effective as treatment at 2 hours after LPS-injection. After this delayed 
treatment we found an 80% survival (Figure 1C); most of the mice showed improved 
sickness scores already 24 hours after the delayed NMPF treatment. In this set-up of 
delayed NMPF treatment, VLPALP was able to reduce the mortality to 50% provided a 
threefold higher dose (15 mg/kg) was used as in the experiments employing VLPALP-
treatment 2 hours after LPS-injection. In this experiment the sickness scores of the mice 
of all 4 experimental groups ranged from 3 to 5 at 24 hours after LPS-injection, which, in 
both NMPF fraction treated groups and the VLPALP-treated group, decreased to 1 or 2 
after 84 hours. At 96 hours after LPS-injection all mice had completely recovered.
Overwhelming inflammatory responses are essential features of septic shock and 
play a central role in the pathogenesis of the tissue damage, multiple organ failure, and 
death induced by sepsis (9). Cytokines, especially macrophage migration inhibitory factor 
(MIF), once released, induce the expression of an array of proinflammatory mediators 
by macrophages and activated T cells, which strongly promote the characteristic 
inflammatory response (7). Therefore 24 hours after the shock induction, we isolated 
splenocytes from BALB/c mice, which were treated 2 hours after LPS (8 mg/kg BW) 
injection with NMPF fraction or VLPALP. These splenocytes were in vitro restimulated 
with LPS (10 mg/ml) and after 12 hours of culture the MIF levels were determined in the 
supernatants. These experiments revealed that the in vivo treatment with either NMPF 
fraction or VLPALP significantly inhibited the MIF production as compared to PBS- 
treated mice subjected to high dose LPS-administration (Figure 2A). We did not find 
significant differences in MIF levels produced by LPS-stimulated splenocytes obtained 
from mice not previously injected with LPS, but only treated with NMPF fractions or 
VLPALP as compared to PBS (Figure 2B). 
Consistent with the clinical improvement induced by NMPF fraction or VLPALP-
treatment, and the MIF release reducing effects of these treatments, NMPF fraction 
and VLPALP reduced the plasma levels of both ALT and AST liver enzymes in the LPS-
injected mice (Figure 2C,D). The plasma levels of these enzymes in mice treated with 
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Figure 2.  Effect of 400-2000Da NMPF-fraction from c-hCG (c-hCG fraction) and u-hCG (u-hCG 
fraction), and vLPALP on the in vitro MIF production by spleen cells and on the plasma 
aminotransferase levels of septic shock mice. 
(A) MIF levels in cultures of splenocytes isolated from LPS-injected mice 24 hours after LPS-injection. 
The mice were treated with PBS, c-hCG fraction, u-hCG fraction or VLPALP 2 hours after LPS injection. 
(B) MIF levels in cultures of splenocytes isolated from PBS-injected control mice 24 hours after PBS-
injection. The mice were treated with either PBS, c-hCG fraction, u-hCG fraction or VLPALP 2 hours after 
PBS-injection (i.e. 22 hours before harvest of the spleen cells). (C) Plasma alanine aminotransferase 
(ALT) and (D) plasma aspartate amniotransferase (AST) levels of mice 24 hours after LPS-injection and 
treated (at 2 hours after LPS-injection) with either PBS, c-hCG fraction, u-hCG fraction or VLPALP. The 
results presented are from a single experiment and representative of at least three independent sets of 
experiments (n=6).
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NMPF fraction or the oligopeptide VLPALP only (and not previously with LPS) were not 
significantly different as compared to PBS-treated mice (data not shown). 
Activation of cellular immune responses requires the expression of major 
Figure 3. Effect of vLPALP (and PBS as control) on the expression of several surface markers 
on spleen cells of BALB/c mice i.p. injected with LPS or PBS as a control. vLPALP (and PBS as 
control) injection was done 2 hours after the injection of LPS (and PBS as control). 
(A), Mean fluorescence intensity (MFI) of MHC II on B220+ cells; (B) MFI of MHC II on F4/80+ cells; and 
(C) percentage of NK1.1+CD3+ cells. Solid bars represent LPS-injected mice; hatched bars represent 
PBS-injected mice. These results are from one experiment and are representative of at least three 
independent sets of experiments, (n=6).
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histocompatibility complex (MHC) molecules on cells of the innate (macrophages) and 
adaptive (B cells) immune systems (10). In sepsis the upregulation of MHC class II 
(MHC II) molecules on macrophages and B cells is a hallmark of the overactivated 
immune system (11). Therefore, we also examined the influence of VLPALP-treatment 
on MHC II expression on F4/80+ (macrophage marker) and B220+ (B cell marker) cells 
during septic shock. In these experiments the LPS-induced MHC II expression on 
both splenic cell populations was significantly decreased in mice treated with VLPALP 
(Figure 3A,B). Mice treated with VLPALP alone (and not previously with LPS) did not 
show a significant change in MHC II expression. Remarkably, mice treated with LPS 
and VLPALP showed an increased percentage of splenic NK1.1+CD3+ cells (Figure 3C). 
Treatment of mice with LPS or VLPALP alone did not show such difference (p=0.44 and 
p=0.15, respectively) as compared to PBS treated mice (Figure 3C).
DISCUSSION
In pregnancy the immune system is tightly regulated in order to maintain the co-
existence of mother and fetus (12). Many women experience less disease severity 
or even remission of Th1 mediated autoimmune diseases during pregnancy. This 
epiphenomenon has been attributed at least in part to a shift from a “Th1” to a “Th2” state of 
the immune system during pregnancy (12), leading to view that pregnancy is associated 
with a state of immunosuppression. Considering that pregnant women in general do 
not show an increased susceptibility to infections, this supposed immunosupression 
must be quite selective in order to provide for the required immunological homeostasis 
between mother and fetus. We have shown in the accompanying paper (4) that a 400-
2000Da NMPF fraction from pregnancy urine and commercial hCG preparation inhibits 
Th1-mediated diabetes in NOD mice. The data presented in the present report show that 
the same NMPF fraction is also capable of inhibiting an acute inflammatory response as 
is the case in high-dose LPS-induced septic shock in mice.
The pathophysiology of septic shock shares characteristics of systemic inflammatory 
response syndrome (SIRS) and multisystem organ failure (MOF) involving bacterial 
products, immunocompetent cells, soluble mediators, and cell-cell interactions between 
blood cells and endothelium (9,12). In the high-dose LPS model for septic shock in mice, 
hCG-derived NMPF, including the synthetic peptide VLPALP, were found to be capable 
of inhibiting the disease severity as well as mortality. This effect was not only apparent 
from the clinical symptoms, but also from the inhibition of the in vitro MIF production 
and the inhibition of the plasma aminotransferase levels and the cellular characteristics 
in the spleen. The LPS-induced increase of plasma aminotransferase level is indicative 
for liver damage which plays a crucial role in septic shock (6).
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Several reports have suggested immunosuppressive and antiproliferative effects of 
hCG in vitro (13,14). In these experiments the main sources of the intact hormone were 
pregnancy urine, commercial hCG preparations and recombinant hCG. In view of the 
anti-diabetic (4) and the anti-shock effects of the 400-2000Da NMPF fraction of hCG 
and the anti-shock effect of the synthetic oligopeptide VLPALP, it is possible that the 
previously reported immunosuppressive and antiproliferative effects were due to hCG 
break down products.
It is of interest that the low molecular weight NMPF fractions and VLPALP were 
also able to decrease the clinical symptoms and mortality due to septic shock when 
treatment was given as late as 24 hours after LPS-administration. Apparently the 
active component(s) interfered with the inflammatory process and the tissue damage 
underlying the clinical symptoms. Preliminary data also shows the inhibition of exotoxin 
shock induced by toxic shock syndrome toxin (TSST-1) by NMPF (data not shown), 
which indicates that the anti-shock activities of NMPF are not limited to endotoxin shock. 
These properties fulfill essential requirements for any anti-sepsis agent, as in patients 
treatment is always started after the onset of the clinical symptoms of septic shock.
The down-regulation of MHC II expression both on macrophages and activated B 
cells may not only be beneficial in controlling acute inflammatory responses, but likely 
also in chronic inflammatory immune reactions, particularly in autoimmunity in which 
MHC II expression plays a critical role in the presentation of autoantigens to T cells (10). 
This suggests that VLPALP might also be effective in the prevention and possibly the 
suppression of autoimmunity. In Figure 3 we showed that NMPF peptide upregulated the 
percentage of NK1.1+CD3+ cells. These so-called natural killer-T cells (NKT cells) are a 
subpopulation of T cells that share some characteristics with NK cells (15,16). NKT cells 
are phenotypically, functionally and developmentally heterogeneous. In general three 
distinct subsets (CD4+, CD8+, and CD4-CD8-) are known. These subpopulations are 
differentially distributed in a tissue-specific fashion (16). We do not know yet to which 
subset(s) the VLPALP-induced NKT cell subpopulation belongs. NKT cells are believed 
to be involved in immune responses ranging from suppression of autoimmunity to tumor 
rejection (16,17).
Most interesting is the observation that the 400-2000Da NMPF fractions and VLPALP 
did not affect the splenic MIF-production, the plasma aminotransferase levels, the MHC 
II expression on splenic macrophages and B cells, and the proportion of NK1.1+CD3+ 
double positive cells in the spleen of otherwise untreated mice. This strongly suggests 
that NMPF do not have a general immunosuppressive effect, but correct disturbances 
of the immune homeostasis as occurs after high dose LPS-injection and during the 
development of diabetes in NOD-mice (4). This warrants studies on the therapeutic 
potential of VLPALP and related NMPF in inflammation, autoimmunity, transplantation, 
allergy and related conditions, including pre-eclampsia and tumor rejection. 
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In summary, our data shows that a low molecular weight fraction from first trimester 
human pregnancy urine and the novel synthetic oligopeptide VLPALP designed from 
b-hCG can inhibit septic shock in BALB/c mice. Moreover, we showed for the first 
time that hCG fragments can regulate the immune balance and therefore might be of 
potential value to correct dysregulation of the immune system in a variety of immune 
and inflammatory diseases.
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ABSTRACT
The marked improvement of several immune-mediated inflammatory diseases 
during pregnancy has drawn attention to pregnancy hormones as potential therapeutics 
for such disorders. Low molecular weight fractions derived from the pregnancy hormone 
human chorionic gonadotropin (hCG) have remarkable potent immunosuppressive 
effects in mouse models of diabetes and septic shock. Based on these data we have 
designed a set of oligopeptides related to the primary structure of hCG and tested 
these in models of septic shock in mice and rhesus monkeys. We demonstrate that 
mice exposed to lipopolysaccharide (LPS) and treated subsequently with selected tri-, 
tetra-, penta- and hepta-meric oligopeptides (i.e. MTR, VVC, MTRV, LQGV, AQGV, 
VLPALP, VLPALPQ) are protected against fatal LPS-induced septic shock. Moreover, 
administration of a cocktail of three selected oligopeptides (LQGV, AQGV and VLPALP) 
improved the pathological features markedly and nearly improved haemodynamic 
parameters associated with intravenous Escherichia coli-induced septic shock in rhesus 
monkeys. These data indicate that the designed hCG-related oligopeptides may present 
a potential treatment for the initial hyperdynamic phase of septic shock in humans.
INTRODUCTION
In immunological terms, pregnancy is an improbable symbiosis of two major 
histocompatibility complex (MHC)-incompatible individuals. Pregnant women are 
eminently capable of combating infections and often produce antibodies against 
paternal alloantigens of the fetus, demonstrating that they are fully immunocompetent. 
Nevertheless, a remarkable improvement of several immune-mediated inflammatory 
diseases, such as rheumatoid arthritis and multiple sclerosis, is often observed during 
pregnancy (1,2). These well-known, albeit poorly understood, features are suggestive 
for a selective modulation of the immune system in such a way that harmful immune 
processes to mother and fetus are suppressed, while beneficial immune processes are 
not affected. Certain hormones that are produced exclusively during pregnancy, such 
as oestriol or human chorionic gonadotropin (hCG), have been held responsible for the 
selective modulation of adverse immunological functions (2–4).
Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein produced by 
trophoblasts (5). Its main hormonal function is to preserve the lining of the uterus, which 
is needed for the healthy development of the implanted embryo (5). Activity-guided 
purification of commercial hCG preparations has shown that oligomeric degradation 
products represent a significant part of the immunosuppressive activity in immune-
mediated inflammatory disease models (6,7), but they lack the endocrine effects of 
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the complete protein. These capacities make hCG-derived oligopeptides a potentially 
interesting source of therapeutics for immune-mediated inflammatory diseases.
The aim of the current study was to test whether such oligopeptides related to hCG 
can also reduce the severity of lipopolysaccharide (LPS)-induced and Escherichia 
coli-induced septic shock. Contamination of the bloodstream with bacteria or bacterial 
endotoxins (e.g. LPS) can cause massive activation of complement and the release 
of proinflammatory cytokines, such as tumour necrosis factor (TNF)-α(8). Irrespective 
of the origin (infectious or non-infectious), this leads to life-threatening haemodynamic 
changes, such as tachycardia and hypotension culminating in multi-organ failure. 
Without adequate treatment, septic shock can be lethal within a few days after onset.
Sepsis is the second leading cause of death in intensive care units (ICUs) in the 
United States (9,10) and is responsible for about 10% of overall deaths annually (11). 
There is a high unmet need for a safe and effective treatment of septic shock, particularly 
to prevent the irreversible multiple organ failure stage.
For the present study we designed a set of hCG-related oligopeptides all related 
to loop 2 of the β-chain, namely MTR, MTRV, LQG, LQGV, VLPALP, VLPALPQ and 
VVC, as well as an alanine variant of LQGV, namely AQGV. This selection was based 
on known nick sites in this loop (12–14). The oligopeptides were first tested in a murine 
LPS infusion model for attenuation of septic shock. The mouse study yielded three 
peptides that rescued 100% of the mice from death after 48 h, namely AQGV, LQGV 
and VLPALP. These three oligopeptides were tested subsequently as a cocktail for 
the rescue of rhesus monkeys from septic shock induced by infusion of living E. coli. 
Administration of a single dose of the oligopeptide cocktail delayed the manifestation 
of septic shock symptoms, reduced pathomorphological changes markedly in the 
gastrointestinal tract and nearly normalized the haemodynamic parameters.
Collectively, the reported data show that the tested oligopeptides are well tolerated 
and display promising therapeutic effects in two relevant animal models of septic 
shock.
MATERIAL AND METHODS
Animals 
Mice. Female 8–16-week-old BALB/c mice were used. The mice were bred under 
specific pathogen-free conditions according to the protocols described in the Report 
of the Federation of European Laboratory Animal Science Association’s (FELASA) 
working group on animal health (15). The mice were bred and used in the facilities for 
experimental animals of the Erasmus MC. The mice had access to pelleted food (Hope 
Farms, Woerden, the Netherlands) and sterilized water ad libitum.
Inhibition of septic shock by hCG-peptides
97
Rhesus monkeys. Eight healthy female rhesus monkeys (Macaca mulatta) were 
purchased from the purpose-bred breeding colony at the Biomedical Primate Research 
Centre. Individual data of the monkeys are given in Table 1. Prior to inclusion in 
the experiment, monkeys received a physical health check and were tested for 
haematological, serological and microbiological abnormalities. Only monkeys that were 
declared healthy by the institute’s veterinarian staff were entered into the experiment.
Oligopeptides 
Selection was based on either the known preferential cleavage sites or known nick 
sites of the sequence MTRVLQGVLPALPQVVC (aa41–57) of loop 2 (Figure 1) of the 
β-subunit of hCG (12–14,17). Oligopeptides selected for the in vivo studies reported in 
this publication were the most effective in pilot studies, i.e. MTR (aa41–43), MTRV (aa41–44), 
LQG (aa45–47), LQGV (aa45–48), AQGV (alanine replaced oligopeptide of LQGV; aa45–48), 
VLPALP (aa48–53), VLPALPQ (aa48–54) and VVC (aa55–57). Oligopeptides were synthesized 
(Ansynth BV, Roosendaal, the Netherlands) using the fluorenylmethoxycarbonyl (Fmoc)/
tert-butyl-based methodology with a 2-chlorotritylchloride resin as the solid support.
LPS-induced acute septic shock in mice
Female 8–12-week-old BALB/c mice (n = 5–6 per group) were injected intraperitoneally 
(i.p.) with a lethal dose of LPS (8 mg/kg; E. coli 026:B6; Difco Laboratories, Detroit, MI, 
USA). This procedure leads to 100% death within 84 h. Mice were treated subsequently 
with either a single i.p. dose of phosphate-buffered saline (PBS) or oligopeptide (5 mg/
kg) in PBS at 2 h or 24 h post-LPS challenge. The optimal oligopeptide dose for this 
model has been defined in a previous study (7). Survival of the mice was monitored 
Table 1. Individual rhesus monkey data and treatment regimen.
Treatment group Animal ID Gender Date of
birth
Date     
experiment
Age
(years)
Weight
(kg)
I Control; 
termination after 8 h
(mean age 7.1 yr)
Ri429
Ri274
Ri8012
F
F
F
15-01-96
24-02-98
01-08-98
28-11-01
24-08-05
20-09-06
5.8
7.5
8.1
5.6
4.9
5.8
II Oligopeptide cocktail;
termination after 8 h
(mean age 7.1 yr)
Ri459
Ri7046
Ri11152
F
F
F
21-06-96
03-07-98
07-11-98
28-11-01
20-09-06
27-09-06
5.4
8.2
7.8
5.4
5.7
5.3
III Oligopeptide cocktail;
recovery allowed
(mean age 8.0 yr)
Ri 427
C 152
F
F
17-06-96
14-02-95
28-11-01
24-08-05
5.4
10.5
4.8
6.2
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for 84 h at least three times per day. Mice were scored in a semi-quantitative fashion 
(scores 1–6) for sickness severity, as described previously (7).
LPS and CD3-induced proliferation of splenocytes
Sixteen-week-old female BALB/c mice (n = 5 per group) were injected i.p. with 
either LQGV or AQGV (5 mg/kg) or the equivalent volume of solvent (PBS). After 1 h 
of treatment the mice were killed and spleens were isolated. Five spleens from a group 
were pooled and splenocytes were isolated. For T cell stimulation splenocytes were 
Figure 1. Structure of β-human chorionic gonadotropin (hCG) with loop 2 and the amino acid 
sequence of loop 2 indicated. 
Adapted from Lapthorn et al. (16). Arrows point to the preferential cleavage sites in loop 2 (aa41–57).
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cultured (2•5 × 105 cells/well) in 96-well flat-bottomed plates (0•2 ml) in triplicate and 
stimulated with anti-CD3 (145-2C11, 10 mg/ml) in combination with interleukin (IL)-2 
(Biosource, CA, USA; 40 U/ml). For B cell and macrophage stimulation, splenocytes 
were cultured (5 × 105 cells/well) in 96-well round-bottomed plates (0•2 ml) in triplicate 
and stimulated with 10 mg/ml of LPS (E. coli 026:B6; Sigma; 69H4022) or with PBS. 
Splenocytes were then incubated at 37°C in 5% CO2 for 12, 24, 36 or 48 h. During the 
final 8–12 h of culture 0•5 mCi of (3H)-thymidine ((3H)TdR) per well was added and the 
incorporation of (3H)TdR was measured on a beta-plate counter.
E. coli-induced acute septic shock in adult rhesus monkeys
Bacteria. The E. coli strain used for septic shock induction was purchased from the 
American Type Culture Collection (ATCC) (E. coli 086a: K61 serotype; ATCC 33985). In 
a control experiment the strain had proved equally sensitive to complement-mediated 
lysis in fresh human and rhesus monkey serum (data not shown).
Prior to the experiment a fresh E. coli culture was set up in brain heart infusion (BHI) 
culture broth. The E. coli strain was cultured for 1 day, harvested and washed five times 
to remove free endotoxin. Just prior to infusion into the monkey a sample of the bacteria 
suspension was collected to assess the concentration and viability. To this end, serial 
dilutions of the E. coli stock were plated on BHI agar and cultured overnight at 37°C. 
The colonies on each plate were counted and the numbers of colony-forming units 
(CFU)/ml were calculated. The body weight measurement on the day of the experiment 
was used to calculate the E. coli dose (1010 CFU/kg). The E. coli stock was suspended 
in pyrogen-free isotonic saline (NPBI, Emmer Compascuum, the Netherlands) adjusted 
to the required concentration, and kept on ice until infusion. Just prior to infusion the 
total dose was resuspended in a volume of 50 ml isotonic saline of room temperature.
Preparation of the animals. Monkeys were fasted overnight prior to the experiment. 
On the morning of the experiment the monkeys were sedated with ketamine hydrochloride 
(AST Pharma, Oudewater, the Netherlands) and transported to the operation chamber. 
Monkeys were placed on their side on a temperature-controlled heating pad to support 
body temperature. Body core temperature was monitored using Ohmeda Excel 210 
SE anaesthesia equipment (Datex-Ohmeda, Hoevelaken, the Netherlands). Monkeys 
were intubated orally and allowed to breathe freely. The femoral or cephalic vein was 
cannulated and used for infusion of isotonic saline, live E. coli, antibiotics and the 
oligopeptide cocktail. Fluid loss was compensated by infusing isotonic saline containing 
2•5% glucose (Fresenius, ‘s-Hertogenbosch, the Netherlands) at a rate of 3•3 ml/kg/h. 
To avoid discomfort to the monkeys they were kept anaesthetized using O2/N2O/
isoflurane inhalation anaesthesia during the two E. coli infusions and a 6-h observation 
period following E. coli challenge. The monkeys were kept under constant veterinary 
inspection during the complete time-course of the experiment.
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Induction of septic shock. A 1-h time-period was included to monitor baseline values 
of heart rate and blood pressure prior to infusion of E. coli. Septic shock was induced 
by infusion of a fatal dose (1010 CFU per kg body weight) of live E. coli over a period of 
2 h followed immediately by intravenous (i.v.) administration of the bacteriostatic agent 
Enrofloxacin (dose: 9 mg/kg; Enrofloxacine (Baytril 2•5%); Bayer, Mannheim, Germany) 
to kill surviving bacteria and to synchronize shock induction. In two independent (dose 
titration) studies with the chosen E. coli strain, a dose of 1010 CFU/kg body weight-
induced acute shock leading to death about 8 h after start of the infusion (unpublished 
observations). Thirty minutes after the start of E. coli infusion the monkeys received a 
single i.v. bolus injection (1 ml per kg body weight) of oligopeptide cocktail containing 
LQGV, AQGV and VLPALP at a concentration of 5 mg/ml each; the dose was extrapolated 
from initial studies in mice (7). The peptide solution was injected into the i.v. cannula 
via which isotonic saline was infused continuously. For experimental reasons explained 
in the Results section, monkey Ri427 was allowed to recover after 8 h and received no 
further treatment. Monkey C152 was allowed to recover after 8 h and received a second 
treatment at this time-point and a third treatment at 24 h.
Pathology
Post-mortem examination of all monkeys was conducted immediately after the 
monkeys were killed. The monkeys underwent gross necropsy in which the abdominal 
and thoracic cavity was opened and internal organs were examined in situ. Pictures 
were made of the internal organs of some of the monkeys. Tissues of all organs were 
preserved in neutral aqueous 4% solution of phosphate-buffered formaldehyde and 
processed subsequently for histopathological examination by a pathologist.
Cytokine production
Cytokine levels in plasma were analysed using  Cytometric Bead Array™ (CBA; BD 
Biosciences, San Diego, CA, USA). TNF-α, IL-1β, IL-6 and IL-8 were detected using 
the human inflammation CBA kit. Tests were performed according to the manufacturer’s 
instructions and known to have cross-reactivity with rhesus monkey. The results were 
expressed as pg/ml. The limits of detection were as follows: 2•6 pg/ml TNF-α, 7•2 pg/ml 
IL-1β, 2•5 pg/ml IL-6, 3•6 pg/ml IL-8.
Statistics
Data were analysed by two-tailed Fisher’s exact test and unpaired Student’s t-test. 
Data differences were considered significant at P < 0•05.
Ethics
The protocols of the mouse studies have been reviewed and approved by the 
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Animal Research Ethics Committee of Erasmus MC (Rotterdam, the Netherlands). 
The protocols of the rhesus monkey studies have been reviewed and approved by 
the Animal Research Ethics Committee of the Biomedical Primate Research Centre 
(Rijswijk, the Netherlands).
RESULTS
Effects of hCG-related oligopeptides on LPS-induced mortality in mice
Intraperitoneal injection of LPS in BALB/c mice induced a fatal septic shock leading 
to 100% mortality within 84 h. Several synthetic oligopeptides related to loop 2 of the 
hCG β-chain (Figure 1) had a marked protective effect on the morbidity and mortality 
induced by the LPS administration. In the first series of experiments a single dose 
(5 mg/kg body weight) of the individual oligopeptide or PBS as control was administered 
2 h after the LPS injection. At the 48 h time-point all (17 of 17) LPS-injected mice 
receiving PBS were dead (Figure 2a, PBS). Oligopeptides LQGV and the alanine-
substituted derivative AQGV were equally effective as VLPALP in rescuing mice (17 
of 17) from LPS-induced septic shock (Figure 2a). In a previous study (7) the latter 
peptide was found to prolong survival time beyond 72 h when administered 2 h after 
a lethal challenge of LPS. In the second series of experiments a single dose of the 
individual peptides was given 24 h after the LPS administration. Here, five of the eight 
oligopeptides prevented mortality completely (Figure 2b). Of all eight oligopeptides 
tested in this model, only AQGV rescued all (17 of 17) mice from septic shock when 
administered early (at 2 h) as well as late (at 24 h) after LPS-injection.
Signs of sickness were apparent in all LPS-treated mice, but the course and severity 
differed between individual animals. In order to quantify the observed differences, a 
semiquantitative sickness scoring system was used, with severity scores ranging 
from 0 to 6. In these experiments, mice injected i.p. with 8 mg LPS/kg body weight 
reached a sickness score of 2 or 3 within 14 h. At 24 h, most of the mice had reached a 
sickness score above 4. Thereafter the mice progressed gradually to a sickness score 
of 5 or had succumbed (score 6). Injection of LQGV, VLPALP or AQGV 2 h after LPS 
injection reduced the average sickness scores to less than 2 at 84 h after LPS injection 
(Table 2). The other oligopeptides were less effective. Although LQGV, VLPALP and 
AQGV all rescued mice from the fatal outcome of septic shock and reduced sickness 
scores, AQGV treated mice had significantly (P < 0•01) lower sickness scores at 48 h 
after LPS injection than LQGV- and VLPALP-treated mice. Treatment of BALB/c mice 
with either MTR, MTRV, VLPALPQ, VVC or AQGV at 24 h after LPS injection rescued all 
mice from septic shock. Here, mice treated with AQGV also had significantly (P < 0•01) 
lower sickness scores 48 h after LPS injection compared to mice treated with MTR, 
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Figure 2. Survival of mice with lipopolysaccharide (LPS)-induced septic shock after treatment 
with a single dose of different human chorionic gonadotropin (hCG)-related oligopeptides. 
Mice were treated with the following oligopeptides (5 mg/kg body weight i.p.): phosphate-buffered saline 
(PBS) (red triangle) MTR (aa41–43; black circle, dashed line), MTRV (aa41-44; brown circle, dashed line), 
LQG (aa45–47; green triangle), LQGV (aa45–48; blue diamond), AQGV (alanine replaced oligopeptide of 
LQGV; aa45–48; orange diamond), VLPALP (aa48–53; black diamond), VLPALPQ (aa48–54; black triangle) and 
VVC (aa55–57; green circle, dashed line). Mice were treated either 2 h (a) or 24 h (b) after administration 
of LPS intraperitoneally. Cumulative data are presented from three independent experiments (five to six 
animals per group/experiment). The survival percentages at 84 h were highly significant (P = 0•000001, 
two-tailed Fisher’s exact test) for peptides LQGV, AQGV and VLPALP at 2 h and for peptides MTR, 
MTRV, VLPALPQ, VVC and AQGV compared to the PBS group.
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MTRV, VLPALPQ and VVC. Remarkably, AQGV not only prevented mortality but also 
reduced the average sickness score from 4•2 at the time of treatment to 1•5 60 h later. 
Two days later all mice that were rescued from septic shock death by the oligopeptide 
treatment had recovered and had a sickness score of 1 or no longer had any signs 
of sickness. The other oligopeptides were less effective in reducing sickness scores 
(MTR, MTRV, VLPALPQ, VVC) and preventing mortality (LQG, LQGV, VLPALP).
LPS and CD3-induced proliferation of splenocytes
The effect of LQGV and AQGV on systemic immune activation was assessed by 
measuring splenocyte proliferation in response to a T cell stimulator (anti-CD3 and IL-2) 
and a B cell and macrophage stimulator (LPS).
Splenocytes derived from LQGV and AQGV-treated mice had a significantly 
(P < 0•05) reduced in vitro proliferative response to CD3/IL-2 after 24 h of stimulation 
(Figure 3). Splenocytes derived from AQGV-treated mice also showed a significantly 
(P < 0•05) reduced in vitro proliferative response to LPS (Figure 3). Both LQGV 
and AQGV treatment were associated with a significantly (P < 0•05) reduced basal 
proliferation level (data not shown).
Table 2. Average sickness scores of mice with lipopolysaccharide (LPS)-induced septic shock 
after treatment with a single dose of different human chorionic gonadotropin (hCG)-
related oligopeptides.
 Average sickness scores after time interval (hr)*
Treatment 2 h after LPS induction  24 h after LPS induction
 0 14 24 48 84  0 14 24 48 84
PBS 0.0 2.8 4.3 -† -  0.0 3.0 4.5 - -
MTR 0.0 2.5 3.0 4.2 2.3  0.0 2.8 4.3 3.8‡ 3.0‡
MTRV 0.0 2.7 4.0 4.0 3.5  0.0 3.0 4.8 3.3‡ 3.2‡
LQG 0.0 3.0 4.7 - -  0.0 2.7 4.7 - -
LQGV 0.0 2.5 3.0 2.7‡ 1.2  0.0 2.8 4.2 - -
VLPALP 0.0 2.5 3.2 2.8‡ 1.7  0.0 2.5 4.0 - -
VLPALPQ 0.0 3.2 4.5 - -  0.0 3.2 4.5 2.7 2.7‡
VVC 0.0 2.8 4.2 4.4 3.7  0.0 3.3 4.7 2.7 2.8‡
AQGV 0.0 2.0 2.3 1.7 1.0  0.0 2.7 4.2 1.8 1.5
*Mice were treated with the various oligopeptides (5 mg/kg body weight intraperitoneally (i.p.)) 2 h or 24 h after 
administration of LPS i.p. (n = 6).  † Indicates that none the mice had survived at that time-point.  ‡ Indicates that 
the sickness scores are significantly higher than the AQGV-treated group (P < 0•01). 
Mice were scored for sickness severity as described previously (7) using the following criteria: score 1: percolated 
fur, but no detectable behaviour differences compared with untreated control mice; score 2: percolated fur, huddle 
reflex, responding to stimuli (such as tap on cage) and just as active during handling as untreated control mice; 
score 3: slower response to tap on cage, and passive or docile behaviour when handled, but still curious when 
alone in a new setting; score 4: lack of curiosity, little or no response to stimuli, and defect mobility; score 5: 
laboured breathing and impaired righting reflex; score 6 was defined as death. The results illustrated are from 
a single experiment and representative of at least three independent sets of experiments (each group: n = 6). 
PBS: phosphate-buffered saline.
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Treatment of E. coli-induced septic shock in rhesus monkeys
The three most promising oligopeptide candidates from the septic shock experiments 
in mice – AQGV, LQGV and VLPALP – were selected for evaluation in a preclinical 
model of E. coli-induced septic shock in rhesus monkeys.
Control animals (group I, consisting of monkeys numbered Ri429, Ri274, Ri8012) 
received 0•9% sodium chloride solution starting at 30 min after initiation of the infusion 
of the E. coli. These monkeys were not allowed to recover from anaesthesia and 
were killed 8 h after start of the infusion. Three other monkeys (group II, consisting of 
monkeys numbered Ri459, Ri7046, Ri11152) received a bolus injection of a cocktail 
containing the three selected oligopeptides (LQGV, AQGV, VLPALP; 5 mg/kg for each 
of the oligopeptides) dissolved in 0•9% sodium chloride solution 30 min after initiation 
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CD3/IL-2 and LPS induced proliferation
Figure 3. The effect of in vivo treatment of BALB/c mice with the oligopeptides LQGv and 
AQGv (5 ml/kg) on (A) the in vitro CD3/IL-2, and (B) the LPS-induced splenocyte proliferation.
Both oligopeptides significantly (*P < 0•05) reduced in vitro the capacity of the splenocytes to proliferate 
upon CD3/IL-2 stimulation. However, splenocytes derived from AQGV peptide-treated mice also showed 
significantly (*P < 0•05) reduced in vitro proliferative response to LPS after 24 h of stimulation, while 
no significant differences in in vitro proliferative response of splenocoytes derived from LQGV peptide-
treated mice to LPS were found. The results presented are from a single experiment and representative 
of at least three independent sets of experiments (n = 5). 
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of the E. coli infusion. Throughout the experiment the clinical condition of the monkeys 
was monitored. At 6 h the veterinarian responsible was asked whether the clinical 
condition would allow recovery from anaesthesia. Although this was approved in two 
of the three treated monkeys, these were nevertheless killed to compare the organ 
histopathology with the control monkeys. Two additional monkeys (group III, numbered 
Ri427, C152), which also received a bolus injection of the oligopeptide mix 30 min 
after initiation of the E. coli infusion, were allowed to recover from the anaesthesia at 
the veterinarian’s consent on the basis of the clinical condition, and remained under 
constant supervision.
The clinical observations made by the veterinarian are summarized in Table 3. 
In the saline-treated control monkeys (group I) the septic shock crisis started 30 min 
after start of the E. coli infusion (= time-point ‘post-E. coli’). The condition of the animals 
worsened rapidly and displayed the typical signs of a septic shock crisis, characterized 
by highly unstable blood pressure and oxygen saturation (data not shown), disturbed 
electrocardiogram (ECG) output and several other abnormal clinical parameters 
(Table 3). The condition of the monkeys treated with the oligopeptide cocktail (groups 
II and III) was much more stable, except in monkey Ri11152. During the first 8 h of 
the experiment, four of five peptide-treated monkeys had a stable heart rate (data not 
shown), normal ECG and normal or depressed respiration (Table 3); however, depressed 
respiration was deep but regular. The outlier peptide-treated monkey Ri11152 displayed 
signs of a transient crisis which was far less serious than in the saline-treated control 
monkeys (Table 3). This monkey was deemed unfit for recovery from anaesthesia and 
was killed at 8 h.
Monkey Ri7046 showed only mild signs of septic shock, but although deemed fit 
for recovery it was killed at 8 h post-E. coli infusion. Monkey Ri459 was in good clinical 
condition 8 h post-E. coli infusion, but was nevertheless killed to allow pathological 
examination and comparison with control animals. The monkeys in group III (Ri427 and 
C152) were allowed to recover from anaesthesia and remained free of septic shock 
symptoms for 33 h and 36 h, respectively, and succumbed with serological evidence of 
organ failure. From this group, Ri427 had not received additional oligopeptide treatment 
while C152 had received two additional injections at 8 h and 24 h post-E. coli infusion.
Taken together, three of three saline treated-monkeys developed severe septic 
shock within 6 h after E. coli infusion. In contrast, three of five monkeys treated with 
the peptide cocktail remained completely devoid of septic shock symptoms during the 
initial observation period of 8 h. The two monkeys that were allowed to recover from 
anaesthesia (Ri427 and C152) finally developed signs of multiple organ failure. In the 
one oligopeptide cocktail-treated monkey that showed clinical signs of septic shock, 
these were far less serious than in the saline-treated control monkeys.
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Table 3. Clinical observations during the first 8 h after induction of septic shock in rhesus 
monkeys.
Treatment Animal ID Clinical observation veterinarian
Group I
PBS; termination 
after 8 h
Ri429 At 8 h the animal showed faecal vomiting 
and convulsions. No pulse and arrhythmia. 
An abnormal ECG. During the last hours 
the animal displayed forced respiration and 
decreased blood clotting as indicated by 
continued bleeding after blood extraction.
No recovery allowed
Ri274 A progressively decreasing heart rate and 
blood pressure was observed. The animal 
also developed arrhythmia. The oxygen 
saturation could hardly be measured and 
at the end decreased rapidly. The animal 
became increasingly unstable.
No recovery allowed
Ri8012 After administration of the Esherichia coli 
there was a rapid development of oedema 
above they eyes and also in the lungs. In 
the final phase the animal displayed forced 
respiration and bronchi at auscultation 
indicative of oedema of the lungs. Abnormal 
ECG. The animal became increasingly 
unstable.
No recovery allowed
Group II
Peptide cocktail; 
termination after 
8 h
Ri459 The animal had a good pulse and a normal 
ECG. The heart sounded normal and lungs 
sounded clean. Although the animal displayed 
depressed respiration, the respiration was 
deep and regular. 
Recovery allowed
Ri7046 The animal remained stable during the 
observation period. The animal developed 
mild oedema after infusion of Escherichia 
coli. The animal showed mild depressed 
respiration, but it was deep and regular.
Recovery allowed
Ri11152 Initial stable clinical parameters became 
less stable after infusion of Escherichia coli. 
After administration of Enrofloxacin a stable 
increased heart frequency was measured but 
blood pressure became difficult to assess. In 
the later phase of the disease oedema was 
diagnosed after auscultation necessitating 
repositioning of the animal on his side so that 
the animal could breath more freely. In the 
final phase the lungs sounded normal but an 
abnormal ECG was measured.
No recovery allowed
Group III
Peptide cocktail; 
recovery allowed
Ri 427 The animal had a good pulse and a normal 
ECG. The heart sounded normal. The left 
lung displayed a slight murmur but overall 
sounded good. This animal had a normal 
regular respiration.
Actually recovered
C 152 The animal had a good pulse and a normal 
ECG. The heart sounded normal and the 
lungs sounded clean at 8 h. This animal 
had a normal respiration and stable clinical 
parameters.
Actually recovered
ECG: electrocardiogram; PBS: phosphate-buffered saline.
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Effects of hCG-related oligopeptide treatment on gross pathology and histology 
of vital organs
Lungs. Gross examination at necropsy of the saline-treated monkeys (Ri274, 
Ri429 and Ri8012) revealed dark red lungs. Microscopically prominent pulmonary 
oedema, vascular congestion and multi-focal areas of extravasated red blood cells 
(haemorrhages) were observed (see Figure 4A). In the oligopeptide-treated monkey 
(Ri11152) that developed septic shock the lung had a similar haemorrhagic appearance. 
In the other two oligopeptide-treated animals (Ri459, Figure 4B; and Ri7046, which 
had mild septic shock-related clinical symptoms) that were euthanized the macro- and 
microscopic changes were reduced markedly and moderately, respectively.
Gastrointestinal tract. Macroscopically, the wall of the small and large intestine 
of saline-treated monkeys Ri274 and Ri8012 (Figure 5A) was moderately thickened 
(oedematous) with multi-focal to coalescing bright red areas present predominantly 
on the intestinal mucosa accompanied by scant greenish liquid faecal material in the 
lumen. Microscopically, the intestinal mucosa of these monkeys exhibited moderate 
vascular congestion, multi-focal areas of haemorrhage and mild to moderate oedema 
with mildly increased numbers of multi-focal lymphoplasmacytic infiltrates (Figure 6C). 
Compared to the saline-treated monkeys, the intestinal mucosa of the oligopeptide-
treated monkeys Ri459, Ri7046 and Ri11152 showed similar but milder gross lesions 
(Figure 5C,E). Microscopically, monkey Ri11152 (Figure 6D) exhibited only mild vascular 
congestion and oedema with few small haemorrhagic foci.
In the stomach of the saline-treated monkeys Ri429, Ri274 and Ri8012 (Figure 5B) 
we observed severely affected gastric mucosa, exhibiting marked oedema, congestion 
Figure 4. Reduced lung pathology treatment with oligopeptide cocktail. 
The picture shows control monkey Ri 429 (A) and the oligopeptide-treated monkey Ri 459 (B). The 
marked difference in pulmonary oedema, vascular congestion and haemorrhages is easily visible.
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Figure 5. Diminished septic shock-related gross pathological findings after treatment of rhesus 
monkeys with a cocktail of three human chorionic gonadotrophin (hCG)-related oligopeptides. 
Escherichia coli-related septic shock was induced in eight rhesus monkeys. Six animals were killed at 
8 h in order to evaluate the effect of treatment with hCG-related oligopeptides at the level of histopathology 
after the acute phase of septic shock relative to phosphate-buffered saline (PBS)-treated control 
monkeys. A significant difference was observed between tissues from control monkeys (e.g. Ri8012; 
A, B) and treated monkeys (e.g. Ri7046: C, D; Ri11152: E, F). The gastric mucosa of control monkey 
Ri8012 (B) exhibits marked oedema, congestion and haemorrhage of the cardia (c) and fundus (f) and 
multiple petechial haemorrhages in the pylorus (p), while the treated monkeys (e.g. Ri7046; D and 
Ri11152; E) have milder lesions in the cardia and pylorus. Furthermore, the intestinal wall of the large 
intestine of control animals (e.g. Ri8012; A) exhibits multi-focal to coalescing areas of haemorrhage and 
oedema, while treated animal Ri7046 (C) shows milder lesions and treated animal Ri11152 (F) exhibits 
only scattered petechial haemorrhagic foci.
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and haemorrhage of the cardia and fundus and multiple petechial haemorrhages in 
the pylorus. Microscopically, these alterations were consistent with marked vascular 
congestion of the gastric mucosa and submucosa, vasodilatation in the lamina propria 
of the gastric mucosa (Figure 6A), multi-focal haemorrhages, marked oedema and 
occasional sloughing (necrosis and loss) of gastric epithelium (degeneration and loss of 
few parietal and chief cells), accompanied by multi-focal lymphoplasmacytic infiltrates.
The oligopeptide-treated monkeys Ri7046 and Ri11152 showed only minimal gross 
lesions. Monkey Ri7046, compared to the control monkey Ri8012, showed milder 
lesions: mild congestion and few small haemorrhagic foci in the cardia and pylorus 
(Figure 5D). Monkey Ri11152 exhibited only minimal to mild vascular congestion and 
oedema with few petechial haemorrhagic foci (Figure 5F). In the cardia of monkey 
Ri274 (data not shown) only few petechial haemorrhages were found. Microscopically, 
these gross lesions were comprised of scattered congested blood vessels, few foci of 
extravasated red blood cells and mild oedema.
Liver. The liver of the oligopeptide-treated and control monkeys was unremarkable 
macroscopically. Microscopic abnormalities in the hepatic parenchyma of saline-treated 
monkeys Ri429, Ri274 and Ri8012 (Figure 6E) consisted of moderate to marked 
sinusoidal and intravascular neutrophilic granulocytosis, multi-focal congested vessels 
and multi-focal pericentral haemorrhages. The only observed microscopic alterations in 
the liver of oligopeptide-treated monkeys Ri459, Ri7046 and Ri11152 (Figure 6F) were 
occasional sinusoidal neutrophils and few apoptotic hepatocytes.
Other organs. The myocardium of the control monkeys Ri429, Ri274 and Ri8012 
exhibited multi-focal degeneration of myocardiocytes and focal haemorrhage in Ri274. 
On the other hand, no significant abnormalities were present in the myocardium of the 
oligopeptide-treated monkeys Ri459, Ri7046 and Ri11152 (data not shown). Similarly, 
the pancreas of the control-treated monkeys Ri429, Ri274 and Ri8012 exhibited mild 
interlobular oedema and random degeneration of acinar cells, while no significant 
findings were present in the pancreas of the oligopeptide treated monkeys Ri459, 
Ri7046 and Ri11152 (data not shown).
Overall, the most serious pathomorphological changes related to septic shock were 
observed in the saline-treated control monkey Ri8012. Similar but less severe changes 
were observed in the two other monkeys from the control group. The least severe 
abnormalities were observed in the oligopeptide-treated monkeys Ri459, Ri7046 and 
Ri11152. These findings indicate a marked beneficial effect of the AQGV–LQGV–VLPALP 
oligopeptide cocktail on the course of this experimentally induced septic shock.
 
Effect of hCG-related oligopeptide treatment on the cytokine burst in rhesus 
monkeys
The effect of the AQGV–LQGV–VLPALP oligopeptide treatment was also evaluated 
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Figure 6. Decreased severity of septic shock-related microscopic lesions after treatment of rhesus 
monkeys with a cocktail of three human chorionic gonadotropin (hCG)-related oligopeptides. 
Microscopic examination of tissues of control monkey Ri8012 (A, C, E) demonstrates marked vascular 
hyperaemia, vasodilation, multi-focal haemorrhages, marked oedema, mildly increased number of 
multi-focal lymphoplasmacytic infiltrates and sloughing (necrosis and loss) of epithelium in the lamina 
propria of the gastric mucosa (A) while the treated monkey Ri11152 (B) displays significantly minimized 
changes. The large intestinal mucosa in control monkey Ri8012 (C) exhibits moderate vascular dilation, 
active mucosal congestion, multi-focal areas of extravasated red blood cells (haemorrhage), mild to 
moderate oedema and mildly increased lymphoplasmacytic infiltrates, while the treated monkey Ri11152 
(D) exhibits mild vascular hyperaemia and oedema with few small haemorrhagic foci. The hepatic 
parenchyma of control monkey Ri8012 (E) shows variable number of multi-focal sinusoidal neutrophils 
(periportal, random sinusoidal and intravascular), multi-focal hyperaemic blood vessels, multi-focal 
haemorrhage and oedema, while microscopic hepatic alterations of the treated monkey Ri11152 (F) are 
restricted to the presence of occasional sinusoidal neutrophils.
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on the plasma levels of proinflammatory cytokines of the control and oligopeptide-
treated monkeys. E. coli infusion was associated with an increase of IL-1β, TNF-α, IL-6 
and IL-8 plasma levels over time in both control and oligopeptide-treated monkeys. The 
plasma levels of these proinflammatory cytokines did not differ markedly between the 
oligopeptide group and the untreated monkeys (Figure 7).
Figure 7. Plasma levels of inflammatory cytokines. 
Escherichia coli infusion of rhesus monkeys was associated with an increase of interleukin (IL)-1β, 
tumour necrosis factor-α, IL-6 and IL-8. The plasma levels of these proinflammatory cytokines did not 
differ markedly between the oligopeptide-treated monkeys and the untreated monkeys.
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DISCUSSION
In previous studies the immunomodulatory activity of the pregnancy hormone 
hCG in LPS-induced acute septic shock and in diabetes in non-obese diabetic (NOD) 
mice was mapped to a 400–2000 Dalton fraction in pregnancy urine (6,7). It was 
hypothesized that the active fraction contained oligopeptides derived from the sequence 
MTRVLQGVLPALPQVVC (residues 41–57) of loop 2 of the hCG-β chain (17). ‘Missing’ 
of loop 2 from the β-subunit (as in hCG β-core fragment) and ‘nicking’ of the β-subunit in 
the loop 2 region of the molecule, specifically between residues 44–49, can both reduce 
the biopotency of hCG. Cleavage of the peptide bonds in this area of the molecule 
also reduced biopotency and immunochemical recognition by monoclonal antibodies 
directed to the heterodimeric hormone (12–14,18,19). Based on known preferential 
cleavage sites in loop 2 several oligopeptides were synthesized, including MTR, MTRV, 
LQG, LQGV, VLPALP and VLPALPQ. In addition, the peptide VVC from the flanking 
COOH-side and the alanine substitution variant AQGV were synthesized. In the current 
study the eight synthetic oligopeptides were tested for their suppressive effect on LPS-
induced septic shock in mice (Table 2). The results showed that all mice that were 
treated at 2 h post-LPS with LQGV, VLPALP or AQGV survived beyond 48 h, while all 
mice in the saline-treated control group had already succumbed from fatal septic shock 
within 24 h. Remarkably, the mice could even be rescued from fatal septic shock when 
treatment with either one of the oligopeptides MTR, MTRV, VLPALPQ, VVC or AQGV 
was started as late as 24 h post-LPS, with sickness scores higher than 4•0 (Table 2). 
Of the evaluated oligopeptides, only AQGV was fully effective in reducing the severity 
and mortality of septic shock at early (i.e. 2 h post-LPS) as well as late (i.e. 24 h post-
LPS) administration. The different in vivo efficacy of AQGV and LQG was mirrored 
by a different in vitro immunosuppressive capacity. While AQGV reduced the in vitro 
proliferative response of splenocytes to LPS as well as CD3/IL-2, LQGV only reduced 
the proliferative response of splenocytes to CD3/IL-2. These data suggest that the 
suppressive effect of AQGV targets macrophages/monocytes, B cells and T cells and 
therefore possibly affects early and late mechanisms of septic shock in which different 
cell types and pathological pathways are active (20,21). Although treatment with LQG, 
LQGV or VLPALP (5 mg/kg) at 24 h after LPS administration failed to reduce mortality, 
VLPALP reduced mortality to around 50% after administration of a threefold higher dose 
(15 mg/kg) at 24 h post-LPS (7). This shows that detailed dose–response studies are 
needed for a full insight into the ability of the various hCG-related oligopeptides to inhibit 
LPS-induced shock in mice early and/or late after LPS administration.
Based on the observed beneficial effects of hCG-derived oligopeptides in the mouse 
septic shock model we chose to evaluate this new treatment principle in a septic shock 
model in deeply sedated rhesus monkeys induced by infusion of live E. coli. We selected 
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the three most effective peptides in the mouse studies, namely AQGV, LQGV and 
VLPALP, and administered them as an i.v. cocktail. With regard to the primary end-point, 
all three monkeys that received mock treatment with saline succumbed from fatal septic 
shock within 8 h after the E. coli infusion. Four of five monkeys that were treated with the 
oligopeptide cocktail were protected completely against septic shock. Haemodynamic 
parameters, such as heart rate, blood pressure and SpO2, varied considerably between 
individual animals, but confirmed the clinical diagnosis of suppressed septic shock by 
oligopeptide treatment.
Two oligopeptide-treated monkeys without marked clinical symptoms were allowed 
to recover to assess whether the single treatment also protected them from late-onset 
shock symptoms. As one of these monkeys had to be killed with clinical signs of septic 
shock at 33 h post-E. coli, the second monkey received an additional infusion of the 
oligopeptide cocktail at 8 and 24 h post-E. coli. However, the additional two oligopeptide 
doses failed to rescue this monkey from multi-organ failure at 36 h, as could be concluded 
from the high serum levels of ASAT and ALAT, indicating liver damage, of creatinine 
and urea reflecting kidney dysfunction, as well as the non-selective markers LDH and 
lactate over the final 20 h (data not shown).
Evaluation of the secondary end-point, histological assessment of septic shock-
related damage to vital organs, showed markedly less severe pathological changes 
in the three oligopeptide-treated monkeys that displayed no (Ri459) minor (Ri7046) 
or moderate clinical signs of septic shock (Ri11152) compared to the three saline-
treated control monkeys. Despite the variability in primary and secondary end-point 
parameters that were obtained from a limited number of investigated cases, the 
overall data set warrants the conclusion that administration of an oligopeptide cocktail 
consisting of AQGV, LQGV and VLPALP protects rhesus monkeys against the clinical 
and pathological consequences of acute septic shock syndrome. Importantly, these 
results were established without any further supportive treatment. Despite the strong 
protective effect of the oligopeptide cocktail during the acute clinical crisis, monkeys that 
were allowed to recover from anaesthesia nevertheless succumbed within the following 
24 h with clinical symptoms of septic shock. Moreover, at autopsy of the monkeys that 
were left alive and killed 1 day later with clinical signs of shock, the same pathological 
changes of septic shock syndrome as in the control monkeys could also be observed. 
This late complication of severe septic shock may be due to the translocation of bacteria 
from the damaged intestines.
To gain insight into the protective effect observed in the monkey model we measured 
TNF-α, IL-1β, IL-6 and IL-8 plasma levels. The plasma levels of these cytokines are 
elevated strongly during the initial 24 h after septic shock induction, and reduction of 
systemic levels and inhibition of these cytokines has been shown to be associated with 
improved survival in some animal models (22). While we have observed that LQGV or 
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AQGV treatment in a rat model of severe haemorrhagic shock reduced TNF-α and IL-6 
serum levels (23), we observed similar plasma profiles for TNF-α, IL-1β, IL-6 and IL-8 
in oligopeptide-treated and untreated rhesus monkeys. These data suggest that the 
oligopeptide treatment had no profound effect on the production or release of these 
proinflammatory cytokines in this model, suggesting that suppression of the systemic 
storm is not a probable explanation for the beneficial effect of the oligopeptide cocktail. 
However, the data on plasma cytokine levels should be interpreted with caution, as 
considerable variation was observed between individual monkeys. Moreover, the 
data were collected from a small number of monkeys used, which differed in genetic 
background and age. Hence, we cannot exclude completely the possibility that the 
oligopeptides affect systemic cytokine release in this model.
Gender-specific differences in immune responses after shock occur and have 
been attributed to the different immunomodulatory effects of male and female steroid 
hormones (24). In our study we used non-pregnant female mice and monkeys, but did 
not check for the oestric cycle or female sex hormone levels. Nevertheless, we consider 
it unlikely that female sex hormones have influenced the different outcome between 
peptide and non-peptide treated animals, as these peptides have been found to inhibit 
haemorrhagic shock-associated inflammation in male rats (23).
Thus far it is unclear by which molecular mechanism the remarkable pleiotropic 
beneficial effects of hCG-related oligopeptides in different models of acute shock are 
mediated. Recently we reported that male rats treated with either LQGV or AQGV 
alone, at 30 min after the onset of severe haemorrhagic shock, displayed not only 
reduced plasma levels of TNF-α and IL-6, but also reduced E-selectin, TNF-α and 
IL-6 mRNA transcript levels in the liver. LQGV treatment was also associated with a 
significant reduction of neutrophil accumulation in the liver (23). Endothelial activation, 
characterized by increased expression of adhesion molecules (E-selectin, intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)) and 
subsequent tissue infiltration by neutrophils is an early event in septic shock and a 
crucial step towards the development of organ failure (20,25,26). E-selectin blockage 
has been shown to protect against neutrophil-induced tissue injury during endotoxaemia 
in mice (27). Considering these data and our previous findings (23), we hypothesize that 
reduced E-selectin expression upon oligopeptide treatment may have contributed to the 
lower inflammatory cell accumulation and reduced organ damage, as was observed in 
the rhesus monkey study presented here.
Gene expression analysis in several rodent models of inflammatory disease confirmed 
that treatment with LQGV or AQGV reduces gene expression for proinflammatory 
cytokines and adhesion molecules (Khan et al. in preparation). This suggests that the 
immune regulatory effect of the hCG-related regulatory oligopeptides in rodents may, 
at least in part, be driven by the regulating gene expression. It is as yet unknown, 
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however, whether the oligopeptides act by binding to surface-expressed or cytosolic 
receptors. Preliminary data exclude that LQGV, AQGV and VLPALP act via binding 
to the luteinizing hormone (LH) receptor as they do not bind to the LH receptor nor 
do they interfere with the binding of hCG to the LH receptor (data not shown). Due to 
their small size and low molecular weight, these oligopeptides might easily pass the 
cell membrane (28) and interfere with signalling cascades or interact with regulatory 
sequences or transcriptional complexes.
In conclusion, the results of the current study show marked beneficial effects of some 
synthetic oligopeptides (3–7 amino acids) related to the primary structure of the pregnancy 
hormone hCG in experimental models of acute septic shock in two different species. No 
adverse effects of the hCG-related oligopeptides were observed in these two species. 
Therefore these oligopeptides may have therapeutic value for this often-fatal condition.
A Phase Ia multi-dose safety trial with AQGV (EA-230) in man has been completed 
(29), in which subjects received three times daily i.v. infusions of EA-230 for 3 days. No 
significant adverse events were found to be associated with the use of EA-230. Also a 
Phase Ib trial – designed as a double-blind, randomized, single-dose, placebo-controlled 
LPS challenge trial with EA-230 – has been completed (30). The primary aim of this trial 
was to determine whether EA-230 administration attenuates the inflammatory response 
induced by LPS infusion into healthy volunteers. In the trial one group each of 12 subjects 
received LPS by injection, followed 30 min later by either administration of EA-230 or 
placebo. Pharmacokinetic analysis of the study subjects showed not just a reduction of 
blood C-reactive protein levels, but also reduction of several proinflammatory cytokines 
(IL-6, IL-8 and TNF-α) compared to the placebo group. In addition, the treatment also 
reduced the rise of body temperature and the drop in white blood cell counts that 
are induced typically by LPS. Correspondingly, the data revealed an increase in the 
anti-inflammatory cytokine IL-10. The outcome of these studies has been considered 
successful, because they suggest that EA-230 may reduce a systemic inflammatory 
response elicited by endotoxin. This LPS study was selected to create an artificial proxy 
for an actual clinical scenario. These study results, combined with the results of Phase 
Ia single-dose trials, provide the basis for the development and implementation of more 
comprehensive Phase II human trials on EA-230.
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ABSTRACT
Background: Synthetic human chorionic gonadotropin (hCG)-related oligopeptides 
are potent inhibitors of pathogenic inflammatory responses induced by in vivo 
lipopolysaccharide exposure or hemorrhagic shock-induced injury. In this study, we 
tested whether hCG-related oligopeptide treatment similarly altered inflammatory 
responses and innate host defenses in mice during experimental Listeria monocytogenes 
infection.
Methods: Mice were infected with L. monocytogenes and treated with hCG-related 
oligopeptides (LQGV, VLPALP, or AQGV) or phosphate-buffered saline. Subsequently, 
mice were analyzed for bacterial loads, cytokine and chemokine responses, and 
inflammatory cell infiltrates in target organs.
Results: Oligopeptide administration increased bacterial numbers in the spleen and 
liver at 6 h after infection. Simultaneously, CXCL1/KC and CCL2/MCP-1 plasma levels 
as well as neutrophil numbers in the spleen, blood, and peritoneal cavity decreased. 
In contrast, at 18 h after infection, systemic tumor necrosis factor α, interleukin 12 p70, 
interleukin 6, and interferon γ levels increased statistically significantly in oligopeptide-
treated mice compared with controls, which correlated with increased bacterial 
numbers.
Conclusion: These data show that treatment with hCG-related oligopeptides 
(LQGV, VLPALP, and AQGV) inhibits early innate immune activation by reducing 
initial chemokine secretion following infection. This leads to bacterial overgrowth with 
subsequent enhanced systemic inflammation. Our data underscore the importance of 
early innate immune activation and suggest a role for hCG-derived oligopeptides at the 
placenta that increases the risk of L. monocytogenes infections.
INTRODUCTION
Listeria monocytogenes is an intracellular bacterium with a predilection for causing 
invasive infection in individuals with compromised host defenses (1). It is also a model 
pathogen used for understanding innate and adaptive immune responses to bacterial 
infection (1). Innate immune receptors, such as Toll-like receptors and nucleotide 
oligomerization-binding domain–like receptors, mediate the earliest recognition of 
L. monocytogenes components and trigger signaling pathways that induce specific 
chemokine and cytokine responses (2–4). Chemokines are critical for directing cellular 
recruitment to infected tissues, and cytokines, such as interferon γ (IFN-γ), tumor 
necrosis factor α (TNF-α), interleukin 6 (IL-6), and interleukin 12 p70 (IL-12p70) are 
crucial for eradicating L. monocytogenes through activation of NK cells and organ-
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specific phagocytes (5, 6). Accordingly, mice that lack key chemokines, cytokines, or 
their cognate receptors and downstream signaling proteins are highly susceptible to 
L. monocytogenes infection (7–11).
Pregnancy is one condition that increases the risk of invasive listeriosis (1). 
Pregnancy transiently biases immune responses of the maternal host toward a type 
2 (humoral) and away from a type 1 (cell-mediated) phenotype (12). This shift is most 
pronounced at the maternal-fetal interface, but it may also modulate systemic immunity 
to some extent. Consequently, pregnancy has deleterious effects on the outcome of 
infections such as leishmaniasis, malaria, toxoplasmosis, and listeriosis (13–16). In 
addition, autoimmune diseases such as systemic lupus erythematosus, in which the 
principal pathology is autoantibody production, tend to flare up during pregnancy, 
whereas rheumatoid arthritis is ameliorated in the maternal host (17).
The pregnancy hormone human chorionic gonadotropin (hCG) exerts endocrine 
and immunosuppressive functions (18). Recently, we demonstrated that hCG induces 
dendritic cells to differentiate toward a tolerogenic phenotype (19). In addition, hCG 
was observed to decrease IFN-γ production and prevent the onset of autoimmune 
diabetes in nonobese diabetic mice (20). Remarkably, the antidiabetic effect was not 
due to native hCG but resided in a 400–2000 Da peptide fraction that likely originated 
from proteolytic degradation of loop 2 of β human chorionic gonadotropin (β-hCG) (21). 
On the basis of preferential cleavage sites within loop 2 of β-hCG, we developed and 
tested the activity of synthetic oligopeptides in experimental inflammation (22–24). 
These studies demonstrated that the oligopeptides LQGV and AQGV (alanine 
substitution) reduced proinflammatory cytokine levels, reduced adhesion molecule 
expression, and diminished granulocytic infiltration into the liver following hemorrhagic 
shock and into the kidneys following ischemia and reperfusion (22, 23). In addition, the 
oligopeptide VLPALP reduced lipopolysaccharide (LPS)–induced mortality as effectively 
as did the 400–2000 Da hCG-derived peptide fraction (25).
To gain more insight into the effects of hCG-related oligopeptides on innate immune 
responses during infection with live bacteria, we tested the extent to which hCG-related 
oligopeptides altered host defenses in experimental L. monocytogenes infection in 
mice. Our data suggest that treatment with hCG-related oligopeptides impairs innate 
immune responses against L. monocytogenes by inhibiting chemokine responses and 
subsequent cellular recruitment to infected organs. This results in delayed bacterial 
clearance and more aggressive bacterial propagation. These data underscore the 
importance of early activation of innate immune responses following L. monocytogenes 
infection.
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MATERIALS AND METHODS 
Animals
Specific pathogen-free C57BL/6 mice (Jackson Laboratory and Harlan) were 
8–16 weeks of age when used in experiments and allowed food and water ad libitum. 
Experiments were approved by the local animal care and use committees.
Bacteria
Inocula of live L. monocytogenes (strain EGD) and heat-killed L. monocytogenes 
(HKLM) were prepared as described elsewhere (26).
L. monocytogenes infection model
Mice were infected by intravenous injection of 2.0–5.5 log10 colony-forming units 
(CFUs) of wild-type L. monocytogenes or 7.0 log10 CFUs of the L. monocytogenes 
Δhly mutant DP-L2161 (27). The hCG-related oligopeptides VLPALP, LQGV, and 
AQGV (GL Biochem Shanghai) were dissolved in phosphate-buffered saline (PBS) 
and intraperitoneally injected (50 mg/kg body weight) starting 24 h before infection and 
continued every 24 h thereafter. PBS-treated mice served as controls. Mice were killed 
at fixed time points.
Tissue collection and evaluation of bacterial CFUs
Peritoneal lavage was performed with ice-cold PBS. Liver, spleen, and bone marrow 
were isolated aseptically at necropsy. Blood was collected from the submandibular vein 
into ethylenediaminetetraacetic acid-containing tubes (Greiner Bio-one), and plasma 
was obtained by centrifugation (3000 rpm for 10 min), immediately frozen, and stored 
at −80°C until assayed. Liver and spleen were divided into sections for evaluation of 
bacterial CFUs or for flow cytometric analysis. Sections were weighed and homogenized, 
and bacterial CFUs were quantified as described elsewhere (26). CFUs of bacteria 
in blood, peritoneal washings, and bone marrow cell suspensions were determined 
similarly. Results are expressed as mean (± standard error of the mean) log10 CFUs of 
bacteria per gram of tissue, per milliliter of blood, per milliliter of peritoneal fluid, or per 
femur.
In vitro stimulation of splenocytes 
Uninfected mice were injected intraperitoneally with PBS or LQGV (50 mg/kg); after 
18 h, splenocytes were isolated and cultured at a density of 106 cells/mL in Roswell Park 
Memorial Institute medium containing antibiotics and 5% fetal calf serum. Cells were 
stimulated with HKLM (103–108) or LPS (100 ng/mL), and supernatants were collected 
after overnight incubation for cytokine level measurements.
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Evaluation of cytokines and chemokines in plasma and culture supernatant
Levels of TNF-α, IL-6, IL-12p70, and CCL2/MCP-1 were determined in plasma by 
means cytometric bead array (BD Biosystems), as described elsewhere (22). CXCL1/
KC level in plasma and TNF-α and IL-6 levels in culture supernatant were determined 
by means of enzyme-linked immunosorbent assay according to the manufacturer’s 
instructions (R&D Systems Europe). Results are expressed as mean (± standard error 
of the mean) in units of picograms per milliliter.
Flow cytometric analysis 
Flow cytometric analysis was performed on blood, peritoneal lavage, bone marrow, 
and spleen cell suspensions, as described elsewhere (26). Briefly, cells were incubated 
with monoclonal antibody directed against Ly6C (ER-MP20 (28)), Ly6G (1A8), 
and CD11b (M1/70; BD PharMingen) for 30 min; washed 3 times with a solution of 
PBS, 0.5% bovine serum albumin, and 20 mmol/L sodium azide; and fixed with 1% 
paraformaldehyde (weight per volume). Monocytes were defined as CD11b-positive, 
Ly6C-positive, and Ly6G-negative. Neutrophils were defined as CD11b-positive, Ly6C-
positive, and Ly6G-positive. Flow cytometric analysis was performed on a FACSCalibur 
flow cytometer (BD Biosciences). Data were analyzed using Flow-Jo software (version 
7.5.4; TreeStar).
Statistical analysis 
Statistical analysis was performed using SPSS software (version 15; SPSS). 
Differences between groups were analyzed using the Kruskal-Wallis statistical test. 
If this resulted in P < .05, the Dunn multiple comparison posttest was performed, and 
a result of P < .05 was considered statistically significant. Correlation coefficients were 
determined with the Pearson correlation analysis with significance set at P <.05.
RESULTS
Association between hCG-related oligopeptide treatment and increased bacterial 
numbers after lethal infection
To assess the effects of LQGV, VLPALP, and AQGV during L. monocytogenes 
infection, oligopeptide-treated mice and control mice were infected with 4 log10 CFUs 
of bacteria (1-3 median lethal doses), and then bacterial loads in target organs were 
measured.
In the spleens of PBS-treated mice, the mean bacterial load increased from 
4.2 log10 CFUs of bacteria at 6 h after infection to 7.4 log10 CFUs at 72 h after infection. 
By comparison, for each oligopeptide, CFUs of bacteria were statistically significantly 
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higher in oligopeptide-treated mice than those in control mice at 6 h after infection. 
Moreover, at each time point, splenic CFUs were statistically significantly higher in the 
LQGV-treated mice (P < .01) and AQGV-treated mice (P < .05) compared with the PBS-
treated mice (Figure 1A). 
There was a mean of 3.8 log10 CFUs detected in the livers of PBS-treated mice at 
6 h after infection, which increased to a mean of 7.6 log10 CFUs at 72 h after infection 
As also found in the spleen, CFUs of bacteria in the liver were statistically significantly 
higher in oligopeptide-treated mice (P < .05) at 6, 18, and 72 h after infection than in 
PBS-treated mice (Figure 1B).
Bacteria were not detected in blood and bone marrow of PBS-treated mice until 
48 and 72 h after infection, respectively. In contrast, bacteremia was noted by 18 h 
after infection in oligopeptide-treated mice, with LQGV-treated mice always showing the 
highest bacterial load in the blood (Figure 1C). In bone marrow, bacteria were present at 
18 h after infection in LQGV-treated mice and by 48 h after infection in VLPALP-treated 
mice and in AQGV-treated mice. LQGV-treated mice and AQGV-treated mice had the 
highest bacterial loads in bone marrow at 72 h after infection (Figure 1D).
Effect of LQGv treatment during sublethal challenge with wild-type 
L. monocytogenes and infection with avirulent L. monocytogenes mutants
Because LQGV treatment consistently produced the highest bacterial loads during 
lethal wild-type infection, subsequent experiments tested the effect of this oligopeptide 
in 2 different models of sublethal infection. First, mice were infected with 2.0 log10 CFUs 
Figure 1.  Increased bacterial loads as a result of human chorionic gonadotropin–related 
oligopeptide treatment after lethal Listeria monocytogenes challenge. 
Phosphate-buffered saline (PBS; control) or one of the oligopeptides (VLPALP, LQGV, or AQGV) was 
administered intraperitoneally daily starting 24 h before infection with 4 log10 colony-forming units 
(CFUs) of bacteria. Mice were killed at the indicated time points, and CFUs of bacteria in tissues were 
quantified. Results are presented as CFUs of bacteria in the spleen (log10 CFUs/g) (A), liver (log10 
CFUs/g) (B), blood (log10 CFUs/mL) (C), and bone marrow (log10 CFUs/femur) (D) from the indicated 
treatment groups at 6, 18, 48, and 72 h after infection. Results shown are from 1 of 3 representative 
experiments (n = 4 mice/group). *P < .05 and #P < .01 compared with PBS-treated mice.
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of wild-type L. monocytogenes (0.01 median lethal doses), and bacterial loads in organs 
were quantified as above. As also found during lethal infection, LQGV treatment resulted 
in statistically significantly increased bacterial loads in the spleen (P < .01) and liver 
(P < .01) at 72 h after infection compared with PBS treatment. Furthermore, 3.0 log10 
CFUs of bacteria were detected in bone marrow from LQGV-treated mice, whereas 
bone marrow from PBS-treated mice remained sterile (Figure 2A). In a second set of 
experiments, mice were infected with 7.0 log10 CFUs of avirulent Δhly L. monocytogenes 
mutants that do not produce listeriolysin O or escape phagosomes and are eliminated 
rapidly. As found above, there were greater numbers of bacteria in the spleens and livers 
of LQGV-treated mice at 6 and 18 h after infection, compared with PBS-treated mice 
(Figure 2B). Collectively, these data suggest that LQGV impairs host defenses against 
bacterial infection in general, rather than acting specifically against mechanisms 
triggered by bacteria that access the cytosol.
Figure 2.  Increased bacterial loads as a result of LQGv treatment following a sublethal Listeria 
monocytogenes challenge or infection with avirulent Δhly L. monocytogenes mutants. 
(A) Results for infection with wild-type L. monocytogenes. Phosphate-buffered saline (PBS) or LQGV 
was administered intraperitoneally daily starting 24 h before infection with 2 log10 colony-forming units 
(CFUs) of wild-type L. monocytogenes. CFUs of bacteria in spleen, liver, and bone marrow were 
quantified at 72 h after infection. (B) Results for infection with Δhly L. monocytogenes mutants. PBS or 
LQGV was administered intraperitoneally daily starting 24 h before infection with 7 log10 CFUs of Δhly 
L. monocytogenes mutants. CFUs of bacteria in spleen and liver were measured at 6 and 18 h after 
infection (n = 4 mice/group). * P < .05 and ** P < .01 compared with PBS-treated mice.
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Decrease of in vitro cellular responsiveness to HKLM and LPS by LQGv treatment 
in uninfected mice
Next, we tested the extent to which LQGV treatment impaired the ability of cells to 
generate proinflammatory cytokines. For this, uninfected mice were treated with PBS 
or LQGV. After 18 h splenocytes were isolated and stimulated in vitro overnight with 
varying amounts of HKLM or 100 ng/mL LPS. The results showed that HKLM induced 
dose-dependent production of TNF-α and IL-6 by splenocytes from both groups of 
mice (Figure 3). However, splenocytes from LQGV-treated mice produced statistically 
significantly less TNF-α and IL-6 than did cells from control mice (P < .05). Similar 
results were obtained when splenocytes were stimulated in vitro with LPS (Figure 3).
Inhibition of early neutrophil accumulation during L. monocytogenes infection by 
oligopeptide treatment
Subsequent experiments tested the degree to which treatment with LQGV, VLPALP, or 
AQGV impaired cellular recruitment following infection. For this, we analyzed neutrophil 
and monocyte numbers in the spleen, blood, and peritoneal cavity of PBS-treated 
or oligopeptide-treated mice at steady state and after infection. The percentages of 
neutrophils in the blood, spleen, and peritoneal cavity were increased over steady state 
at 6 h after infection in PBS-treated mice. Interestingly, treatment with each oligopeptide 
resulted in lower neutrophil counts in each compartment at 6 h after infection as well 
as at 18 h after infection, with the exception of the peritoneal cavity (Figure 4A and 4B). 
Figure 3. Impaired production of proinflammatory cytokines displayed by splenocytes from 
LQGv-treated mice. 
Uninfected mice were treated with phosphate-buffered saline (PBS) or LQGV. After 18 h splenocytes 
were isolated and subsequently cultured in vitro overnight with increasing amounts of heat-killed Listeria 
monocytogenes (HKLM) or 100 ng/mL lipopolysaccharide (LPS). Concentrations of tumor necrosis 
factor α (TNF-α) (A) and interleukin 6 (IL-6) (B) in culture supernatants were measured by means of 
enzyme-linked immunosorbent assay. Data depicted are from 1 of 3 representative experiments (n = 4 
mice/group). U.S., unstimulated. * P < .05 for LQGV-treated cells compared with PBS-treated cells.
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Figure 4. Inhibition of the initial mobilization of neutrophils by synthetic human chorionic 
gonadotropin-related oligopeptides during Listeria monocytogenes infection. 
(A) Dot plots showing representative flow cytometric profiles from the spleen, blood, and peritoneal 
cavity from mice 6 h after infection with 4 log10 CFUs of L. monocytogenes and from uninfected mice. 
CD11b-positive cells were selected, and monocytes and neutrophils were analyzed on plots of Ly6C vs 
Ly6G. Monocytes were defined as CD11b-positive, Ly6C-positive, and Ly6G-negative. Neutrophils were 
defined as CD11b-positive, Ly6C-positive, and Ly6G-positive. Neutrophil (upper box) and monocyte 
(lower box) windows are shown. (B) Quantification of percentages of neutrophils in spleen, blood, and 
peritoneal lavage. (C) Neutrophil numbers in spleen and peritoneal cavity. Data depicted are from 1 of 3 
representative experiments with similar findings (n = 4 mice/group) and are given as mean (± standard 
error of the mean). * P < .05 for oligopeptide-treated groups compared with phosphate-buffered saline 
(PBS)-treated control group or for PBS-treated mice compared with uninfected mice.
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At 18 h after infection, the percentage and absolute numbers of neutrophils in the 
peritoneal lavage decreased in all mice compared with the percentage and absolute 
numbers at 6 h after infection, but this decrease was not as marked in oligopeptide-
treated mice as in PBS-treated mice (Figure 4B and 4C). In contrast to the results 
with neutrophils, monocyte populations were not altered in any of the oligopeptide-
treated groups (data not shown). These data suggest that the previously demonstrated 
increased in bacterial loads in target organs could be due to inhibition of neutrophil 
accumulation.
Alteration of systemic cytokine and chemokine levels upon hCG-related 
oligopeptide treatment during L. monocytogenes infection
Next, we tested whether reduced mobilization of inflammatory cells in vivo correlated 
with inhibition of systemic proinflammatory chemokine and cytokine levels. At 6 h after 
infection, plasma concentrations of CCL2/MCP-1 and CXCL1/KC increased statistically 
significantly in PBS-treated mice compared with uninfected mice (CCL2/MCP-1 
concentration, 148 vs 20 pg/mL, respectively (P < .05); CXCL1/KC concentration, 1086 
vs 215 pg/mL, respectively (P < .05)) (Figure 5). Although oligopeptide-treated mice 
also showed increased CCL2/MCP-1 levels at 6 h after infection, both CCL2/MCP-1 
and CXCL1/KC levels were statistically significantly lower in oligopeptide-treated mice 
than the levels found in PBS-treated mice (P < .05). Increased concentrations of TNF-α, 
IL-12p70, IL-6, and IFN-γ were first detected in plasma at 18 h after infection in all mice, 
and they were statistically significantly higher in oligopeptide-treated mice (P < .05) 
than in PBS-treated mice (Figure 5). At 18 h after infection, CCL2/MCP-1 and CXCL1/
KC levels further increased in all mice to comparable levels. These data demonstrate 
that the elevation of systemic levels of chemokines precedes the elevation of systemic 
levels of proinflammatory cytokines and that administration of LQGV, VLPALP, or AQGV 
initially inhibits the early chemokine response.
Determination of chemokine and cytokine plasma levels by bacterial load
To explain the apparent contradiction between depression of early chemokine levels 
but enhanced proinflammatory cytokine levels following oligopeptide treatment, we 
hypothesized that increased levels of proinflammatory cytokines at 18 h after infection 
were related to increased bacterial loads in target organs at this time point. To test this 
hypothesis, mice were infected with increasing amounts of bacteria (4 log10, 5 log10, 
and 5.5 log10 CFUs), and cytokine and chemokine plasma levels were measured at 
18 h after infection. The results revealed a statistically significant positive correlation 
between increasing amounts of infecting bacteria and higher plasma levels of TNF-α, 
IL-12p70, IL-6, IFN-γ, CCL2/MCP-1, and CXCL1/KC (Figure 6A) as well as greater 
bacterial loads in vivo (Figure 6B). These data support a causal relationship between 
bacterial load and the concentration of inflammatory mediators in plasma. Moreover, 
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statistically significant correlations between TNF-α, IL-12p70, IL-6, and IFN-γ plasma 
levels and splenic CFUs were observed at 18 h after infection in LQGV-treated mice, 
VLPALP-treated mice, and AQGV-treated mice. In contrast, this correlation did not hold 
for CCL2/MCP-1 and CXCL1/KC (Figure 6C). These data indicate that the increased 
cytokine levels in plasma at 18 h after infection in LQGV-treated mice, VLPALP-treated 
mice, and AQGV-treated mice are caused by the increased bacterial load at this time 
point.
Figure 5.  Massively increased levels of cytokines as a result of treatment with LQGv, vLPALP, 
or AQGv following lethal challenge with Listeria monocytogenes. 
Phosphate-buffered saline (PBS), VLPALP, LQGV, or AQGV was administered intraperitoneally daily 
starting 24 h before infection with 4 log10 CFUs of L. monocytogenes. Mice were killed at fixed time 
points. Plasma levels of tumor necrosis factor α (TNF-α), interleukin 12 p70 (IL-12p70), interleukin 
6 (IL-6), interferon γ (IFN-γ), CCL2/MCP-1, and CXCL1/KC in different experimental groups were 
determined at 6 and 18 h after infection Data depicted are from 1 of 3 representative experiments with 
similar findings (n = 4 mice/group). * P < .05  for oligopeptide-treated groups compared with PBS-treated 
control group or for PBS-treated mice compared with uninfected mice. B.D., below detection limit.
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DISCUSSION
Innate immune responses against L. monocytogenes are characterized by the 
early mobilization of neutrophils and monocytes, as well as by the production of 
proinflammatory cytokines and chemokines (29). In this study we show that hCG-related 
oligopeptides inhibit innate immune activation during L. monocytogenes infection, 
which results in overwhelming bacterial propagation and excessive inflammation. 
In addition, we demonstrate that a systemic chemokine response manifested by 
increased plasma concentrations of CCL2/MCP-1 and CXCL1/KC precedes similar 
Figure 6.  Positive correlation between systemic cytokine and chemokine levels and bacterial 
load. 
Mice were infected with 4 log10, 5 log10, or 5.5 log10 colony-forming units (CFUs) of wild-type Listeria 
monocytogenes. Mice were killed at 18 h after infection, and plasma levels of tumor necrosis factor 
α (TNF-α), interleukin 12 p70 (IL-12p70), interleukin 6 (IL-6), interferon γ (IFN-γ), CCL2/MCP-1, and 
CXCL1/KC were determined. (A) Mean (± standard error of the mean) plasma concentrations of TNF-α, 
IL-12p70, IL-6, IFN-γ, CCL2/MCP-1, and CXCL1/KC determined from groups of 4 mice. Statistical 
differences between groups of mice are shown (* P <.05; ** P <.01). (B) Correlation analysis between 
plasma cytokine and chemokine concentrations and CFUs of bacteria in spleens of mice infected with 
different inocula. Statistical significance was determined by means of Pearson correlation analysis. 
(C) Correlation analysis between plasma levels and splenic CFUs in different experimental groups 
determined at 18 h after infection. Data depicted are from 1 of 3 representative experiments (n = 4 
mice/group). PBS, phosphate-buffered saline; L.M., L. monocytogenes.
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elevations of proinflammatory cytokines. These observations are in line with other studies 
that showed MyD88-independent production of CCL2/MCP-1 in the spleen within 6 h 
of infection (30). Inhibition of this early response leads to a more aggressive infection, 
as was also found in our studies (30). These data underscore the importance of the 
magnitude and rapidity with which innate immune activation follows L. monocytogenes 
infection.
Neutrophil migration to infected foci is important for controlling bacterial growth locally 
and for preventing bacterial dissemination (31). In this study we show that treatment 
with hCG-related oligopeptides reduced neutrophil accumulation in the blood, spleen, 
and peritoneal cavity after L. monocytogenes infection. Reduced neutrophil recruitment 
is likely related to diminished CXCL1/KC production, as reflected by decreased plasma 
levels and splenic messenger RNA levels (data not shown) at 6 h after infection. 
Consequently, bacterial numbers increased more rapidly in the spleen and liver and were 
detected earlier in the blood and bone marrow than in control mice. These data are in 
line with previous studies that demonstrated that both reduced neutrophil migration and 
neutrophil depletion lead to overwhelming bacterial propagation in L. monocytogenes 
infection and in cecal ligation and puncture models (13, 32, 33). CCL2/MCP-1 regulates 
monocyte recruitment during the initial stage of inflammation (34). We observed 
decreased CCL2/MCP-1 levels upon treatment with hCG-related oligopeptides, but we 
found no statistically significant effect on monocyte recruitment. This finding may be 
explained by preserved expression of other monocyte-attracting chemokines, such as 
CCL7/MCP-3 (35).
Neutrophil recruitment to infected organs, IFN-γ production by NK cells, and TNF-α 
and IL-6 production by monocytes, macrophages, and TNF-α– and inducible nitric 
oxide synthase–producing dendritic cells are all essential features of the innate immune 
response against L. monocytogenes (29). In this study we found that LQGV treatment 
of uninfected mice impaired the ability of splenocytes to produce TNF-α and IL-6 in vitro 
in response to HKLM or LPS stimulation. This finding suggests that LQGV interferes 
with innate immune receptor-mediated activation, although the mechanisms involved 
are not yet clear. In contrast to decreased cytokine production in vitro, IFN-γ, TNF-α, 
IL-6, and IL-12p70 plasma levels increased dramatically when mice were treated with 
hCG-related oligopeptides prior to L. monocytogenes infection. These increased plasma 
levels correlated statistically significantly with splenic bacterial numbers, suggesting 
a causal relationship between bacterial load in target organs and the magnitude of 
the systemic inflammatory response. This notion was confirmed experimentally by 
infecting mice with increasing doses of L. monocytogenes as well as by in vitro data 
from HKLM stimulation of splenocytes. LQGV clearly impaired the ability of splenocytes 
to produce TNF-α and IL-6 upon HKLM stimulation. Nevertheless, both TNF-α and IL-6 
levels increased markedly when cells were stimulated with greater amounts of HKLM, 
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and they exceeded cytokine levels produced by splenocytes from PBS-treated mice 
stimulated with a lower dose of HKLM. This mimics the in vivo situation of oligopeptide-
treated mice having a higher bacterial burden than did PBS-treated mice and supports 
the notion that the increased cytokine levels detected in vivo in oligopeptide-treated 
mice are due to greater bacterial loads. In sublethal L. monocytogenes infection, LQGV 
treatment also was associated with increased bacterial numbers in the spleen and liver, 
as well as with greater bacterial numbers in the bone marrow. The latter finding is 
significant because the bone marrow was sterile in control mice. This finding underscores 
the strong immunosuppressive capacity of LQGV in mice. These data show that early 
innate immune activation is important for the initial infiltration of phagocytes at the sites 
of infection to control L. monocytogenes growth locally, a response that is fully active 
within the first 6 h after infection (36). This rapid response also is essential for limiting 
bacterial dissemination to other organs or compartments, such as the bone marrow.
An alternative explanation for increased bacterial numbers following oligopeptide 
treatment could be a reduced capacity of resident effector cells to kill bacteria 
immediately following infection. Although we cannot fully exclude this possibility, we 
consider it to be less likely, because after cellular invasion, virulent bacteria escape 
from phagosomes in a listeriolysin O-dependent fashion, then replicate intracellularly 
and infect neighboring cells (37, 38). L. monocytogenes Δhly mutants lack listeriolysin 
O and are easily eradicated by the immune system (27). Our results showed decreasing 
CFUs of Δhly mutants in the spleen and liver of LQGV-treated mice, similar to results 
seen in the spleen and liver of PBS-treated mice, but with delayed kinetics. This finding 
suggests that LQGV treatment does not significantly impair bacterial internalization and 
killing by effector cells. More rapid bacterial replication following treatment with hCG-
related oligopeptides therefore is likely due to decreased chemokine production and 
subsequent reduced neutrophil recruitment, although formally we cannot exclude the 
possibility that LQGV interferes with bactericidal activities. Our data are in line with other 
studies that demonstrated that treatment with hCG preparation also reduces chemokine 
production during thioglycolate-induced inflammation (39).
Pregnant women are prone to placental infection with L. monocytogenes, which 
typically occurs during later stages of pregnancy (1, 29, 40). During the third pregnancy 
trimester, increased nicked β-hCG and β-core fragment levels occur in urine and 
plasma, compared with the first trimester (41). At present we are unable to detect 
hCG-derived oligopeptides in blood or urine. However, the relative amounts of nicked 
β-hCG and β-core fragments can be detected (42), which provide an indirect estimate 
for the concentration of hCG-derived oligopeptides. We postulate that high amounts 
of smaller fragments, including LQGV and VLPALP, may be liberated from the loop 
2 region during the third trimester of pregnancy. This not only could cause local 
immunosuppression at the placenta, which is needed to prevent fetal allograft rejection, 
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but also could make the host more prone to placental L. monocytogenes infection 
later in pregnancy. Interestingly, the placentas of humans and guinea pigs are much 
more susceptible to infection with L. monocytogenes compared with mouse placentas 
(43–45). The explanation for differential susceptibility to L. monocytogenes infection 
is unclear, but studies have shown evidence of structural similarities between human 
and guinea pig placentas, whereas the mouse placenta is more different (43, 46, 47). 
Alternatively, a placental immunological environment in humans and in guinea pigs that 
is more permissive for growth of L. monocytogenes than that in mice could explain 
this differential susceptibility. Interestingly, β chorionic gonadotropin (β-CG)-derived 
oligopeptides could contribute to such an immunological environment in humans and 
guinea pigs, because both species produce the β-CG subunit and share 63% homology, 
whereas mice lack the β-CG gene and thus do not produce β-CG. Clearly, more studies 
on animal models of pregnancy with L. monocytogenes infection are needed to unveil 
the precise role of CG-related oligopeptides during pregnancy.
Elsewhere, we reported that LQGV and AQGV attenuated life-threatening 
inflammation and organ damage associated with hemorrhagic shock and renal ischemia 
and reperfusion (22, 23). In addition, we showed that VLPALP treatment reduced 
mortality upon LPS injection (25). Although the exact mechanism of action of LQGV, 
VLPALP, and AQGV are not yet known, our current study suggests that suppressive 
effects on innate immune responses have contributed to beneficial outcomes found 
in these models. These data show that hCG-related oligopeptides have strong 
immunosuppressive activity, which provides the underlying foundation for phase 1 trials 
as currently performed in humans.
In summary, we demonstrate that a chemokine response precedes the
proinflammatory cytokine and cellular response in L. monocytogenes infection. 
This chemokine response is essential for rapid cellular recruitment to prevent 
further progression of infection. Furthermore, this study reveals that the 
synthetic hCG-related oligopeptides LQGV, VLPALP, and AQGV inhibit early 
innate immune responses with subsequent increased bacterial propagation. 
Our data underscore the importance of early innate immune activation 
following bacterial infection and suggest that hCG-derived oligopeptides at the 
placenta could increase host susceptibility to certain infections, such as with 
L. monocytogenes.
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ABSTRACT
Severe hemorrhagic shock followed by resuscitation induces a massive inflammatory 
response, which may culminate into systemic inflammatory response syndrome, multiple 
organ dysfunction syndrome and finally death. Treatments that effectively prevent this 
inflammation are limited so far. In a previous study, we demonstrated that synthetic 
oligopeptides related to the primary structure of human chorionic gonadotropin can 
inhibit the inflammatory response and mortality that follow high-dose lipopolysaccharide-
induced inflammation. Considering this powerful anti-inflammatory effect, we investigated 
whether administration of similar synthetic hCG-related oligopeptides (LQGV, AQGV, 
LAGV), during hemorrhagic shock, were able to attenuate the inflammatory response 
associated with this condition. Hemorrhagic shock was induced in rats for 60 minutes 
by blood withdrawal until a mean arterial pressure of 40 mmHg was reached. Thirty 
minutes after induction of hemorrhagic shock, rats received a single injection with one 
of the hCG-related oligopeptides (LQGV, AQGV or LAGV) or 0.9% NaCl solution, as 
control. Treatment with LQGV, AQGV or LAGV prevented systemic release of TNF-α 
and IL-6 and was associated with reduced TNF-α, IL-6 and E-selectin mRNA transcript 
levels in the liver. LQGV treatment prevented neutrophil infiltration into the liver and was 
associated with reduced liver damage. Our data suggest that hCG-related oligopeptides, 
in particular LQGV, have therapeutic potential by attenuating the life threatening 
inflammation and organ damage that is associated with (trauma-) hemorrhagic shock 
and resuscitation.
INTRODUCTION
Severe hemorrhagic shock is caused by massive blood loss, which cannot be 
compensated for by the body without treatment. The primary treatment of hemorrhagic 
shock is focused on controlling bleeding and restoring intravascular volume to improve 
tissue perfusion. Many patients with severe hemorrhagic shock who are successfully 
resuscitated develop an inflammatory response, which may culminate into systemic 
inflammatory response syndrome (SIRS) and finally multiple organ dysfunction 
syndrome (MODS) (1). In addition, approximately 40% of patients with hemorrhagic 
shock develop sepsis as a result of increased gut permeability and development of 
compensatory anti-inflammatory syndrome (1, 2). Sepsis and MODS are the leading 
causes of death in critically ill patients on the intensive care unit all over the world with 
approximately 50% mortality (3).
The inflammatory response following hemorrhagic shock and resuscitation is 
characterized by increased expression of adhesion molecules, such as E-selectin and 
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intracellular adhesion molecule-1 (ICAM-1), on endothelial cells and hepatocytes (4). 
Up-regulation of these adhesion molecules facilitates tissue infiltration by neutrophils, 
resulting in cell-mediated organ injury (5). Furthermore, increased levels of cytokines, 
such as TNF-α, IL-1b, IL-6 and IL-10, are found systemically and locally in liver, 
lungs and intestine (6-8). These cytokines, mainly produced by immune cells, affect 
organ integrity directly or indirectly through induction of secondary mediators, such as 
thromboxanes, leukotrienes, and complement (9, 10).
The last decade, research has focused on reducing systemic and local inflammatory 
responses with therapeutic agents that neutralize cytokine activity or inhibit inflammatory 
mediator production. However, in the case of hemorrhagic shock such treatments require 
initiation before the onset of shock to achieve an effect (11-13). Clearly, this is impossible 
in most clinical settings. Therefore, therapies that efficiently inhibit the inflammatory 
response when initiated after hemorrhage-induced shock are more relevant. Studies on 
such treatments are limited (14), but are highly needed.
During pregnancy, the maternal immune system tolerates the fetus by reducing cell-
mediated immune responses while retaining normal humoral immunity. Also, clinical 
symptoms of cell-mediated autoimmune diseases regress in many patients during 
pregnancy (15). Most likely a specific hormonal environment is responsible for modulating 
the immune system during pregnancy (15). The hormone human chorionic gonadotropin 
(hCG) is secreted by placental syncytiotrophoblasts during human pregnancy. Human 
CG preparations exhibit not only endocrine effects, but also immunosuppressive 
activity (16). We found that hCG preparations inhibited the onset of autoimmune type-I 
diabetes in nonobese diabetic mice (17). This anti-diabetic/anti-inflammatory activity 
was not due to the heterodimeric hCG nor to its α- or b-subunits, but resided in a peptide 
fraction of 400-2000 Dalton, which likely originates from proteolytic cleavage of loop 2 of 
the hCG b-subunit (17-19). Subsequently, we successfully demonstrated that synthetic 
oligopeptides, related to the primary sequence of loop 2 of the hCG b-subunit, inhibit 
inflammation, disease severity, and mortality in high-dose lipopolysaccharide-induced 
SIRS (18, 19). Considering this powerful effect of synthetic hCG-related oligopeptides 
on inflammation, we hypothesized that the administration of such oligopeptides after 
induction of hemorrhagic shock could inhibit the inflammatory response associated with 
this condition. To this end, we used LQGV, which is part of the primary structure of loop 
2 of the b-subunit of hCG, and two alanine replacement variants, namely AQGV and 
LAGV.
Using a rat model of (trauma-) hemorrhagic shock and resuscitation, we 
demonstrate that either LQGV, AQGV or LAGV, administered after the induction of 
hemorrhagic shock, significantly prevented TNF-α and IL-6 release into the plasma 
and attenuated the increase in TNF-α, IL-6 and E-selectin mRNA transcript levels in the 
liver. In addition, LQGV treatment significantly prevented neutrophil accumulation in the 
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liver, which correlated with decreased organ damage as reflected by reduced lactate 
dehydrogenase and aspartate aminotransferase plasma levels.
MATERIALS AND METHODS
Animals
Adult male specific pathogen-free Wistar rats (Harlan CPB, Zeist, The Netherlands), 
weighing 350–400g were used. Rats were housed under barrier conditions at 25°C 
with a twelve-hour light/dark cycle, and were allowed food and water ad libitum. The 
experimental protocol was approved by the Animal Experiments Committee under the 
Dutch Experiments on Animals Act and adhered to the rules laid down in this national 
law that serves the implementation of “Guidelines on the protection of experimental 
animals” by the Council of Europe (1986), Directive 86/609/EC. 
hCG-related synthetic oligopeptides
The hCG-related oligopeptides (LQGV, AQGV and LAGV) were synthesized by 
Ansynth Service B.V. (Roosendaal, The Netherlands) and dissolved in 0.9% NaCl at a 
concentration of 5 mg/ml.
Surgical procedures 
Rats were food deprived overnight before the start of the experiment, but were 
allowed water ad libitum. Rats were anesthetized using a mixture of N2O/O2/isoflurane 
(Pharmachemie B.V., Haarlem, The Netherlands). Body temperature was continuously 
maintained at 37.5°C by placing the rats on a thermo controlled ‘half-pipe’ (UNO, 
Rotterdam, The Netherlands). Endotracheal intubation was performed, and rats were 
ventilated at 60 breaths per minute with a mixture of N2O/O2/isoflurane. Polyethylene 
tubes (PE-50, Becton Dickinson; St. Michielsgestel, The Netherlands) were flushed 
with heparin and placed via the right carotid artery in the aorta and in the right internal 
jugular vein. A 5 cm midline laparotomy was performed and a supra pubic catheter was 
inserted to monitor urine production. 
Experimental procedures
After an acclimatization period of 15 minutes, the rats were randomized into five 
different groups (eight rats per group): 1) sham, 2) hemorrhagic shock (HS), 3) hemorrhagic 
shock with LQGV treatment (HS/LQGV), 4) hemorrhagic shock with AQGV treatment 
(HS/AQGV) and 5) hemorrhagic shock with LAGV treatment (HS/LAGV). Hemorrhagic 
shock was induced by blood withdrawal, reducing the circulating blood volume until a 
mean arterial pressure (MAP) of 40 mmHg was reached. This level of hypotension was 
Chapter 8
144
maintained for 60 minutes. Thirty minutes after the induction of hemorrhagic shock, rats 
received a single intravenous (IV) bolus injection of 5 mg/kg bodyweight of either LQGV, 
AQGV, LAGV or 0.9% NaCl solution. The peptides and dosage were based on previous 
studies, in which we performed dose-escalation experiments (20). Sixty minutes after 
induction of hemorrhagic shock, rats were resuscitated by four times their shed blood 
volume over a period of 30 minutes to normalize the MAP, and monitored for another 
120 minutes after which they were sacrificed (Figure 1A). The rats received no heparin 
before or during the experiment. Sham animals underwent the same surgical procedure 
as the hemorrhagic shock animals, but without blood withdrawal and administration of 
oligopeptide. 
Figure 1.
(A) Schematic representation of the experimental design of induction of hemorrhagic shock in rats. (B) 
The measured blood pressure in mmHg was recalculated in percentages to standardize the experiment 
and to compensate for animal differences.
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Measurements of mean arterial pressure
During the experiments, MAP was continuously measured using transducers 
(Becton Dickinson, Breda, The Netherlands) that were connected in line to an electronic 
recorder (Hewlett Packard, 78354-A, Cheshire, USA). 
Plasma collection and storage
Arterial blood was obtained 15 minutes before and 30, 60, 90, 120, 150 and 180 
minutes after onset of hemorrhage (Figure 1A). After blood withdrawal, leukocyte 
numbers were determined using a coulter counter (Beckman Coulter, Mijdrecht, The 
Netherlands) and corrected for the hematocryte. Approximately, 0.3 ml of blood was 
placed into mini collect tubes (Greiner, Bio-one, Alphen aan den Rijn, The Netherlands); 
plasma was obtained by centrifugation (1500 rpm; 5 min), immediately frozen, and 
stored at -80°C until assayed.
Tissue collection and storage
Liver, lungs, ileum and sigmoid were surgically removed at 180 minutes after 
hemorrhagic shock induction, snap-frozen, and stored at -80°C until assayed.
Evaluation of cytokines in plasma
TNF-α, IL-6 and IL-10 plasma levels were determined by ELISA (R&D Systems, 
Abingdon, UK), according to the manufacturer’s instructions. 
Evaluation of mRNA levels by real-time quantitative (RQ)-PCR 
RNA was isolated using the Qiagen RNeasy kit (QIAGEN, Hilden, Germany), 
according to the manufacturer’s instructions. TNFA (encoding TNF-α), IL6 (encoding 
IL-6), IL10 (encoding IL-10), SELE (encoding E-selectin), and ICAM1 (encoding ICAM-1) 
gene expression levels were determined by RQ-PCR using an Applied Biosystems 
7700 PCR machine (Foster City, CA, USA). The expression levels of these genes were 
quantified by normalization against the mRNA levels of the household gene GAPDH. 
Primers and probes used are available upon request. 
Immunohistochemical analysis
Cryo-sections (6 mm) were fixed in acetone/0.05%H2O2 for five minutes and 
subsequently air dried for 10 minutes. Neutrophils were visualized by staining for 
myeloperoxidase (MPO). Hereto, sections were incubated overnight at 4°C with a 
mouse-anti-rat MPO monoclonal antibody (Hbt, Uden, The Netherlands). Subsequently, 
sections were incubated for 60 minutes at room temperature with a goat-anti-mouse-
Horse Radish Peroxidase (HRP)-labeled monoclonal antibody (Dako B.V., Glostrup, 
Denmark). For visualization of HRP activity, 3-amino-9-ethylcarbazole substrate 
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(Sigma Co., St Quentin Fallavier, France) dissolved in 50mM sodium acetate/0.02% 
hydroxyperoxide was used. Sections were embedded in Kaisers Gycerol/gelatin (Boom 
B.V., Meppel, The Netherlands). Numbers of MPO positive cells were counted per 
high power field (HPF) at a magnification of 200x. Per section a total of 15 HPF were 
analyzed. Per organ a total of three consecutive sections, each separated 18mm from 
each other, were analyzed. 
Blood biochemical analysis
Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
lactate dehydrogenase (LDH) were determined at the Erasmus MC diagnostic facility 
according to standard procedures.
Statistical analysis 
Data are presented as the mean values ± standard deviation (SD) of the eight rats per 
group. Statistical analysis was performed using SPSS version 11 software (SPSS Inc., 
Chicago,Ill). Intergroup differences were analyzed with Kruskal-Wallis statistical test. If 
Kruskal-Wallis statistical testing resulted in a p < 0.05, a Dunn’s Multiple Comparison 
test was performed and a p < 0.05 was considered statistically significant. 
RESULTS
Induction of hemorrhagic shock
Rats were rapidly bled, within 10 minutes, to a MAP of 40 mmHg, which was 
successfully maintained for 60 minutes in all four experimental groups (Figure 1B). 
No change in MAP was observed in sham treated rats (Figure 1B). Sixty minutes 
after hemorrhagic shock, rats were resuscitated to induce organ reperfusion, which 
was associated with a normalization of urine production (data not shown). These 
data indicate that shock was induced equally in all four experimental groups and was 
followed by successful organ reperfusion. Heart rates in all four experimental groups 
increased immediately after induction of hemorrhagic shock and returned to normal 
after resuscitation. Over time, heart rate slowly increased in all four experimental HS 
groups (data not shown).
Oligopeptide treatment prevents the release of pro-inflammatory cytokines into 
plasma 
Before induction of hemorrhagic shock, TNF-α plasma levels were comparable in all 
five groups (~15-24 pg/ml) (Figure 2). In the HS group, TNF-α levels started to increase 30 
minutes after induction of hemorrhagic shock. These levels were significantly increased 
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after 60 minutes as compared to the sham group (331 pg/ml vs 29 pg/ml; p < 0.01). 
TNF-α levels reached a maximum of 384 pg/ml after 90 minutes in the HS group, after 
which levels declined again but continued to remain increased compared to the sham 
group (Figure 2). In contrast, none of the oligopeptide-treated HS groups showed 
an increase in TNF-α plasma levels during the experiment (Figure 2). In this model 
of hemorrhagic shock, IL-6 levels are known to increase at a later time-point than 
TNF-α (21). Therefore, we determined IL-6 levels in blood samples collected 120, 150 
and 180 minutes after the onset of hemorrhagic shock. In the HS group, IL-6 plasma 
levels were significantly increased as compared to the sham group at 120 minutes (2003 
pg/ml vs 331 pg/ml; p < 0.001), at 150 minutes (2444 pg/ml vs 333 pg/ml; p < 0.001) and 
at 180 minutes (2940 pg/ml vs 343 pg/ml; p < 0.001) (Figure 3). Although, IL-6 levels 
tended to increase in the HS/oligopeptide treated rats as compared to sham treated rats, 
this never reached significance. Treatment with oligopeptides significantly diminished 
the release of IL-6 into plasma as compared to the non-treated hemorrhagic shock 
group (p < 0.05; Figure 3). IL-10 was undetectable in plasma of all groups throughout 
the experiment (data not shown). These data demonstrate that treatment with a single 
dose of either LQGV, AQGV or LAGV, after induction of hemorrhagic shock, significantly 
attenuated the increase in TNF-α and IL-6 into plasma.
Figure 2. 
TNF-α plasma levels in different experimental groups determined at 15 minutes before and 30, 60, 90, 
120, 150 and 180 minutes after the onset of hemorrhagic shock. Data are presented as the mean of 
eight rats per group ± SD.
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Oligopeptide treatment is associated with a decrease in TNF-α and IL-6 mRNA 
transcript levels in the liver 
We also analyzed the TNF-α and IL-6 mRNA transcript levels in liver, lungs, ileum 
and sigmoid tissues at 180 minutes after the onset of hemorrhagic shock. In the liver, 
TNF-α transcript levels were significantly increased in the HS group as compared to the 
sham group (p < 0.001). Oligopeptide treatment was associated with reduced TNF-α 
transcript levels in the liver as compared to non-treated HS rats, with only HS/LQGV 
showing a significant reduction (p < 0.05; Figure 4A). In the HS group, IL-6 transcript 
levels in the liver were increased ~83 times as compared to the sham group (p < 0.001; 
Figure 4B). None of the oligopeptide treated groups showed a significant increase in 
IL-6 transcript levels as compared to the sham group. LQGV and AQGV treatment was 
associated with significantly lower IL-6 transcript levels as compared to the HS group 
(p < 0.05; Figure 4B). Although, IL-10 was undetectable in plasma, IL-10 transcript 
levels were increased in the livers of the HS group as compared to the sham group, 
which approached significance (p = 0.08). Although not significant, LQGV treatment 
was associated with decreased IL-10 transcript levels as compared to the non-treated 
HS group (data not shown). In lungs, ileum and sigmoid tissues no differences could 
Figure 3. 
IL-6 plasma levels in different experimental groups determined at 120, 150 and 180 minutes after the 
onset of hemorrhagic shock. Data are presented as the mean of eight rats per group ± SD.
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be detected between the various groups for TNF-α, IL-6 and IL-10 transcript levels 
(data not shown). These data imply that oligopeptide treatment after shock induction 
significantly attenuated the increase in TNF-α and IL-6 transcript levels in the liver. 
Oligopeptide treatment is associated with a decrease in E-selectin mRNA 
transcript levels in the liver 
In the HS group, the ICAM-1 transcript level was significantly increased in the liver as 
compared to the sham group (p < 0.001; Figure 5A). ICAM-1 transcript levels in the liver 
tended to decrease in the oligopeptide treated groups as compared to the non-treated 
HS group. The E-selectin transcript level in the liver of the HS group was significantly 
increased as compared to the sham group (p < 0.001). LQGV and AQGV treatment was 
associated with significantly lower E-selectin transcript levels in the livers as compared 
to the non-treated HS-group (p < 0.05; Figure 5B). These data demonstrate that 
LQGV and AQGV treatment after shock induction significantly attenuated the increase 
in E-selectin transcript levels in the liver, while ICAM-1 transcript levels were down 
regulated to a lesser extent. 
LQGv treatment prevents neutrophil accumulation in the liver 
In the HS group, the number of neutrophils in the liver was significantly increased 
as compared to the sham group (p < 0.05; Figure 6A). LQGV treatment significantly 
(p < 0.05) prevented this neutrophil accumulation, while AQGV and LAGV treatment did 
not prevent neutrophil accumulation in the liver (p < 0.05; Figure 6). 
Figure 4. 
Relative expression of TNF-α (A), IL-6 (B) mRNA transcripts in the liver, 180 minutes after the onset 
of hemorrhagic shock. Transcript levels are normalized to the expression level of GAPDH. Data are 
presented as the mean of eight rats per group ± SD.
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LQGv treatment attenuates organ damage
ALT, AST and LDH plasma levels were significantly increased in the HS group as 
compared to the sham group ((ALT; p <0.01; Figure 7A), (AST; p < 0.01; Figure 7B) and 
(LDH; p < 0.01; Figure 7C)), while LQGV treatment significantly (p <0.05) attenuated 
this rise in AST and LDH. AQGV and LAGV treatment did not affect ALT, AST and LDH 
plasma levels as compared to the untreated HS group.
DISCUSSION
In this study we used a rat model of (trauma-) hemorrhagic shock to test the 
therapeutic capacity of three synthetic hCG-related oligopeptides (LQGV, AQGV or 
LAGV). We demonstrate that a single administration of either LQGV, AQGV or LAGV, 30 
minutes after shock induction, markedly prevents TNF-α and IL-6 release into plasma 
and diminishes the increase of TNF-α, IL-6 and E-selectin mRNA transcript levels in the 
liver. In addition, LQGV treatment significantly prevented neutrophil accumulation into 
the liver, which coincided with lower AST and LDH plasma levels.
Hemorrhagic shock followed by resuscitation is characterized by a massive 
production of pro-inflammatory cytokines, such as TNF-α and IL-6, by immune 
cells (10). Despite improvement in treatment strategies, (trauma-) hemorrhage patients 
may still develop an inflammatory response that can lead to sepsis, MODS and 
Figure 5. 
Relative expression of E-selectin (A) and ICAM-1 (B) mRNA transcripts in the liver, 180 minutes after 
the onset of hemorrhagic shock. Transcript levels are normalized to the expression level of GAPDH. 
Data are presented as the mean of eight rats per group ± SD.
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finally death. In our model of hemorrhagic shock and resuscitation, we observed an 
inflammatory response, as reflected by significantly increased levels of TNF-α and IL-6 
in plasma. TNF-α is a key mediator of the innate immune system that is crucial for the 
generation of a local protective immune response against infectious or non-infectious 
agents (22). However, uncontrolled TNF-α production is lethal, as it induces tissue 
damage and promotes the production of secondary pro-inflammatory mediators, such 
as IL-6 (23). 
Experimental treatment strategies aimed at neutralizing bioactive cytokines, 
especially monoclonal antibodies against TNF-α, have been successfully applied 
in several inflammatory disorders, including Crohn's disease and rheumatoid 
arthritis (24, 25). However, clinical studies using monoclonal antibodies against TNF-α 
Figure 6.
(A) Number of neutrophils per HPF (magnification 200x) in the liver 180 minutes after the onset of 
hemorrhagic shock. Data are presented as the mean of eight rats per group ± SD.
Representative examples of livers from sham (B), HS (C) and HS/LQGV (D), 180 minutes after the 
onset of hemorrhagic shock.
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showed no improvement in trauma-patients (26). IL-6 is a highly pluripotent cytokine, 
which facilitates neutrophil infiltration into organs, thereby contributing to cell-mediated 
organ damage (27). In our model of (trauma-) hemorrhagic shock and resuscitation, 
oligopeptide treatment was associated with significantly decreased levels of TNF-α 
and IL-6 in plasma. Reducing TNF-α and IL-6 plasma levels is of clinical importance, 
because high systemic levels of TNF-α and IL-6 correlate with poor outcome and 
decreased survival in patients with severe trauma and infection (28). We found local 
TNF-α and IL-6 production in the liver after hemorrhagic shock and resuscitation, which 
was reduced upon oligopeptide treatment, in particular with LQGV. In lungs, ileum and 
sigmoid, we found no effect of hemorrhagic shock on the transcript levels of TNF-α and 
IL-6. Trauma-hemorrhage has been recognized to induce acute lung injury/inflammation 
in humans and animals (29, 30). In our model we detected no increase of TNF-α, IL-6, 
E-selectin and ICAM-1 transcript levels in the lungs three hours after hemorrhagic 
shock, suggesting that a pulmonary inflammatory response was not (yet) evident. We 
have found that hCG-related oligopeptides efficiently inhibited SIRS and mortality that 
was induced upon LPS administration, which is an inflammatory model characterized by 
involvement of several organ systems, including the lungs (18, 19). Therefore, although 
we cannot conclude it from the current study, we expect that hCG-related oligopeptides 
can prevent hemorrhagic shock-induced pulmonary inflammation.
IL-10 is an anti-inflammatory cytokine that reduces cell-mediated immune responses 
and pro-inflammatory cytokine production following hemorrhagic shock (8). We were 
unable to detect IL-10 in plasma during the time frame of the experiments. However, 
Figure 7.
Plasma levels of ALT (A), AST (B) and LDH (C) 180 minutes after the onset of hemorrhagic shock. Data 
are presented as the mean of eight rats per group ± SD.
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local IL-10 production in the liver was detected, since IL-10 transcripts increased in 
the HS group. LQGV treatment was associated with decreased IL-10 mRNA levels 
as compared to the non-treated HS group. Although this did not reach statistical 
significance, we propose that this may be of biological relevance since high IL-10 levels 
are associated with a high incidence of infection, MODS and increased mortality in 
(trauma-) hemorrhage patients (31). 
Neutrophils induce organ damage and enhance inflammation by the release of 
oxygen radicals, proteolytic enzymes and cytokines (32, 33). Neutrophil infiltration 
into organs is an early event of hemorrhagic shock and resuscitation, and neutrophil 
depletion has been shown to prevent hemorrhagic shock induced inflammation 
and organ damage (5, 34). These data indicate a central role for neutrophils in the 
pathophysiology of hemorrhagic shock and resuscitation. Leukocyte migration from 
blood into organs requires the consecutive events of rolling and sticking to activated 
endothelial cells, followed by diapedesis and chemotaxis (35). Among these processes, 
selectin-mediated rolling is indispensable for initiation of leukocyte transmigration 
and inflammation (36). In line with this, L- or E- selectin blockage, using monoclonal 
antibodies, reduced liver infiltration by neutrophils as well as inflammation and organ 
damage following hemorrhagic shock (37). In our experiments, treatment with LQGV 
or AQGV significantly decreased E-selectin transcript levels in the liver. Furthermore, 
LQGV treatment prevented neutrophil accumulation in the liver and was associated 
with lower AST and LDH plasma levels after hemorrhagic shock and resuscitation. 
These data suggest that oligopeptide treatment, in particular LQGV, after hemorrhagic 
shock and resuscitation diminishes the expression of adhesion molecules, thereby 
inhibiting tissue infiltration by neutrophils and subsequent organ damage and systemic 
inflammation. 
In this model, LQGV, originating from the primary sequence of loop 2 of the b-subunit 
of hCG, was the most effective oligopeptide for every parameter determined. Alanine 
replacement in this sequence reduced the biological activity. We cannot exclude 
that the decreased TNF-α and IL-6 mRNA levels, upon oligopeptide treatment, that 
we observed in the liver are the result of a diminished cellular infiltrate. However, the 
decrease in E-selectin mRNA, which is only expressed by endothelial cells, indicates 
that the tested oligopeptides also interfere with mechanisms that regulate expression/
activation of genes involved in inflammation and immunity. So far it is unclear what the 
underlying mechanism is by which these oligopeptides exert their effects. It is possible 
that they use yet unidentified receptors. However, we cannot exclude the possibility that, 
due to their small size and molecular weight, they penetrate the cell membrane (38) 
and exert their action either by interfering with signaling cascades or the transcriptional 
machinery. Therefore, we do not exclude that different oligopeptides have different 
modes of action. Studies are in progress to reveal how these hCG-related oligopeptides 
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exert their action.
In summary, we demonstrated that administration of a synthetic hCG-related 
oligopeptide (LQGV, AQGV or LAGV) after the induction of severe hemorrhagic shock 
significantly attenuated the pro-inflammatory response both systemically and locally 
in the liver. Treatment with LQGV prevented neutrophil infiltration into the liver and 
subsequent liver damage. These data suggest that these oligopeptides, in particular 
LQGV, have therapeutic potential and may reduce the morbidity and mortality associated 
with hemorrhagic shock and resuscitation.
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ABSTRACT
Background: We have previously reported that small synthetic oligopeptides 
related to human b-chorionic gonadotropin (b-hCG) can reduce inflammation. Here we 
investigated whether such oligopeptides can reduce renal ischemia reperfusion injury 
in the mouse. 
Methods: Ten different oligopeptides were administered 1 minute before induction of 
renal ischemia and 1 minute before reperfusion. 
Results: Survival at 72 hours post reperfusion was significantly higher in mice 
treated with oligopeptides MTRV, LQG, VLPALPQ or AQGV as compared to placebo 
treated mice. Some oligopeptides were more effective than others. AQGV completely 
prevented mortality and best preserved kidney function. Next, AQGV was tested in a 
dose-escalating study in a range of 0.3 to 30 mg/kg. A survival gain was observed with 
all doses. Improvement of kidney function was observed from 1 mg/kg. Highest survival 
and best preserved kidney function was observed at 3 and 10 mg/kg. 
Upon treatment with AQGV, a significantly lower influx of neutrophils was found, 
apoptosis was decreased, whereas tubular epithelial cell proliferation was significantly 
increased at 24 hrs post-reperfusion. Serum levels of TNF-α, INF-g, IL-6 and IL-10 
were significantly decreased at 24 hours post reperfusion. E-selectin mRNA levels in 
kidneys were significantly decreased at 6 hours post-reperfusion. AQGV did not reduce 
mortality when treatment was started after reperfusion. 
Conclusions: This study shows that small oligopeptides related to the primary 
structure of b-hCG, especially AQGV, are promising potential drugs for preventing the 
development of renal ischemia-reperfusion injury.
INTRODUCTION
Inflammation plays a major role in the pathophysiology of renal ischemic injury (1). 
The initial ischemic injury results in up-regulation of adhesion molecules on activated 
endothelium and release of cytokines, reactive oxygen species (ROS) and eicosanoids. 
Leukocytes, recruited by chemokines and pro-inflammatory cytokines, potentiate injury 
by generating more ROS and eicosanoids, thereby further enhancing inflammation.
Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by 
placental trophoblasts (2), but is also produced by the pituitary gland and leukocytes 
in non-pregnant females and males (3,4). It consists of an α- and b-chain. In human 
pregnancy urine and in commercial hCG preparations hCG occurs in a variety of forms, 
including breakdown oligopeptide products. During pregnancy, the urine contains 
increasing proportions of nicked hCG and hCG b-core fragments (5). Nicked hCG has 
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peptide bond cleavages in loop 2 of the b-chain between residues 44 and 52, whereas 
hCG b-core completely lacks the b-chain loop 2, which consists of amino acid residues 
41-54.
We have previously shown that the 400 – 2000 Dalton peptide fraction of pregnancy 
urine, but not of normal female or male urine, is able to inhibit the development of 
diabetes in NOD mice, whereas fractions greater than 2000 Dalton, including hCG, 
did not have this activity (6). We then reported that the synthetic hexapeptide VLPALP, 
which is part of the primary structure of the hCG b-chain loop 2, reduced mortality in 
a murine model of lipopolysacharide (LPS) induced systemic inflammatory response 
syndrome (7,8). 
Based on these findings, and known preferential cleavage sites of the hCG b-chain 
loop 2 (5,9-12), we selected six different synthetic oligopeptides (MTR, MTRV, LQG, 
LQGV, VLPALP and VLPALPQ), which are part of the primary structure of loop 2 of the 
hCG b-chain, as well as four alanine variants of LQG and LQGV (AQG, LAG, AQGV 
and LAQV) (Figure 1), and tested these in a murine model for their capacity to reduce 
renal I/R injury.
MATERIALS AND METHODS
Experimental design
The experimental protocol was approved by the Animal Experiments Committee 
under the Dutch Experiments on Animals Act and adhered to the rules laid down in 
this national law that serves the implementation of “Guidelines on the protection of 
experimental animals” by the Council of Europe (1986), Directive 86/609/EC.
Ten different hCG-related oligopeptides (MTR, MTRV, LQG, LQGV, VLPALP, 
VLPALPQ, AQG, AQGV, LAG and LAGV) were evaluated for their capacity to reduce 
ischemia-reperfusion induced renal injury as compared to mice treated with phosphate-
buffered saline (PBS). Five mg/kg body weight of oligopeptide or PBS in a volume of 
0.1 mL was administered intravenously (i.v.) 1 minute before clamping the kidney, and 
1 minute before releasing the clamp.
Subsequently a dose-escalating study was performed with AQGV. The AQGV was 
given in doses of 0.3, 1, 3, 10, and 30 mg/kg in a volume of 0.1 mL and was administered 
i.v. 1 minute before clamping, and 1 minute before releasing the clamp. Possible toxic 
side effects were studied by careful observation of control and peptide treated mice for 
signs of discomfort. 
Contra-lateral kidney samples were obtained for further analysis. At 24, and 72 
hr post-reperfusion, mice were sacrificed and clamped kidneys were harvested and 
snap frozen for further analysis. Serum urea levels were measured to determine kidney 
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function. Infiltrating cells were analysed using immunohistochemistry. In all groups 
survival was assessed and analyzed by Kaplan-Meier analysis. 
In an additional experiment AQGV was given in a dose of 5 mg/kg BW in a volume 
of 0.1 mL and administered i.v. 1 minute before clamping, and 1 minute before releasing 
the clamp. At 6 and 24 hr post-reperfusion, mice were sacrificed and blood was obtained 
for cytokine measurements in serum. From the 6hr post-reperfusion group the clamped 
kidney was harvested for determination of mRNA expression levels. 
Furthermore, survival experiments were performed in which mice received PBS or 
AQGV (5mg/kg BW) at 12 and 24 hours, or at 6 and 12 hours post-reperfusion. 
Figure 1. Structure of β-hCG with loop 2 and the amino acid sequence of loop 2 indicated. 
Adapted from Lapthorn et al. (35). Arrows indicate the preferential cleavage sites in loop 2.
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Mice
Male C57BL/6JOlaHsd mice of 12-16 weeks of age were obtained from Harlan (Horst, 
The Netherlands). Mice were kept under standard laboratory conditions (temperature 
20-24ºC, relative humidity 50-60%, 12 h light/12 h dark) and were allowed free access 
to food (Hope Farms, Woerden, The Netherlands) and water. 
Ischemia model
Mice were anaesthetized by isoflurane inhalation. Anaesthesia was maintained 
using a mixture of N2O/O2/isoflurane. Blood was collected by retro-orbital 
puncture. Body temperature was maintained by placing the mice on heating pads. 
Following a midline abdominal incision, the left renal pedicle was localized and clamped 
for 25 minutes using an atraumatic micro-vascular clamp. After inspection for signs of 
ischemia, the wound was covered with PBS soaked cotton and the animal was covered 
with a tin foil insulation sheet. After release of the clamp, restoration of blood-flow was 
inspected visually and a contra-lateral nephrectomy was performed. The abdominal 
wound was closed in two layers, and mice were given 0.5 ml PBS subcutaneously.
Oligopeptides
Selection was based on either the known preferential cleavage sites or known in 
vivo nick sites of the sequence MTRVLQGVLPALPQ (aa41-54) of loop 2 of the b-subunit 
of hCG (14, 16-19). Selected oligopeptides were MTR (aa41-43), MTRV (aa41-44), LQG 
(aa45-47), AQG and LAG (alanine replaced oligopeptides of LQG), LQGV (aa45-48), AQGV 
and LAGV (alanine replaced oligopeptide of LQGV), VLPALP (aa48-53), VLPALPQ 
(aa48-54). Oligopeptides were synthesized (Ansynth BV, Roosendaal, The Netherlands) 
using the fluorenylmethoxycarbonyl (Fmoc)/tert-butyl-based methodology with a 
2-chlorotritylchloride resin as the solid support. Oligopeptides were dissolved in PBS at 
a concentration of 1 mg/ml and stored at -20°C in small aliquods.
Functional measurements
Serum urea and creatinine values were measured using a kinetic urease method 
where the decrease in NADH adsorbance is measured photometrically, using an ELAN 
multianalyser (Eppendorf-Merck, Germany).
Immunohistochemistry
Primary antibodies used were rat-anti-mouse CD4, CD8, CD45, neutrophils, 
macrophages, CD54 (Serotec, Oxford, UK). Antibodies were diluted in PBS/5% BSA 
solution. Primary antibody was applied on for 30 min at RT and slides were subsequently 
incubated with a mixture of goat-anti-rat IgM+IgG (H+L) alkaline-phosphate conjugated 
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antibody (Southern Biotech, Birmingham, USA) for 30 min at RT. Enzyme detection was 
performed using Naphthol AS-MX, New Fuchsine, sodium-nitrite and levamisol mixture 
in Tris-HCl pH8 as a substrate for 30 min at RT in the dark.
Formalin-fixed-paraffin sections (3 mm) were used for Ki-67 staining. Slides were 
deparaffinized and rehydrated and boiled for antigen retrieval in a 0.01M sodium 
citrate solution for 30 min in a microwave-oven. Endogenous peroxidase was blocked 
with a 0.03% H2O2 solution. The sections were incubated overnight at 4
oC with rat-
anti-mouse Ki-67 primary antibody (Dako Cytomation, Glostrup, Denmark) and 
subsequently incubated for 30 min at RT with rabbit-anti-rat IgG conjugated with HRP 
secondary antibody (Dako Cytomation, Glostrup, Denmark). Enzyme detection was 
performed using DAB as a substrate. Slides were rinsed in tap water, counterstained 
with haematoxylin and rinsed with tap water again. As a negative control the primary 
antibody was omitted. Positive cells were counted in 10 high power fields (400X) using 
a semi quantitative scoring system as follows: 0: no positive cells, 1: 1-10 cells, 2: 11-30 
cells, 3: 30-60 cells, 4 > 60 cells.
Measurement of apoptotic cells
Formalin-fixed-paraffin sections were stained for apoptotic cells by TUNEL staining 
using the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Millipore, USA) 
according to the manufacturers instructions. Positive cells were counted in 10 fields at 
a magnification of 400x .
Cytokine measurements
TNF-α, IFN-g, IL-6, IL-10, IL-12, and MCP-1 were measured using a commercially 
available cytometic bead array (CBA) (BD Biosciences, San Jose, CA, USA) and a BD 
FACSArrayTM Bioanalyzer (BD Biosciences). Analysis of the data was performed using 
FCAP ArrayTM software (BD Biosciences). Assay sensitivity was 2.5 pg/ml.
Real-time quantitative (RQ)-PCR analysis
Sections of kidney were homogenized and RNA was isolated using the Qiagen 
RNeasy kit (Qiagen, Hilden, Germany). In total 1mg of RNA was reverse transcribed and 
RQ-PCR using an AppliedBiosystems 7700 PCR machine (Foster City, CA, USA) was 
performed as described previously (13). In all 6h samples the mRNA transcript levels 
of TNF-α, IFN-g, IL-6, IL-10, IL-12, MCP-1, and the adhesion molecules E-selectin 
and ICAM-1 were determined. Transcript levels of these genes were quantified by 
normalization against ABL. 
Statistical analysis
Survival data were compared by log-rank analysis. Other data were analysed using 
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ANOVA, followed by a Mann-Whitney – U test. Calculations were performed using 
SPSS v11.0 for Windows. A p value ≤0.05 was considered statistically significant. Data 
are presented as mean values ± standard error of the mean. 
RESULTS
Effect of hCG-related oligopeptide treatment on survival
25 minutes of warm renal ischemia and contra-lateral nephrectomy resulted in a 
survival of 50% in the control group at 3 days post-reperfusion (Table 1). The groups 
treated with oligopeptides MTR, LQGV, VLPALP, AQG, LAG and LAGV (5 mg/kg), 
had survival rates not significantly different from controls. Treatment with LQG led to a 
significant better survival (90%), while treatment with oligopeptides MTRV, VLPALPQ or 
AQGV totally prevented mortality.
Effect of hCG-related oligopeptide treatment on kidney function
Treatment of mice with oligopeptide MTRV, AQGV or LAGV provided significant 
(p<0.05) functional protection against renal I/R injury at both 24 and 72 h, as measured 
by serum urea levels (Figure 2). Although treatment with LQG resulted in significantly 
decreased serum urea at 24 hours post-reperfusion (p<0.05), at 72 hours no significant 
beneficial effect was found. While treatment with VLPALPQ did not cause a significant 
Table 1. Effect of various hCG-related oligopeptides (5 mg/kg) on 
the survival of mice subjected to ischemia-reperfusion 
damage.
Treatment
Survival
p24h 72h
PBS 90% 50%  
MTR 100% 60% ns
MTRV 100% 100% < 0.05
LQG 100% 90% < 0.05
LQGV 100% 80% ns
VLPALP 100% 70% ns
VLPALPQ 100% 100%  < 0.01
AQG 100% 70% ns
AQGV 100% 100% < 0.01
LAG 100% 70% ns
LAGV 90% 90% ns
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decrease in serum urea at 24 hours, at 72 hours it was significantly decreased as 
compared to the control group (p<0.05). Treatment with AQGV provided the most 
powerful protection against renal ischemia-reperfusion injury at both 24 hours (p<0.01) 
and 72 hours (p<0.01).
Effect of different doses of AQGv (0.3 – 30 mg/kg) on survival
Because AQGV showed the most powerful protection against warm renal I/R injury, 
we determined the optimal dose of this oligopeptide in a dose escalating study. Therefore, 
AQGV was administered in doses ranging from 0.3 to 30 mg/kg, and compared to 
mice treated with PBS. A survival rate of 60% was seen in the control group (Table 
2). Although treatment with 0.3, 1 and 30 appeared to result in a survival benefit, no 
significant difference could be measured (80%, 90%, and 80%, respectively). The doses 
of 3 and 10 mg/kg totally prevented mortality (p<0.05).
Figure 2. Renal function as reflected by serum urea levels. 
Pre-operative values and 24 and 72 hours post reperfusion values in the different oligopeptide treated 
groups were compared to PBS-treated controls. Treatment with MTRV and AQGV significantly reduced 
renal function loss both at 24 hours and 72 hours after ischemia reperfusion injury. Treatment with 
LQG reduced serum urea levels at 24 hours. Treatment with VLPALPQ and LAGV showed significantly 
reduced serum urea levels at 72 hours. *p<0.05 and #p<0.01 (n=10 animals / group).
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Effect of different doses of AQGv (0.3 – 30 mg/kg) on kidney function
Treatment of mice subjected to renal I/R damage with 1, 3, 10 and 30 mg/kg AQGV 
resulted in significant reduction of serum urea levels at 72 hours (p<0.05). A dose of 
3 mg/kg resulted in best preservation of kidney function, with return to normal function 
already observed at 72 hrs (p<0.01). With 0.3 mg/kg no significant benefit was observed 
(Figure 3). Creatinine values confirmed these data but in our model did not show the 
same level of responsiveness to the injury as urea.
Effects of AQGV on cellular infiltration, apoptosis and proliferation
To study the mechanism underlying the protective effect of AQGV, we investigated 
the cellular infiltrate and proliferation in the kidneys of mice treated with 5 mg/kg AQGV. 
At both 24 and 72 hr post reperfusion the neutrophil influx was significantly decreased 
in the AQGV-treated group (p=0.03 and p=0.022, respectively) (Figure 4A). Additional 
staining for CD4+, CD8+ cells and macrophages revealed no differences between 
the two groups (data not shown). TUNEL staining identified apototic cells which were 
localized mainly in the tubular epithelium (Figure 4B, middle and lower panels). The 
number of TUNEL-positive cells was significantly lower in AQGV treated animals 
24 hours after reperfusion (Figure 4B). Ki-67 staining showed a significantly higher 
proliferative activity of renal tubular epithelial cells in AQGV-treated mice at 24 hours 
(Figure 4C). At 72 hours this difference had disappeared.
Effects of AQGv on serum cytokine levels and renal mRNA transcript levels
Using the bead-array we determined serum cytokine levels at 6 and 24 hr post-
reperfusion. MCP-1 was below the detection limit in all samples. No differences in serum 
TNF-α, IFN-g, IL-6, IL-10, and IL-12 levels were observed at 6hrs post-reperfusion. At 24 
hrs post-reperfusion the levels for all cytokines were decreased upon AQGV treatment, 
Table 2. Effect of different doses of AQGv on the survival of 
mice subjected to ischemia-reperfusion damage.
Treatment
(mg/kg)
Survival
p24h 72h
PBS 100% 60%  
0.3 100% 80% ns
1.0 100% 90% ns
3.0 100% 100% < 0.05
10 100% 100% < 0.05
30 100% 80% ns
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with IL-6, IL-10, IFN-g (p< 0.05), and TNF-α (p< 0.01) being significantly lower (Figure 
5A). 
AQGV treatment showed no effect on inflammatory cytokine mRNA levels 6 hrs 
post-reperfusion (data not shown). AQGV treatment did result in a significant (p< 0.05) 
down regulation of renal E-selectin, but not ICAM-1 mRNA expression at 6 hr post-
reperfusion as compared to PBS treated mice (Figure 5B). 
Figure 3. Renal function as reflected by serum urea (A) and creatinine (B). 
Values are shown pre-operative, and after 24 and 72 hours in groups treated with AQGV in a dose 
escalation study (0.3 – 30 mg/kg), and compared to a PBS-treated control group. Treatment with AQGV 
in a dose from 1 mg/kg up to 30 mg/kg significantly reduced renal function loss after renal ischemia-
reperfusion injury. The dose of 3 mg/kg was the most potent. *p<0.05 and #p<0.01 (n=10 animals / 
group). 
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Effect of post-reperfusion AQGv treatment on survival
AQGV treatment given either at 12 and 24 hr post-reperfusion or at 6 and 12 hr post-
reperfusion did not improve survival (~50%) as compared to the control group (data not 
shown).
Figure 4. 
A. Renal neutrophil influx as assessed by immunohistochemical staining. AQGV treatment reduced 
neutrophil infiltration after 25 minutes of renal warm ischemia as assessed at 24 and 72 hours post-
reperfusion. Data are expressed in a semi-quantitative way as described in the Material and Methods 
section. *p<0.05 (n=10 animals / group). B. AQGV treatment significantly reduced the number of 
apoptotic cells in the kidney 24 hours after renal ischemia reperfusion injury. *p=0.01 vs PBS treated 
controls at 24 hours (n=6 - 10 animals / group, upper panel). Middle and lower panels: representative 
photomicrographs of TUNEL stained control-, and AQGV treated kidneys respectively, 24 hours after 
reperfusion (200x). C. Proliferation as assessed by Ki-67 immunohistochemistry. AQGV treatment 
significantly enhanced cellular proliferation at 24 hours after renal ischemia-reperfusion injury. Although 
a higher trend of proliferation was seen at 72 hours as well, no statistically significant difference was 
found. Data are expressed in a semi-quantitative way as described in the Material and Methods section. 
*p<0.05 (n=10 animals / group).
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DISCUSSION
We investigated whether treatment with synthetic oligopeptides, consisting of 3 to 7 
amino acids, based on the primary structure of hCG, was able to reduce warm ischemia-
reperfusion injury of the kidney. We demonstrate for the first time that oligopeptides as 
small as three or four amino acids can significantly reduce mortality seen after severe 
renal I/R injury and improves kidney function as measured by serum urea levels. 
Especially AQGV showed superior results in enhancing survival and preservation of 
kidney function after 25 minutes of renal ischemia. A dose of 3-10 mg/kg proved to be 
Figure 5.
A. Treatment with AQGV reduces serum cytokine levels at 24 hours after renal ischemia reperfusion 
injury. *p<0.05, †p<0.01 (n=5 per group). B. Treatment with AQGV reduces renal E-selectin (left panel) 
but not ICAM-1 (right panel) mRNA levels at 6 hours after renal ischemia reperfusion injury. Data are 
presented as mean value ± sem. *p<0.05 (n=6 animals / group).
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the most potent with regard to reducing mortality as well as preserving kidney function. 
Furthermore, up to 30 mg/kg, no toxicity was observed. Also in rats, dogs and a human 
phase I study no harmful side effects of single and repeated AQGV administration were 
found. Data of these studies will be published elsewhere (manuscript in preparation).
Both natural hCG and commercial hCG preparations have been investigated for 
their role on the immune system, because of their putative immunomodulating role 
during pregnancy in protecting the fetus from rejection (14).
Our previous work (6) shows that short-term treatment of female NOD mice, with a 
hCG preparation purified from first trimester pregnancy urine, starting prior to the onset 
of hyperglycemic symptoms, inhibits the development of type I diabetes. Interestingly, 
however, the anti-diabetic activity of the used hCG preparation did not reside in the 
heterodimeric hCG molecule, or its subunits, but in a 400-2000 Dalton fraction.
Subsequently, we showed in a model of LPS-induced systemic inflammatory 
response syndrome in mice that treatment with this low weight molecular fraction was 
capable of inhibiting the septic shock morbidity as well as mortality (7). The same 
beneficial effect was obtained with the synthetic oligopeptide VLPALP, which sequence 
is part of loop 2 of the b-chain of hCG (7). Recently, we showed that hCG-related 
oligopeptides reduce inflammation and liver injury in a rat model of hemorhagic shock 
and resuscitation (15).
During pregnancy, hCG occurs in a variety of forms and breakdown products in 
serum and urine, including intact hCG, α- and b-subunits, nicked hCG, hCG b-core 
fragment, and smaller peptide fragments. Both nicked hCG and the b-core subunit 
consist of a b-chain with a defective loop 2. This loop, consisting of the amino acid 
residues 41-54, is absent in b-core subunit, and is cleaved in nicked hCG (9-12). Since 
the immunomodulatory activity of hCG resided in the low molecular weight fraction, 
we hypothesised that in vivo liberated breakdown products, such as those originating 
from the proteolytic cleavage of peptide bonds between amino acid residues 41-54, 
may have significant biological activity (8). Based on known preferential cleavage 
sites(5,9,10,12), we tested synthetic oligopeptides MTR, MTRV, LQG, LQGV, VLPALP, 
VLPALPQ and, based on alanine replacement mapping, the LQG and LQGV analogs 
AQG, LAG, AQGV and LAGV (Figure 1). Of these oligopeptides, MTRV, LQG, VLPALPQ 
and AQGV appeared able to reduce mortality and decline in kidney function induced 
by warm renal ischemia-reperfusion injury, AQGV being the most effective (Table 1 and 
Figure 1).
Cell migration plays an important role during the initial phase of renal I/R injury. 
Up-regulation of adhesion molecules on endothelial cells, induced by locally produced 
pro-inflammatory mediators, is amongst the first changes observed after renal 
I/R injury and is central to the pathogenesis of ischemic acute kidney injury (1,16). 
Subsequently leukocytes become activated by local pro-inflammatory factors, thereby 
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facilitating adherence to endothelial cells and subsequent renal tissue infiltration (1). 
Sequestered neutrophils induce parenchymal damage, followed by cytokine production 
by resident renal cells and infiltrating cells, which promotes further tissue damage 
(1,17). It has been demonstrated that renal mRNA expression of the early adhesion 
molecule E-selectin peaks within 6 hours post-reperfusion, with neutrophils infiltrating 
in parallel. E-selectin blockage with the selectin specific ligand sPSGL has been shown 
to inhibit renal neutrophil infiltration after I/R and to preserve kidney function (18). In 
mice treated with AQGV we observed decreased E-selectin mRNA levels 6 hrs post-
reperfusion and decreased renal neutrophil infiltration at 24 hours post-reperfusion. 
Apoptotic cell death, an important determinant of cellular damage in ischemic kidneys 
(19) was also significantly reduced in AQGV treated mice. Additionally, serum levels of 
the inflammatory cytokines TNF-α, INF-g, IL-6, and IL-10 were significantly decreased 
24 hours post-reperfusion upon AQGV treatment. This data is indicative of decreased 
renal injury and fits with the preservation of kidney function we observed upon AQGV 
treatment. The lower levels of systemic cytokines observed upon AQGV treatment 
may be a reflection of reduced formation as well as better renal clearance of these 
cytokines (20). The lower serum cytokine levels likely contribute to the decreased 
mortality by preventing systemic inflammation and subsequent complications in these 
animals (21). 
Our data indicate that AQGV treatment protects against renal I/R injury by interfering 
with early E-selectin upregulation, thereby reducing neutrophil influx, parenchymal 
damage and possibly cytokine production. So far it is unclear what the molecular 
mechanism of action is by which AQGV exerts its effects. It is possible that AQGV 
mediates its effect by an as yet unidentified receptor. However, we cannot exclude the 
possibility that, due to the small size and molecular weight, AQGV penetrates the cell 
membrane (22) and exerts its action either by interfering with signaling cascades or the 
transcriptional machinery. E-selectin is expressed de novo on endothelial cells after 
transcriptional induction by pro-inflammatory agents (23). Whether AQGV inhibits the 
local production of pro-inflammatory mediators that induce E-selectin or directly interferes 
with the intracellular signalling cascade involved in activating E-selectin transcription 
is not clear so far. In contrast to E-selectin, ICAM-1 expression was not altered by 
peptide treatment. The transcription factor HMGA1 is required for optimal activation 
of E-selectin gene transcription while it has no role in activating ICAM-1 transcription 
(24,25) Therefore it is possible that AQGV interferes specifically with pathways required 
for E-selectin transcriptional activation.
Although previous work revealed a pathophysiologic role of the T-cell as mediator of 
ischemic ARF (26,27), we did not find a significant difference between the AQGV and 
placebo treated mice in numbers of CD4+, CD8+ T-cells or macrophages. Our data 
fit with the observation that RAG-1 deficient mice (lacking both T- and B-cells) are not 
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protected from renal I/R injury (28). 
Ki-67, a marker for cellular proliferation, is part of a nuclear protein complex 
expressed in the G1, S, G2 and M phases of the cell cycle in proliferating cells (29,30). 
Mice treated with AQGV showed significantly increased numbers of Ki-67 positive 
renal tubular epithelial cells at 24 hr post-reperfusion, reflecting enhancement of the 
regenerative process (31). The increase in proliferation is likely facilitated by a reduction 
in inflammation-induced tissue injury, since high levels of pro-inflammatory cytokines 
have been shown to suppress regeneration of ischemically damaged kidneys (32).
AQGV treatment, at a dose of 5 mg/kg BW, given at either 12 and 24 hr post-reperfusion 
or at 6 and 12 hr post-reperfusion was not associated with improved survival. Although 
we cannot formally exclude that these post-reperfusion treatment regimens improved 
kidney function, it appears that in the currently used model AQGV only prevents the 
onset of renal ischemia reperfusion injury. This may indicate that AQGV inhibits the 
activation of pathophysiological pathways involved in renal ischemia reperfusion injury, 
but is unable to reverse these pathways once activated. However, since we do not 
exclude that higher doses of AQGV given post-reperfusion do reverse renal-ischemia 
reperfusion injury, detailed dose-response studies are warranted to gain full insight into 
the renoprotective effect of AQGV, and other hCG-related oligopeptides. 
In conclusion, this study shows that treatment of mice with 5 mg/kg of either one 
of the hCG-related oligopeptides MTRV, LQG, VLPALPQ or AQGV shortly before 
and immediately after renal pedicle clamping can significantly reduce mortality and 
ameliorate kidney injury in a model of warm ischemia reperfusion injury. Of the various 
oligopeptides evaluated, AQGV appeared to be the most potent one. The renoprotective 
effect of AQGV was associated with decreased renal E-selectin transcripts, decreased 
renal neutrophil infiltration, reduced numbers of apoptotic tubular epithelial cells and 
a reduction of systemic levels of TNF-α, IFN-γ, IL-6 and IL-10. This data implies that 
AQGV interferes with the early renal inflammatory response induced by I/R and as 
such prevents parenchymal damage and organ dysfunction. These new renoprotective 
oligopeptides show great promise for preventing the development of renal ischemia-
reperfusion injury and may well be used in clinical situations where renal I/R is forseeable, 
such as semi-elective surgeries including kidney transplantation, cardiac surgery, and 
abdominal aorta surgery. So far, phase IA and phase 1B studies with AQGV (EA-230) 
have been successfully completed and phase II studies are underway (33,34).
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ABSTRACT
Human chorionic gonadotropin (hCG) preparations have been recognized to inhibit 
the growth of Kaposi’s sarcoma in vitro and in vivo, an activity demonstrated to reside 
in an as yet unidentified hCG-associated factor (HAF) (1-3).
We found previously that synthetic oligopeptides related to the loop-2 sequence 
MTRVLQGVLPALPQ of the hCG-b chain exerted biological activity in several different 
experimental models (4-7). Here we show that one of these oligopeptides, LQGV, inhibits 
the growth of Lewis Lung Carcimoma (LLC) in an in vivo transplantable LLC model 
in mice. Targeting of tumor vasculature by low-molecular-weight vascular-disrupting 
agents is considered a novel potential therapy to treat cancer (8). Our data imply that 
LQGV may exert its anti-tumor activity at least partly by specific disruption of the tumor 
vessel integrity, which is different from the anti-tumor activity as previously described 
for HAF (1-3). Our data suggest that the hCG-b chain related oligopeptide LQGV is a 
promising small molecule to treat cancer, either alone or in combination with cytotoxic 
drugs.
Human chorionic gonadotropin (hCG) is a dimeric glycoprotein hormone, which is 
especially produced during human pregnancy by the placental syncytiotrophoblasts (9). 
Besides endocrine functions, recombinant hCG and urinary hCG preparations exert 
other actions such as immunosuppression (10-13). While complete hCG may facilitate 
tumor progression (14) it has also been shown that b-hCG prevents the onset of breast 
cancer (15). Furthermore, several reports demonstrated anti-Kaposi’s sarcoma activity 
of hCG preparations in vivo and in vitro (1,3,16). This anti-tumor activity was not due 
to the heterodimeric hCG nor its α- or b-subunit, but was ascribed to a yet unidentified 
Table 1. Tumor size and response rates 21 days after tumor transplantation.
Response Rate
Treatment Avg volume 
day 21
Responses
(CR plus PR)
CR PR NC PD
PBS 1600 mm3 0/6 0 0 0 6
LQGV (5 mg/kgBW) 270 mm3 3/6 2 1 2 1
AQGV (5 mg/kgBW) 1030 mm3 2/6 0 2 1 3
LAGV (5 mg/kgBW) 1600 mm3 2/6 1 1 1 3
PD = progressive disease (increase of tumor volume > 25% within 7 days); NC = No change (tumor volume remains 
equal) (-25% to +25%) to initial volume); PR = partial remission (tumor volume decreased 25-90%); CR = complete 
remission (tumor volume less than 10% of initial volume).
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Figure 1.
Effect of β-hCG related synthetic tetrapeptides on tumor growth.
A. Anti-tumor activity screening for the tetrapeptides LQGV, AQGV and LAGV. After tumor transplantation, 
mice (n=6 per group) were i.p. injected every other weekday with either the tetrapeptide LQGV, AQGV or 
LAGV at a dose of 5mg/kg BW. Control animals received PBS as control. Tumor volume was measured 
and mean values are shown. Error bars indicate standard deviation. LQGV, which is related to the 
primary sequence of loop-2 of b-hCG, reduced tumor growth while its alanine replacement variants 
AQGV or LAGV only revealed marginal or no effect on tumor growth, respectively. B-F. Dose escalation 
study with LQGV showing all individual mice per experimental group. After tumor transplantation, mice 
(n=11 per group) were i.p. injected every other weekday with the tetrapeptide LQGV at a concentration 
of either 1.7 (C), 5 (D), 17 (E) or 50 (F) mg/kg BW. Control mice (B) received PBS. At day 22 post-tumor 
transplantation LQGV treatment at a dose of 17 mg/kg BW was associated with a significantly (p< 0.002) 
reduced tumor volume as compared to control. 
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hCG-associated factor of peptide nature (1,2,16). 
We found that hCG preparations inhibited diabetes in NOD mice as well as LPS-
induced inflammation(6,17). Comparably also these activities were not inflicted by 
the heterodimeric hCG nor its α- or b-subunit, but resided in a 400-2000 Dalton fraction 
of peptide nature, which likely originates from proteolytic degradation of the hCG 
b-subunit (4,6,17). Subsequently we demonstrated that synthetic oligopeptides related 
to the primary sequence of b-hCG loop-2 inhibited inflammation and tissue damage 
following shock induced by LPS or hemorrhage/resuscitation (5,6) . 
Considering the suggestion that the anti Kaposi’s sarcoma activity was due to an 
hCG-associated factor of peptide nature, and our observation that synthetic oligopeptides 
related to the primary structure of b-hCG exert powerful biological activity, we tested 
the synthetic oligopeptide LQGV, which is related to the primary structure of loop 2 of 
b-hCG, as well as its alanine replacement variants AQGV and LAGV, for tumor growth 
inhibiting activity.
First the ability was tested of the oligopeptides LQGV, AQGV, and LAGV to inhibit 
growth of the transplantable Lewis Lung Carcinoma (LLC) in mice. Treatment with 
LQGV (5 mg/kg BW) induced a delay in tumor growth with an average tumor volume 
of 270 mm3 after 21 days (Figure 1A). The alanine replacement variants appeared less 
effective; AQGV did delay tumor growth but to a lesser extent than LQGV, while LAGV 
had no effect (Figure 1A). All mice receiving PBS control demonstrated progressive 
tumor growth, which reached on average a tumor volume of 1600 mm3 in 21 days 
(Figure 1A). Although at a dose of 5 mg/kg the LQGV treated mice did not show a 
significant tumor growth reduction compared to the controls, the tumor response rate of 
mice treated with LQGV was significantly lower as compared to control mice (p< 0.015) 
with two mice showing complete tumor remission and one mouse showing partial 
remission (Table 1). These results indicate that administration of the tetrapeptide LQGV 
resulted in tumor growth delay and tumor control for at least three weeks.
Table 2. Response rates 26 days after tumor transplantation.
Treatment PD TR RR
PBS 8 3 27 %
1.7 mg/kg 9 2 18 %
5 mg/kg 4 7 64 %
17 mg/kg 3 8 73 %
50 mg/kg 4 7 64 %
170 mg/kg 4 7 64 %
PD = Progressive Disease; TR = Tumor Response; RR = Response Rate
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To establish the optimum dose for LQGV to inhibit tumor growth, a dose escalation 
study was performed up to day 26. This revealed that the maximum tumor response 
was established by LQGV administration of 17 mg/kg BW (Table 2 and Figure 1B-F). At 
this dose significant tumor growth reduction was observed compared to the control mice 
at 22 days (p< 0.002). Above 50 mg/kg BW no further improvement of tumor response 
was observed (data not shown).
We examined the tumor vascularization of the three progressively growing tumors 
despite LQGV treatment (17 mg/kg BW) and compared them with those of the control 
Figure 2. 
Effect of the β-hCG related synthetic tetrapeptide LQGV on tumor associated vasculature.
A. Immunohistochemical staining for CD31 was performed to visualize tumor vasculature. Semi-
quantitative analysis of CD31 staining revealed no differences in the level of tumor vascularization 
between LQGV (17 mg/kg BW) or control mice. B. Representative CD31 staining (magnification 16x) 
of tumor tissue from a control mouse. C. Representative CD31 staining (magnification 16x) of tumor 
tissue from an LQGV treated mouse. D. Hematoxylin eosin staining (magnification 2.5x) of viable rim of 
tumor tissue from a control mouse. E. Hematoxylin eosin staining (magnification 2.5x) of viable rim of 
tumor tissue from an LQGV (17mg/kg BW) treated mouse. Black arrows indicate dilated vessels, white 
arrow indicates necrotic area. Hemorrhages are indicated by arrowheads. F. Hematoxylin eosin staining 
(magnification 16x) of viable rim of tumor tissue from an LQGV (17mg/kg BW) treated mouse, arrows 
indicate dilated and destructed vessels. The boxed area is magnified (100x) in G, showing a dilated 
vessel with destroyed endothelial lining indicated by arrows. 
Inhibition of murine tumor growth by LQGV
181
mice. Immunohistochemical analysis using the endothelial marker CD31 (PECAM-1) 
revealed no difference in the level of vascularization between tumor tissue from control 
mice and tumors from the LQGV treatment group (17 mg/kg BW) (Figure 2-C). Closer 
examination of the CD31 staining did however reveal larger and more irregularly lined 
vessels after LQGV treatment (Figure 2C). This was supported by hematoxylin-eosin 
staining of tumor tissues from LQGV treated mice, revealing vessel and endothelial 
abnormalities, such as dilated vessels as well as disrupted endothelial lining (Figure 
2D-G). In addition, LQGV treatment was associated with necrotic areas and hemorrhages 
as reflected by extravasation of erythrocytes into the viable rim of the tumor (Figure 2E), 
which is likely the result of the observed loss of endothelial integrity. 
The development of tumor associated vasculature (TAV) is essential for the growth 
of solid tumors, as studies using anti-angiogenic agents clearly demonstrated that 
inhibition of vascular growth reduces tumor development (18,19). Folkman therefore 
suggested inhibition of angiogenesis as a promising approach in cancer therapy 20. In 
line with this, destruction of already established TAV by vascular-disrupting agents has 
also been shown to improve tumor outcome (8,21). 
Our data suggest that LQGV interferes with TAV integrity and possibly development, 
which may explain its tumor growth inhibiting effect in this model. Whether LQGV exerts 
a direct effect on TAV or whether its action is due to secondary mediators is unclear so 
far. We have observed that LQGV significantly increases basel as well as VEGF-induced 
numbers of vessels branches in the chicken chorioallantoic membrane (CAM) assay. 
Therefore, it is possible that interference of LQGV with TAV integrity in combination with 
an increase in vascularity contribute to the anti-tumor effect. Indeed, recently Noguera-
Troise et al. have shown that increase of Notch activity results in decreased tumor 
vascular density, whereas blockade of this activity results in markedly increased vessel 
density (22). Paradoxically, this increased vascularity seemed to be non-productive and 
resulted in decreased tumor growth, even for tumors that are resistant to anti-VEGF 
therapy (21). Importantly, no toxic side effects and vessel abnormalities in other organs 
were observed upon LQGV treatment. In addition, the LQGV treatment was without 
effect on liver and kidney parameters, leukocyte and platelet count and had no effect on 
animal weight and behavior (data not shown).
Upon LQGV treatment (17 mg/kg BW) outgrowth of only 3 out of 11 transplanted 
tumors occurred, suggesting that LQGV especially interferes with early tumor 
development. Inflammation is an important component of tumorigenesis, for instance 
pro-inflammatory cytokines within the microenvironment of an early neoplastic 
process drive tumor growth by enhancement of tumor cell proliferation, survival and 
angiogenesis (23-25). For instance, TNF-α-/- mice have been shown to develop 
skin tumors less frequently upon exposure to 12-O-tetradecanoylphorbol-13-acetate 
(TPA) (26) while endogenous TNF-α enhances the malignant character of LLC 
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in mice (26). Previously, we found that LQGV reduced systemic and local levels of 
pro-inflammatory cytokines such as TNF-α and IL-6 and expression of adhesion 
molecules such as ICAM-1 and E-selectin after hemorrhagic shock resuscitation, 
suggestive of anti-inflammatory activity (5). Besides being an endothelial cell-specific 
glycoprotein that mediates rolling and arrest of leukocytes to endothelium during 
inflammation, E-selectin is also suggested to play a role in angiogenesis (27-29). 
Possibly, LQGV treatment reduced tumor associated cytokine expression and E-selectin 
expression on endothelial cells of the developing TAV, thereby reducing (out)growth of 
the transplanted LLC fragments. 
Previously, an hCG-associated factor of peptide nature was identified and shown 
to exhibit anti-Kaposi’s sarcoma activity due to induction of apoptosis and inhibition of 
cell growth (1,2). These authors stated (1,30) that certain b-hCG peptides (of which 
no sequences were revealed but which may be released in vivo during pregnancy) 
inhibited growth of Kaposi’s sarcoma cell lines both in vivo and in vitro. During pregnancy, 
besides intact hCG, nicked hCG and hCG b-core fragments occur in serum and urine. 
Both nicked hCG and hCG b-core contain a b chain with a defective loop 2, or with 
b-core completely lacking this loop (residues 41-54; MTRVLQGVLPALPQ) (4). Here 
we demonstrate that the synthetic tetrapeptide LQGV, a sequence present within hCG 
b-loop 2, inhibits the growth of LLC in mice. Although the mechanism of action requires 
further elucidation it appears that the anti-tumor effect of LQGV is at least partly due 
to TAV disruption. TAV disruption results in increased permeability and shutdown of 
these vessels leading to secondary tumor-cell death (8). Although LQGV on its own 
had a profound effect on tumor growth, it may be that combination therapy of LQGV 
with cytotoxic agents may be beneficial for augmented accumulation of the latter at the 
tumor site. 
From an immunological point of view it is attractive to interfere with pathological 
conditions, such as tumor growth, with small molecules of only four amino acids as 
these are not expected to elicit an immune response, which typically requires peptides 
of at least 8 amino acids in length (31). 
METHODS SUMMARY
LLC tissue cubes (~2 x 2 x 2 mm) were subcutaneously transplanted in C57BL/6 
mice (age 8 wks; Harlan; Horst, The Netherlands). The oligopeptides (Ansynth BV, 
Roosendaal, The Netherlands) LQGV, related to the primary sequence of the hCG-b 
loop 2, and the alanine replacement variants AQGV and LAGV were tested for their 
ability to interfere with LLC tumor growth. Every other weekday the mice were injected 
i.p. with one of the oligopeptides (5 mg/kg BW) or PBS as negative control. Every 
Inhibition of murine tumor growth by LQGV
183
weekday, tumor diameter (including skin) was measured in 2 dimensions and tumor 
volume was calculated. Tumor volume changes were classified as: progressive disease 
(PD: volume increase >25% within 7 days), no change (NC: volume equals (-25% to 
+25%) the initial volume), partial remission (PR: volume decrease 25% – 90%), and 
complete remission (CR: volume <10% of initial volume). Mice were removed preliminary 
if a tumor diameter was > 20 mm, in case of ulcerations or drastic weight loss. Mice 
were checked daily for treatment related side effects.
A dose escalation study was performed with LQGV. To determine treatment toxicity, 
blood levels of ALAT, ASAT, BUN and CREAT, white blood cell count and platelet count 
were measured 7 days before, and 8 and 19 days after tumor transplantation. Upon 
experiment termination, tumor, liver, lung, spleen and kidney were removed. Formalin 
fixed tissue sections were stained with hematoxylin-eosin. Frozen tumor samples were 
sectioned and every fifth section, up to six sections per tumor, was stained for CD31 
(BD Biosciences Pharmingen, San Diego, U.S.A.) to visualize vasculature. CD31 
expression was quantified using nine digital recordings (magnification of 16x) from 
every section and analyzed with Image Tool (http://ddsdx.uthscsa.edu/dig/itdesc.html). 
Averages and SEM were calculated from all slides per group. Statistics, Mann-Whitney 
U Test, was performed using SPSS v11.0 for Windows 2000. The experimental protocol 
was approved by the local Animal Experiments Committee.
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We designed a number of oligopeptides based on the primary structure of loop-2 of 
b-hCG, notably MTR, MTRV, LQG, LQGV, VLPALP and VLPALPQ. In the experimental 
studies of this thesis we evaluated the putative regulatory influence of these oligopeptides 
on several physiological and pathophysiological processes. In some of these studies 
these oligopeptides were compared to commercial hCG or a low molecular weight (400-
2000D) fraction thereof (NMPF). To this end we employed animal disease models that all 
share the involvement of inflammatory processes: diabetes, septic shock, haemorrhagic 
shock, ischemia reperfusion-related kidney failure, and a particular mouse model of 
transplantable lung cancer.
hCG-related oligopeptides and inflammation
In female NOD mice the individual oligopeptides inhibited the development of Th1 
mediated diabetes only partially, whereas a commercial hCG-preparation and NMPF 
completely inhibited the development of this type of diabetes (chapter 4). In this model 
the treatment with the oligopeptides LQGV and VLPALP was associated with a reduction 
of NF-kB activity in splenic dendritic cells. 
As these oligopeptides could not prevent or inhibit the disease in all experimental 
animals, we suggest that multiple inflammatory pathways are involved in diabetes 
development in this model. In contrast to this chronic Th1 mediated autoimmune disease 
model, both LQGV and VLPALP, as well NMPF, did inhibit LPS induced acute shock in 
all female BALB/c mice involved in the experiments (chapters 5 and 6). This inhibition 
of LPS induced shock was associated with lower MIF production by spleen cells, a less 
increased plasma level of liver aminotransferase, an increased percentage of NK1.1 
positive T-cells, reduced LPS-induced MHC-II expression on B-cells and macrophages, 
and a reduced proliferative response of splenic cells in vitro. 
The observation that NMPF, in contrast to LQGV and VLPALP, did inhibit the 
development of diabetes in all NOD mice tested, makes sense because in vivo multiple 
oligopeptides, with different characteristics, might be liberated from the b-hCG-loop-2 
(chapter 2) and thus might dampen various pathophysiological processes involved 
in the b-cell destruction leading to diabetes. Therefore, in future experiments various 
oligopeptide mixtures should be evaluated for their therapeutic value in chronic Th1 
mediated diabetes models. 
 In order to determine the critical amino acids required for the in vivo activity of 
LQGV, the most effective oligopeptide in most studies, various alanine replacement 
variants were synthesized: AQGV, LAGV, LQAV and LQGA. All these four alanine 
replacement variants were tested in the acute LPS-induced shock model in mice. 
A single treatment with AQGV oligopeptide appeared the most effective in inhibiting 
the mortality. AQGV oligopeptide was at least equally effective as LQGV in this model. 
This was found independent of whether the peptide was administered in an early or in 
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a late stage of LPS-induced shock development. LAGV, LQAV and LQGA were less 
effective in the LPS-induced shock model (data not shown).
The evaluation of the anti-shock activity of the oligopeptides applied in mice was 
extended to Escherichia coli induced hyperinflammation and septic shock in a non-
human primate model, namely in fully anaesthetized rhesus monkeys (chapter 6). 
Control female rhesus monkeys did not survive the first 8 hours of E.coli intravenously 
(i.v.) induced septic shock, while rhesus monkeys treated with a mixture of three 
oligopeptides each effective in mice (LQGV, VLPALP, AQGV), survived the septic shock 
during 8 hours after E.coli administration. In this study a single injection of this mixture 
of oligopeptides markedly improved the pathological features and nearly completely 
improved the hemodynamic parameters associated with the E. coli-induced septic shock 
without any supportive therapy. However, in this model the mixture of oligopeptides did 
not significantly decrease the proinflammatory serum levels of TNF-α, IL-1b and IL-6. 
This might be due to the individual variability among the animals, the limited stability of 
the measured cytokines, the variability in clearance rates by the liver, and differences 
in the induction of innate immune responses by whole bacteria (E.coli) as compared to 
LPS.
A Phase 1A multi-dose safety trial with AQGV (EA-230) in man has been completed 
since then (1,2; Appendix I) and no significant adverse events were found to be 
associated with the use of EA-230. Also a Phase 1B trial - designed as a double-blind, 
randomized, single dose, placebo-controlled LPS challenge trial with EA-230 in human 
volunteers - has been completed (1,3; Appendix I). Pharmacokinetic analysis of the 
study subjects showed not just a reduction of blood C-reactive protein (CRP) levels, 
but also reduction of several pro-inflammatory cytokines (IL-6, IL-8 and TNF-α) as 
compared to the placebo group. The treatment also significantly reduced the rise of 
body temperature and clinical complaints, and the drop in white blood cell counts that 
are typically induced by LPS. This clearly shows that EA-230 reduces the systemic 
inflammatory response elicited by endotoxin in humans. According to the website of 
Exponential Biotherapies Inc., currently a Phase 2 study is in progress to test the safety 
and efficacy of EA-230 in reducing kidney damage in patients undergoing on-pomp 
cardiovascular surgery (4).
Human sepsis is an intrinsically complex disease. Populations of patients 
are heterogeneous with respect to the inciting cause of their disease, the 
co-morbid conditions that define its course, and the acute severity of their initial 
presentation (5-7). Septic patients undergo various stages of disease and different 
subgroups have different characteristics (5-7). Moreover, in each stage of the disease 
there is a potential imbalance between inflammation versus anti-inflammation, 
coagulation versus anti-coagulation, oxidant versus anti-oxidant levels and apoptotic 
versus anti-apoptotic processes (5-7). Therefore, although it is recognized that 
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inflammatory cytokines play a major role in the pathogenesis of sepsis, anti-inflammatory 
therapy alone generally does not lead to therapeutic success (7). 
In some cases, where harmful effects of leukocytes outweigh their efficiency in 
killing microorganisms, inhibiting strategies may be beneficial. This seems to be the 
case in e.g. bacterial meningitis where rapid sequestration of neutrophils in the brain 
can cause irreversible tissue injury and death (8). However, inhibiting leukocyte function 
does not seem to be beneficial in cases where control of local or systemic infection is 
crucial for reducing mortality (9). Increasing neutrophil numbers and function during 
sepsis, especially in severely immunocompromised patients, is associated with an 
overall favorable outcome (9). The results of our Listeria monocytogenes study have 
shown that inhibition of early immune activation by LQGV, AQGV and VLPALP leads 
to bacterial overgrowth with subsequent enhanced systemic inflammation (chapter 7). 
The present possibilities and insights into oligopeptide treatment of septic shock are far 
from sufficient yet. Therefore, further studies are needed.
We also tested the hCG-related oligopeptides in a severe hemorrhagic shock 
(HS) model in male rats (chapter 8). HS followed by resuscitation induces a massive 
inflammatory response, which culminates in a systemic inflammatory response 
syndrome (SIRS), multiple organ dysfunction syndrome and, finally, death. A single 
treatment with oligopeptide LQGV significantly reduced the inflammatory parameters 
associated with HS, including the systemic release of TNF-α and IL-6. The other 
oligopeptides tested, AQGV and LAGV, were equally effective in reducing most of 
the parameters investigated. Furthermore, LQGV significantly reduced the TNF-α, 
IL-6, ICAM-1 and E-selectin mRNA transcript levels in the liver. LQGV treatment also 
prevented neutrophil infiltration into the liver and was associated with reduced liver 
damage. Thus, the reduction of the systemic inflammatory parameters in this model 
was associated with a reduced inflammatory response in the liver.
Together these studies show that several b-hCG-loop-2 related oligopeptides, 
including the alanine-replacement variant AQGV, can inhibit acute systemic inflammatory 
responses. To determine whether b-hCG-loop-2 related oligopeptides have the capacity 
to also influence the local acute inflammatory response in an organ, we tested several 
b-hCG-loop-2 related oligopeptides in an ischemia-reperfusion induced acute renal 
failure model in male mice (chapter 9). MTRV, LQG, VLPALPQ and AQGV significantly 
reduced the mortality in this model as compared to placebo treated mice. AQGV even 
completely prevented mortality and largely preserved the kidney function. AQGV also 
significantly lowered the influx of neutrophils, decreased neutrophil apoptosis in this 
model and increased tubular epithelial cell proliferation. In addition, AQGV decreased 
the serum levels of TNF-α, INF-g, IL-6 and IL-10, and decreased the E-selectin mRNA 
levels in kidneys. 
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Together these studies show that the designed oligopeptides can inhibit the following 
inflammation related parameters: proinflammatory cytokines (TNF-α, IL-6, MIF), MHC-
II expression on B-cells and macrophages, E-selectin expression, neutrophil infiltration, 
proliferation and organ damage. The oligopeptides tested can also stimulate regeneration 
in acute systemic as well as in local inflammation models. In these models the nature 
of the inflammatory responses were either different or were partially overlapping. 
Individual hCG-related oligopeptides might each inhibit a particular spectrum of 
inflammatory responses. The value of the inhibition of that particular spectrum for the 
effective treatment of inflammatory pathophysiology may vary between different models. 
By extrapolation it can be expected that similar differences may be found if such peptides 
would be applied in patients suffering from different inflammatory disorders. 
The common part of the immune system that is affected by at least some of the anti-
inflammatory oligopeptides is the innate immune system. This appears from our study 
on the effect of LQGV, VLPALP and AQGV on Listeria monocytogenes infection in mice 
(chapter 7). These oligopeptides were found to inhibit the very early innate immune 
activation required for the clearance of bacteria. This explains why treatment with these 
oligopeptides promoted the overgrowth of bacteria in this model. This is consistent 
with the observations that especially pregnant women, newborn babies and patients 
with a compromised innate immune system are susceptible to Listeria monocytogenes 
infection (10-12).
hCG has been extensively studied for its function in regulating placental angiogenesis 
and endothelial integrity (13,14). It has critical functions in trophoblast differentiation and in 
fetal nutrition through myometrial spiral artery angiogenesis (14). Our initial experiments 
with LQGV in the chicken chorioallantoic membrane (CAM) assay showed significantly 
increased basel vessel branching as well as VEGF-induced vessel branching (chapter 3). 
In addition, we have shown that LQGV inhibits the growth of Lewis Lung Carcinoma 
(LLC) in an in vivo transplantable LLC model in mice. In this model LQGV exerted its 
antitumor activity at least partly by stimulating the tumor vascularity in combination with 
disrupting the tumor associated vascular (TAV) integrity (chapter 10). 
TAV integrity has emerged as a critical step promoting local tumor progression and 
metastatic spreading (15,16). Solid tumors show typical signs of inflammation and 
are infiltrated by many leukocyte populations, i.e. neutrophils, eosinophils, basophils, 
monocytes/macrophages, dentritic cells, natural killer (NK) cells and lymphocytes (17-19). 
This suggests an important role of inflammation in promoting or suppressing tumor 
growth. LQGV reduces systemic and local levels of proinflammatory cytokines such 
as TNF-α and IL-6 and expression of adhesion molecules such ICAM-1 and E-selectin 
(chapter 8 and 9). It may be that LQGV treatment also reduced tumor associated 
cytokine expression and adhesion molecules expression on endothelial cells of the 
developing tumor associated vascularity and thereby reduced tumor (out)growth. 
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Recently, it has been shown that blockade of Notch activity results in markedly 
increased vessel density with non-productive vascularity which in turn induces hypoxia 
and thereby inhibits tumor growth (20,21). It may well be that this also holds for LQGV 
inhibition of LLC growth. We recently started studies to determine the effect of b-hCG-
loop-2 oligopeptides on Notch activity. Although LQGV on its own in the LLC mouse 
model already had a profound effect on tumor growth, it may be that combination 
therapy of LQGV and cytotoxic agents has a synergistic therapeutic effect.
Figure 1. Treatment of mice with a single subcutaneous (s.c.) injection of AQGv (EA-230; 0.625 
mg/mouse) 3 days after increasing doses of whole body irradiation (WBI) ranging from 7.4 till 
11 Gy. 
Treatment with AQGV led to a dose sparing of 1.25, i.e. AQGV-treated mice could accommodate 1.25 
times more irradiation to show the same LD50. The test is called the Dose Reduction Factor (DRF) test, 
which is defined as the ratio between the LD50 of the treated group to the LD50 of the control group. 
An acceptable DRF value is 1.20. This means that to pass the test, at day 30 after WBI a candidate drug 
must have the LD50 at a radiation dose that is at least 20% higher (an increase by a factor of 1.20) than 
the LD50 dose for the control animals. If e.g. the LD50 for the control animals is 8.2 Gy than the LD50 
for a candidate drug should be at least 20% higher, which in this case would mean a dose of 10.4 Gy. 
AQGV passed this test and showed a DRF of 1.25. Data from Appendix II.
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AQGv and regeneration
Our experiments from 2001 had already revealed that LQGV has the ability to reduce 
gamma irradiation (TBI) induced morbidity in mice (22). In subsequent studies the 
30-day survival (LD50) was determined for groups of mice that received increasing 
doses of TBI up to 11 Gy and were treated with AQGV (0.625 mg/mouse s.c.) or placebo 
(23; Appendix II). The groups of mice that received AQGV at day 3 after TBI showed a 
dose sparing of 1.25, i.e, they could accommodate 1.25 times more irradiation for LD50 
(Figure 1). 
TBI-induced death of mice is typically caused by infection and/or massive 
hemorrhage predominantly occurring between day 10 and 20. If mice are free of specific 
pathogens, sepsis is not an issue and thrombocytopenia is the dominant determinant 
of the irradiated animal’s fate. Therefore, we have applied 5 Gy TBI to groups of 
mice, and administered either 25 mg/kg (0.625 mg/mouse) of AQGV or the diluent i.p 
3 days post-TBI*. At day 13, at a moment that irradiated mice are faced with a nadir in 
their systemic blood leukocyte and platelet counts, we killed the mice and determined 
(a) spleen cellularity; (b) the femoral bone marrow cellularity; (c) the femoral bone 
marrow content of a variety of hemopoietic progenitors (CFU-G, CFU-M, CFU-GM, 
CFU-Meg, BFUe, and a series of CFU-Mix type colony forming cells).
Mice treated with AQGV at 3 days post-TBI showed considerable regeneration of 
hemopoietic progenitors and the less primitive stem cell subsets in the femoral marrow. 
Also in the spleen an increased hemopoietic activity was found (Ploemacher, Khan, 
Dik et al., unpublished observations). These stem cell compartments were significantly 
expanded as compared to the other 5 Gy irradiated groups.
From previous work of Ploemacher c.s. we know that repopulation of the stem cell 
pool following irradiation starts relatively late and takes months to arrive at levels that 
do not exceed 70-80 percent of the pre-irradiation levels (24-26). In the first days post-
TBI there is extensive repair and apoptosis and necrosis in all damaged cell systems, 
including the stem cell compartment (26,27). Directly following 5 Gy of gamma irradiation 
up to day 4, the stem cell compartment is reduced down to 0.2 - 1.5 per cent of the 
control size (28-34). It is only in the remaining 10 days after administration that AQGV 
could have delivered the therapeutic effect on the mice. It is therefore remarkable that 
AQGV was able to fully restore levels of neutrophils and platelets within this period.
Other agents used to treat irradiation damage, e.g. thiols and bacterial cell wall 
products, can be applied between 3 days before to about 30 minutes after irradiation in 
order to obtain a radioprotective effect on cell survival (35). Our data, however, shows 
that AQGV does not inhibit irradiation-induced apoptosis or necrosis, but stimulates the 
regeneration of functional end cells from stem cells that survived the TBI. Thus, in our 
model AQGV is not a radioprotective agent (also because it was not present at the time 
of irradiation), but a regeneration stimulating agent. This regenerative signal seems 
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to stimulate all irradiation surviving stem cell compartments, progenitors (CFU-C) and 
maturing cells, up to the level of the functional end cells. This makes AQGV a unique 
compound in radiation biology.
The regeneration-stimulating effect is not limited to the bone-marrow compartment. 
Our experiments from 1998 had already revealed that NMPF, a low molecular weight 
hCG fraction which presumably contains b-hCG-loop-2 derived oligopeptides, has 
the ability to regenerate severely damaged insulin producing islets in the pancreas of 
diabetic female NOD mice (chapter 4) and to enhance the repair of the in vivo cellular 
damage due to UVB radiation in female BALB/c mice (36). In ischemia-reperfusion 
experiments in male C57BL/6 mice, AQGV treatment led to significantly increased 
numbers of Ki-67-positive renal tubular epithelial cells, reflecting enhancement of the 
regenerative process in acute renal failure (chapter 9). Furthermore, LPS-induced 
shock experiments in female BALB/c mice showed that several of the oligopeptides 
used can rescue mice from death even when treatment was performed at the time (e.g. 
24 hr after LPS-injection) when multiple organ damage had already occurred and the 
mice were in the state of shock (chapter 6).
The potential clinical application of AQGV for stimulating regeneration may 
not be limited to the post-irradiation situation following nuclear incidents or terrorist 
acts, but may be extended to the treatment of hematopoietic insufficiency, especially 
thrombocytopenia, and to clinical stem cell transplantation where conditioning may 
involve either chemotherapy or radiotherapy, or both.
 
Putative mechanisms underlying the anti-inflammatory, proliferation-modulating 
and regeneration-stimulating activities of hCG-related oligopeptides
Notch signaling is involved in the regulation of cell-fate decisions by modulating 
cellular differentiation, proliferation and survival in a wide range of organs and tissues 
from insects to humans (37). The mammalian Notch receptor family comprises four 
members: Notch1, Notch2, Notch3 and Notch4 (38,39). The Notch ligand family consists 
of 5 members: Jagged1, Jagged2, Dll1, Dll3 and Dll4 (39). Notch expressed on the cell 
surface as a heterodimer is the mature, ligand-accessible form of the receptor (39). 
In the absence of ligand binding, heterodimeric Notch receptors are inactive. 
When Notch ligand binds to the Notch receptor on an adjacent cell, a series of proteolytic 
cleavages occurs, resulting in the release of the Notch intracellular domain (NotchIC) that 
subsequently translocates into the nucleus (39,40). In the absence of nuclear NotchIC, 
the transcription factor C protein binding factor 1 (CBF1) binds to the DNA sequence 5’-
(C/T)GTGGGAA-3’ within Notch target gene promoters and represses transcription (38). 
When Notch signaling is activated, nuclear NotchIC binds to CBF1 and, following 
recruitment of the nuclear protein Mastermind-like (MAML), resulting in the formation 
of a ternary complex that functions as a transcriptional activator (39,41). MAML 
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recruits the histone acetyltransferase protein p300, resulting in histone acetylation and 
conversion of the local chromatin structure to a form amenable to active transcription. 
This results in the transcription of various Notch target genes including those belonging 
to the HES (Hairy/Enhancer of Split) and HEY (Hairy/Enhancer of split related with 
YRPW motif) families (42). Both the HES and HEY families function as transcriptional 
repressors (42). 
Notch receptors and ligands are expressed in embryonic vasculature and are required 
for its remodeling (43). hCG has been shown to act on stromal fibroblasts during the 
window of uterine receptivity to inhibit apoptosis and to enhance differentiation through 
the activation of Notch1 (44). Under these conditions activation of Notch1 provides 
a temporary survival signal and inhibits apoptosis by upregulating anti-apoptotic 
genes (45,46). This suggests that hCG and Notch1 coordinately regulate decidualization 
by preventing apoptosis of endometrial stromal fibroblasts, averting uterine sloughing, 
and promoting cell survival and differentiation into the decidualized phenotype, which is 
critical for the maintenance of pregnancy (46). 
Notch and TLR pathways have also been shown to cooperate to activate canonical 
Notch target genes, including the transcriptional repressors HES and HEY, and to 
increase the production of canonical TLR-induced cytokines TNF, IL-6 and IL-12 (47). 
Cooperation by these pathways to increase target gene expression is mediated by the 
Notch-pathway component and transcription factor RBP-J (recombination signal binding 
protein for immunoglobulin kappa J region), which also contributes to lethality after 
endotoxin injection (47). TLR- and Notch-induced Hes1 and Hey1 attenuate IL-6 and IL-
12 production (47). This HES- and HEY-mediated feedback inhibitory loop is abrogated 
by interferon-γ (IFN-γ), which blocks TLR-induced activation of canonical Notch target 
genes by inhibiting Notch2 signaling and downstream transcription (47). Importantly, 
Notch ligand transcripts are also upregulated by endogenous NF-kB activiation through 
TLR (48). This demonstrates that NF-kB can trigger the Notch signaling pathway 
in neighboring cells by inducing the production of its ligands. This highlights the 
interplay between the Notch and NF-kB signaling pathways in the immune system. 
Together Notch, TLR, NF-kB and IFN-γ can modulate specific effector functions in 
macrophages, implicating a role of Notch signaling in innate immunity.
The dosage of Notch signaling determines its type of effect (49). In a leukemic 
T-cell line, low or high concentrations of Notch1IC promote or inhibit NF-kB 
transactivation, respectively. Ex vivo culture of cord blood progenitor cells with a 
low concentration of immobilized Dll1 promotes the survival of CD34+ cells, while a 
high concentration of Dll1-induced Notch activation inhibits the generation/survival of 
CD34+ cells (50). Similarly, the level of Notch signaling within the thymic micro 
environment can determine the differentiation fate of hematopoietic precursor cells (51). 
Interestingly, microenvironmental factors may also influence the level of Notch 
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signaling. For example, hypoxia increases Notch1 protein expression in neuroblastoma 
cells (52) and estrogen induces Notch1 and Jagged1 mRNA expression in MCF7 
breast cancer cells (53). Moreover, the relative expression of Notch signal modulators 
such as Fringe (Frng) and Deltex (Dx) influence the intensity and ligand dependence 
of the Notch signal (54,55). Notch signaling can also influence cell growth and 
differentiation without an influence on cell fate decisions. There are several examples 
in Drosophila and Caenorhabditis elegans wherein activation of the Notch signaling 
pathway can induce cell-cycle arrest, promote cellular proliferation, or even promote 
apoptosis (56-58).
 Alternatively, activation of Notch signaling can protect cells from apoptosis (59,60). 
Interestingly, Drosophila is acutely tolerant to low O2 environment and withstands 3-4 
h of total O2 deprivation without showing any evidence of cell injury (61,62). Recently, 
it has been shown that Notch pathway genes play an important role in this hypoxia 
resistance and the same genes can also be beneficial in mammalian cell resistance to 
hypoxia (63). Thus, the pleiotropic effects that Notch signaling can exert on progenitor 
cells is determined in part by the strength and duration of the Notch signal delivered, as 
well as by the development context of the cell. These findings highlight the importance 
of precise Notch signal regulation for proper cellular development.
Most hematopoietic cytokines promote either the survival or the differentiation or 
both of hematopoietic stem cells ex vivo (64). Wnt, Notch and Hedgdhog signaling 
pathways have been implicated in self-renewal and proliferation in vivo (65). In irradiated 
adult zebrafish, Notch activity has been shown to increase the number of multilineage 
hematopoietic precursor cells followed by the accelerated recovery of all mature blood 
cell lineages (66). Notch signaling is crucial to the development of a fetus and has been 
also implicated in the development of cytokine producing NK cells, regulatory T cells, 
lymphocytes development, vasculogenesis and angiogenesis and hematopoiesis (66-71). 
This all defines the Notch pathway as critical for controlling homeostasis, cell fate and 
signal integration in development.
Based on the present data we predict that hCG-related peptides such as LQGV 
and AQGV have direct or indirect effects on Notch and particular other evolutionary 
old developmental pathways. If this turns out to be true, then LQGV, AQGV and 
comparable oligopeptides will support regeneration processes in clinical situations not 
limited to irradiation damage and innate immunity related cellular damage, but also in 
wound healing, revascularization, repair of central nervous system and peripheral nerve 
damage, ventilator induced lung injury, etc. 
hCG-related oligopeptides and pregnancy
Pregnancy is suggested to represent a controlled state of inflammation with a 
prominent role for the innate immune system (72). There are two distinct immunological 
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interfaces in pregnancy: locally in the decidua between maternal immune cells and 
fetal trophoblasts; and systemically between circulating maternal immune cells and the 
syncytiotrophoblasts that form the placental villous surface. This syncytiotrophoblast 
layer releases proinflammatory cytokines such as TNF-α, IL-1b and IL-6 and the 
pregnancy hormone hCG (73). TNF-α and IL-1b receptors are involved in the hCG 
release from trophoblasts by stimulating IL-6 release, while hCG in turn stimulates the 
production of IL-6 (74). 
hCG produced by trophoblasts enters into the maternal blood and interacts with 
maternal immune cells. At an early stage the inflammatory condition is predominant 
at the implantation site. Later in pregnancy this is extended to the maternal 
circulation (74). There is now strong evidence that in normal pregnancy, compared with 
the non-pregnant state, not only Th2 cytokine levels are raised, but also the levels of 
particular Th1 cytokines. This is in contrast to the previously reported decreased Th1 
levels due to a decreased Th1/Th2 ratio (75). This systemic inflammatory response in 
normal pregnancy is characterized by leukocytosis, increased NK cell numbers in the 
decidua, increased monocyte priming, increased phagocytic activity, and the production 
of pro-inflammatory cytokines, including IL-6, IL-1b, TNF-α and MIF (76). It has been 
suggested that these inflammatory changes can be as strong as those observed in patients 
with sepsis, but surprisingly do not seem to harm the mother and fetus in any way (75). 
This all supports the notion that the dominant immune interaction during pregnancy 
involves the innate rather than the adaptive immune system (72,75). This is consistent 
with our previous results in mouse models that hCG stimulates innate immunity (77,78). 
Since the inflammatory changes during pregnancy are under tight control, this suggests 
that pregnancy-specific factors, including the hCG-level (Figure 2), help to control this 
inflammatory response. Uncontrolled inflammatory responses are dangerous not only 
for the fetus, but also for the mother, such as during preeclampsia (75,76). 
On the basis of our results we propose that particular oligopeptides from b-hCG-
loop-2 are among such factors that have opposite effects to hCG, e.g. inhibiting the 
innate immunity and preventing overstimulation of innate immunity by factors such 
as hCG. Based on the observation that these oligopeptides affected various basic 
physiological processes, including immune responses, hematopoiesis, angiogenesis, 
proliferation and regeneration in different models, we predict that these peptides on 
the molecular level affect well conserved signaling pathways and molecular targets. 
As discussed above, the Notch signaling pathway is a likely candidate target, and subject 
of our further studies. This all implies that hCG itself contains regions with oligopeptide 
sequences that control the biological function of itself. This may explain why hCG is 
extensively degraded in vivo, especially after the first 3 months of pregnancy. 
This breakdown is likely related to the extent of hyperglycosylation of the hCG- 
molecule. It is striking that the extent of hyperglycosylation of hCG decreases from week 
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3 after the last menstruation period onwards, and that at week 10 of gestation hCG is 
hardly hyperglycosylated anymore (Figure 2). This kinetics of loss of hyperglycosylation 
of hCG increasingly facilitates the proteolytic breakdown of hCG during pregnancy.
We conclude that breakdown products of hCG as small as three or four amino acid 
residues not only play a central role in hCG-physiology and pregnancy success, but 
likely also constitute an active component in the regulation of inflammatory circuits 
and homeostasis. This is supported by the observation that hCG also occurs in non-
pregnant individuals (79,80).
A B
C
serum
serum
urine
Figure 2. The kinetics of glycosylated and non-glycosylated hCG in serum and of β-core in urine 
during pregnancy.
A. hCG concentrations in serum during pregnancy. The high baseline hCG concentration (1) with 
markedly shortened doubling time suggests multiple pregnancy or a trophoblastic tumour. The low 
baseline hCG concentration suggests the presence of an unviable or ectopic pregnancy or threatened 
miscarriage. B. Hyper-glycosylated hCG in serum during pregnancy. C. β-core hCG in urine during the 
pregnancy. Modified from Cole et al., 2009 (13,120) and Tran, 2006 (121).
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Oligopeptides derived from other proteins than hCG; future prospects
The data presented in chapter 2 in combination with our experimental studies 
show that proteases are not just non-specific degradative molecules but, at least in 
the case of hCG, can liberate small oligopeptides with a most relevant physiological 
activity. In this context, it is interesting that several parasites (such as Trypanosoma 
brucei brucei) and bacteria (such as Bacillus anthracis) bear similar sequences in 
particular proteins (81,82). It might be that, after penetration of the epithelium, these 
microorganisms release such peptide sequences into their surroundings to suppress 
the local inflammatory reaction of the host, in order to make their life comfortable. 
The identified hCG-related regulating small oligopeptides may cross cellular 
membranes without requiring membrane-bound receptors (83). Sequences of 
oligopeptides up to 5 amino acids overlap for 100% between human, bacterial and 
viral proteins (84). Therefore they are not recognized by the immune system and 
immunological side effects are highly unlikely. Numerous small peptides exist in 
endocrine and neurocrine systems that are cleaved out from larger polypeptide 
precursors, i.e. gonadotropin-releasing hormone (GnRH), oxytocin, antidiuretic hormone 
(ADH), b-endorphin, vasoactive intestinal peptide (VIP), pro-opiomelanocortin (POMC; 
a precursor for adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone 
(MSH), b-endorphin, lipotropins), thyrotropin-releasing hormone (TRH), substance P 
(SP), neurokinin A (NKA), neuropeptide Y (NPY), insulin growth factors (IGFs) and 
somatostatin. It may be that hCG-related oligopeptides have overlapping functional 
homology with other endogenous small peptides and at physiological or supra-
physiological doses affect various endocrine and neurocrine axes and their feedback 
systems.
Gene expression analyses and other studies taught us that these oligopeptides 
have a distinct regulating effect on the expression of a variety of genes involved in 
inflammatory pathways and immunity (81). In view of the central role of inflammatory 
pathways in a variety of pysiological and pathophysiological processes (85-88), this 
may explain the broad therapeutic activity of the identified hCG-related regulating 
oligopeptides in the disease models tested. 
We are convinced that the case of regulation of gene expression by hCG-related 
small oligopeptides is not unique in biology (89). Where it was generally thought that 
the smallest breakdown products of proteins have no specific biological function on 
their own, our results show that the body may utilize the normal process of proteolytic 
breakdown to generate physiologically important compounds. So far ~500 human genes 
encoding proteases/peptidases have been identified (90). This stresses the importance 
of regulation of biological processes by proteases/peptidases. 
Many peptide components have been identified in tissues/organs and body 
fluids from different species (91-98) as well as in blood cells and their culture 
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supernatants (99-103). Several of these peptides are hemoglobin derived, are between 
2-35 amino acids in length (103), and exhibit a wide variety of biological activities 
(e.g. analgesic, cytolytic, proliferative/antiproliferative, ACE inhibition, enhancement of 
antibody production, neuronal or hormonal) (104-118). 
Many natural oligopeptides can be found by computer analysis of fragments of 
bovine hemoglobin molecules (111). In this analysis 125489 hits were found. Of them 
128 dipeptide fragments also occur among natural non-hemoglobin fragments (111). 
Hemoglobin fragments sharing natural non-hemoglobin oligopeptides consist of 2 to 
14 amino acid residues. Oligopeptides containing the same hemoglobin fragment can 
have different functions and demonstrate a wide spectrum of biological activities (111). 
A characteristic feature of the natural non-hemoglobin oligopeptides sharing sequences 
with hemoglobin is the fact that the majority of them were neuropeptides and hormones 
(111). It has also been shown that tetrapeptides of non-hemoglobin origin are included 
in all these natural hemoglobin oligopeptides (111,112). This demonstrates that 
hemoglobin most likely acts not only as a carrier for oxygen transport, but also as a 
source of peptide fragments with regulatory functions which differ from those of the 
parent molecule. Small peptides derived from other proteins suggest the same (94-
96). 
This data demonstrates that naturally occurring proteolytic breakdown products, even 
down to the length of 2-6 amino acids and derived from proteins with known functions, 
exert powerful biological activity. Therefore these peptides are likely to play a role in 
regulating biological processes. This notion is strengthened by profound differences 
in peptide content between different organs of the same animal (104,106), while the 
peptide content of specific organs appears to be conserved between individuals and 
amongst species (93,105). This implies the existence of tissue and organ specific peptide 
contents, suggestive of conserved effector functions of specific peptides amongst 
individuals and species. Thus the concept emerges that tissue and organ specific 
proteins are degraded by peptidases, resulting in a large group of (small) peptides that 
represent the tissue or organ specific peptide pool or peptidome (105). This peptide 
pool might represent the final class of bioregulators resulting from the sequel genome, 
transcriptome, proteome, peptidome (105,106,108). In line with this, changes in peptide 
pools have been observed under pathological conditions (91,96,98,102,117,118). 
Whether such changes are causal to or the consequence of disease is so far unknown. 
Nevertheless, we cannot exclude that peptide pool changes influence the biological 
functioning of cells, tissues, organs and finally organisms.
We have generated antiproliferative oligopeptides based on the primary structure 
of several other human proteins than hCG and found them to inhibit the cell cycle 
gene pCDG and the auxin responsive markergene DR5::GUS involved in proliferation 
in a plant model (119; Appendix 2), suggesting that small oligopeptides are part of a 
Chapter 11
200
conserved regulatory system in biology. We predict that further research on the dissection 
of proteins will unlock (i) a wealth of small regulatory oligopeptides; (ii) that normally 
occurring regulatory peptides play a crucial role in physiological and pathophysiological 
processes; and (iii) that this represents a novel level of regulation that will find its way 
into biological and biomedical research in the coming years. Needless to say, should 
this be true, we foresee many new potential pharmaceutical molecules, which may 
correct pathological conditions and restore homeostasis.
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SUMMARY
Pregnancy is a unique physiological event. The unborn child is in immunological 
terms foreign to the mother, since it has half of its genetic material from its father. From 
the immunological point of view there are commonalities between the unborn child 
and a foreign transplant. While without enough immunosuppressive therapy a foreign 
transplant is rejected, the unborn child undisturbingly develops within its mother’s womb. 
Interestingly, many women who suffer from autoimmune disease (like rheumatoid 
arthritis, multiple sclerosis and Crohn’s disease) are less affected by their disease during 
pregnancy. It seems that the natural suppression of their immune responses against the 
unborn child has a side effect which suppresses their autoimmune disease as well. 
However, there is no generalized immunosuppression of the maternal immune system 
during pregnancy since, generally, pregnant women are not more prone to infections 
than non-pregnant women. Apparently, the immune system enables the immunological 
acceptance of unborn.
We hypothesized that human chorionic gonadotropin (hCG) hormone (‘pregnancy 
hormone’) might account for the immunosuppression during pregnancy. hCG is one of 
the first hormones that are produced in pregnancy. We tested the effect of a commercially 
available hCG preparation on the development of autoimmune mediated type 1 diabetes 
in non-obese diabetic (NOD) mice. In this mouse model the diabetes is (predominantly) 
caused by Th1 cell-mediated destruction of insulin-producing b-cells in the islets of 
Langerhans of the pancreas. We showed that treatment of NOD mice with a commercial 
hCG preparation or a low molecular weight fraction thereof (NMPF) before the onset 
of clinical symptoms decreased or even prevented the increased blood glucose levels. 
Also the established inflammatory infiltrate in and around the islets of Langerhans was 
eliminated, and the development of diabetes was inhibited for prolonged time.
hCG consists of an α and a b chain, and occurs in a variety of forms in serum and 
urine of pregnant women, but only intact hCG stimulates the hCG receptor. Besides 
heterodimeric hCG, b-core fragment and nicked hCG are two other major forms of hCG 
that are found in pregnancy serum and urine samples. The nicked hCG and b-core 
fragment have peptide bond cleavages in between residues 44-54 of loop 2 of b-hCG 
and completely miss loop 2 (residues 41-54), respectively. 
Several investigators have studied the biological effects of heterodimeric hCG and 
its variants on gonadal tissues and/or their role in immune modulation. So far, however, 
the possible biological activity of fragments liberated from the breakdown of hCG into 
the different variants was ignored. We postulated that the loop 2 region, consisting of 
residues 41-54 with amino acid sequence MTRVLQGVLPALPQ, which is absent in 
b-core, can also be nicked in vivo and can liberate smaller fragments (3-7 amino acids 
long oligopeptides) with biological activity.
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We have tested the biological activities of the designed oligopeptides in various 
animal models for acute inflammation such as inflammation induced abortion, shock 
induced by septic (E.coli) or aseptic (LPS; hemorrhage and resuscitation) inflammation, 
renal failure by ischemia-reperfusion injury and Listeria infection, and we have evaluated 
the effect of several of the peptides in a tumor transplantation model in mice. In these 
animal models various oligopeptides designed from loop-2 of b-hCG had therapeutic 
effects (MTR, MTRV, LQGV, VLPALP, VLPALPQ). These therapeutic effects were 
confirmed in a nonhuman primate model for septic shock (combination treatment of 
LQGV, VLPALP and AQGV, an alanine-analogue of LQGV). We selected AQGV as 
the lead compound for clinical development. In collaboration with EBI Anti Sepsis we 
performed and successfully completed a phase 1 study with AQGV for various clinical 
indications including SIRS/Sepsis, renal failure and radiation sickness. Subsequently 
we confirmed the therapeutic effect of AQGV in human volunteers challenged with LPS. 
EBI Anti Sepsis BV has announced a Phase 2 study to test the safety and efficacy 
of AQGV in reducing kidney damage in patients undergoing on-pomp cardiovascular 
surgery. Our studies suggest that the oligopeptides from loop-2 of b-hCG may have 
an important function in the regulation of inflammation and in the proliferation and 
differentiation of cells. Various cell signaling pathways, including Notch, Wnt, Hedgdhog 
and NF-kB pathways, are candidates for further mechanistic studies.
Our experiments on Lewis Lung Carcinoma (LLC) in mice showed that LQGV can 
inhibit the growth of this tumor in a transplantation model. This anti-tumor activity was 
likely due to stimulation of the tumor vascularity in combination with disrupting the tumor 
associated vascular (TAV) integrity. Furthermore, AQGV has the ability to reduce gamma 
irradiation induced morbidity and mortality. In these experiments AQGV had profound 
effects on blood, spleen and femoral bone marrow cellularity, and on the regeneration 
of hemopoietic stem cells.
The cellular parameters affected by the designed oligopeptides were proinflammatory 
cytokines (TNF-α, IL-6, MIF), MHC-II expression on B-cells and macrophages, E-selectin 
expression, neutrophil infiltration in inflammatory sites, proliferation, regeneration and 
organ damage repair. In the employed models the affected inflammatory parameters 
varied. Apparently, individual oligopeptides may inhibit a particular spectrum of 
inflammatory responses. The common pathway of immunity that is affected by the 
designed hCG-related oligopeptides is the innate immune system. This especially 
appeared from the studies on the effect of LQGV, VLPALP and AQGV on Listeria 
monocytogenes infection in mice. 
Our work supports the concept that tissue and organ specific proteins are degraded 
by peptidases, resulting in a large group of (small) peptides that represent the tissue or 
organ specific peptide pool or peptidome. This peptide pool may represent an important 
class of bioregulators resulting from the sequel genome, transcriptome, proteome, 
peptidome. 
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We also designed a series of antiproliferative oligopeptides based on the primary 
structure of several other human proteins than hCG (i.e. C-reactive protein, b-catenin, 
p53) and tested these in a plant model. Many of the designed peptides appeared 
capable to inhibit the pCDG and DR5::GUS genes involved in cellular proliferation in 
this model system. The fact that these peptides, that are part of human proteins, can 
inhibit the proliferation of plant cells suggests that these oligopeptides are part of a 
conserved regulatory system in biology. 
We hypothesize that many endogenous (and possibly exogenous) proteins are 
broken down in vivo yielding small peptides with regulatory properties. In our view 
these normally occurring regulatory peptides play a crucial role in the fine-tuning of 
physiological processes and in pathophysiological processes. This likely represents a 
novel level of regulation that will find its way into biological and biomedical research in 
the coming years. Should this be true, this will allow the development of many potential 
pharmaceutical molecules.
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Zwangerschap is een unieke fysiologische gebeurtenis. Het ongeboren kind 
is, immunologisch gezien, vreemd aan de moeder omdat het de helft van de 
erfelijke eigenschappen van de vader heeft. Uit immunologisch gezichtspunt zijn er 
overeenkomsten tussen het ongeboren kind en een lichaamsvreemd transplantaat. 
Zonder voldoende immunosuppressieve therapie wordt een vreemd transplantaat 
afgestoten, maar het ongeboren kind ontwikkelt zich ongestoord in de baarmoeder. 
Interessant is, dat veel vrouwen die lijden aan een autoimmuunziekte (bijvoorbeeld 
reumatoïde arthritis, multipele sclerose, en de ziekte van Crohn), daar tijdens hun 
zwangerschap minder last van hebben. Het lijkt erop dat de natuurlijke suppressie 
van hun immuunreactie tegen het ongeboren kind als neveneffect heeft dat ook hun 
autoimmuunziekte wordt onderdrukt. Er is echter geen algemene immunosuppressie 
van het afweersysteem van een zwangere, want zwangere vrouwen krijgen in het 
algemeen niet vaker een infectieziekte dan niet-zwangere vrouwen. Klaarblijkelijk wordt 
tijdens de zwangerschap het afweersysteem zo gereguleerd dat het ongeboren kind 
immunologisch wordt geaccepteerd.
Wij zijn in het onderzoek voor dit proefschrift uitgegaan van de hypothese dat 
het humaan chorion gonadotropine (hCG) hormoon (‘zwangerschapshormoon’) 
verantwoordelijk is voor de immunosuppressie tijdens de zwangerschap. hCG is een 
van de eerste hormonen die worden geproduceerd bij zwangerschap. Wij hebben het 
effect getest van een commercieel beschikbaar hCG preparaat op de ontwikkeling van 
autoimmuun gemedieerde type 1 diabetes in non-obese diabetische (NOD) muizen. 
In dit muizenmodel wordt de diabetes veroorzaakt door (vooral) Th1 cel gemedieerde 
destructie van insulineproducerende β-cellen in de eilandjes van Langerhans in de 
pancreas. Wij hebben aangetoond dat door behandeling van NOD muizen met een 
commercieel hCG preparaat, of een fractie daarvan met een laag molecuulgewicht 
(NMPF) vóór het begin van de klinische symptomen, de toename in bloedglucosespiegel 
verminderd of zelfs voorkomen werd. Ook werd het ontstekingsinfiltraat in en rond de 
eilandjes van Langerhans tenietgedaan en werd de ontwikkeling van diabetes voor 
langere tijd geremd.
hCG bestaat uit een α en een β keten, en komt in een variëteit van vormen voor 
in serum en urine van zwangere vrouwen, maar alleen intact hCG stimuleert de hCG 
receptor. Naast heterodimeer hCG zijn β-core fragment en ‘nicked’ hCG twee andere 
belangrijke vormen van hCG die voorkomen in serum en urine van zwangeren. Het 
‘nicked’ hCG en β-core fragment hebben breuken in de peptideketen tussen de 
aminozuurresiduen 44-54 van ‘loop 2’ van β-hCG, respectievelijk missen volledig ‘loop 
2’ (residuen 41-54). 
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Verschillende onderzoekers hebben de biologische effecten van heterodimeer hCG 
en zijn varianten bestudeerd op de geslachtsorganen en hun rol in immuunmodulatie. 
Tot dusver werd echter de mogelijke biologische activiteit van de bij de afbraak van 
hCG vrijgekomen fragmenten genegeerd. Centraal in dit proefschrift staat onze 
veronderstelling dat het ‘loop 2’ gebied, bestaande uit de residuen 41-54, met de 
aminozuurvolgorde MTRVLQGVLPALPQ, dat afwezig is in β-core, in vivo door bepaalde 
enzymen geknipt kan worden, waardoor kleinere fragmenten (oligopeptiden van 3-7 
aminozuren) met biologische activiteit vrijkomen.
Wij hebben de biologische activiteit van zulke synthetisch geproduceerde 
oligopeptiden getest in verschillende diermodellen voor acute ontsteking, zoals 
abortus geïnduceerd door ontsteking, shock geïnduceerd door septische (E.coli) 
of aseptische (LPS; bloeding en reperfusie) ontsteking, nierfalen door schade 
bij ischemie-reperfusie en Listeria infectie, en wij hebben de invloed van enkele 
peptiden getest op de groei van een bepaalde tumor in een muizenmodel. In deze 
diermodellen hadden verschillende oligopeptiden die gemaakt waren van ‘loop-2’ van 
β-hCG (o.a. MTR, MTRV, LQGV, VLPALP, VLPALPQ) een therapeutisch effect. Deze 
therapeutische effecten werden bevestigd in een apenmodel voor septische shock 
(combinatiebehandeling met LQGV, VLPALP en AQGV; de laatste is een alanine-
analoog van LQGV). Wij hebben AQGV geselecteerd als belangrijkste verbinding 
voor verdere klinische ontwikkeling. In samenwerking met de firma EBI Anti Sepsis BV 
hebben wij een Fase 1 studie met vrijwilligers, die AQGV kregen toegediend, succesvol 
afgerond. Vervolgens hebben wij in vrijwilligers het therapeutische effect van AQGV na 
toediening van LPS kunnen bevestigen. Deze studies zijn van belang in verband met 
de mogelijke klinische toepassing van AQGV voor de behandeling van SIRS/Sepsis, 
nierfalen en stralingsziekte. EBI Anti Sepsis BV heeft een Fase 2 studie aangekondigd 
om de veiligheid en effectiviteit van AQGV te testen om nierschade te reduceren bij 
patiënten die een cardiovasculaire operatie ondergaan. Onze studies suggereren dat 
de oligopeptiden van ‘loop-2’ van β-hCG een belangrijke functie kunnen hebben bij de 
regulatie van ontsteking, en bij proliferatie en differentiatie van cellen. Wat dit betreft 
zijn verschillende cel signaleringsroutes, inclusief Notch, Wnt, Hedgdhog en NF-kB, 
kandidaten voor mechanistische studies.
Onze experimenten met Lewis Long Carcinoom (LLC) in muizen toonden aan dat 
LQGV de groei van deze tumor in een transplantatiemodel kan remmen. Deze anti-tumor 
activiteit werd vermoedelijk veroorzaakt door stimulatie van de bloedvatontwikkeling in 
de tumor in combinatie met verstoring van de tumorgeassocieerde vasculaire (TAV) 
integriteit. Voorts kan AQGV de morbiditeit en mortaliteit reduceren die geïnduceerd 
wordt door radioactieve straling. In deze experimenten bleek AQGV het herstel van de 
bloed-, milt- en beenmergcellulariteit, en de regeneratie van hemopoetische stamcellen 
te bevorderen. 
Samenvatting
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De cellulaire parameters, die beïnvloed werden door de door ons ontworpen 
oligopeptiden, waren de productie van ontstekingsbevorderende cytokinen (TNF-α, IL-6, 
MIF), MHC-II expressie op B-cellen en macrofagen, E-selectine expressie, infiltratie 
van neutrofiele granulocyten bij ontstekingen, proliferatie, regeneratie en herstel van 
orgaanschade. In de geteste modellen bleken de betreffende ontstekingsparameters, 
die werden beïnvloed door de verschillende oligopeptiden, deels te verschillen. 
Blijkbaar kan elk van de door ons ontworpen oligopeptiden een bepaald spectrum van 
ontstekingsreacties onderdrukken. De gemeenschappelijke route, die wordt beïnvloed 
door deze hCG-gerelateerde oligopeptiden in de door ons gebruikte diermodellen voor 
ontsteking, is het aangeboren (‘innate’) immuunsysteem. Dit bleek vooral uit de studies 
naar het effect van LQGV, VLPALP en AQGV bij Listeria monocytogenes infectie bij 
muizen.
Ons onderzoek sluit aan bij het concept dat weefsel- en orgaanspecifieke eiwitten 
in vivo worden afgebroken door peptidasen, resulterend in een grote groep (kleine) 
peptiden die een weefsel- of orgaanspecifieke verzameling van peptiden (peptidoom) 
vormen. Deze groep peptiden zou een belangrijke klasse van bioregulatoren kunnen 
vertegenwoordigen als onderdeel van de sequentie genoom – transcriptoom – proteoom 
– peptidoom.
Wij hebben tevens een serie antiproliferatieve oligopeptiden ontworpen, gebaseerd 
op de primaire structuur van verschillende andere humane eiwitten dan hCG (namelijk 
C-reactive protein, β-catenin, p53), en hebben deze getest in een plantenmodel. Veel 
van de ontworpen peptiden bleken in staat om de pCDG en DR5::GUS genen voor 
proliferatie in dit modelsysteem te remmen. Het feit dat deze peptiden, die onderdeel zijn 
van menselijke eiwitten, de proliferatie van plantencellen kunnen remmen, suggereert 
dat deze peptiden deel zijn van een geconserveerd regulatiesysteem in de natuur.
Wij veronderstellen dat veel endogene (en wellicht ook exogene) eiwitten in vivo 
worden afgebroken tot kleine peptiden met regulerende eigenschappen. In onze 
visie spelen deze normaal voorkomende regulatoire peptiden een cruciale rol in de 
fijnregulatie van fysiologische processen en in pathofysiologische processen. Zij 
vertegenwoordigen vermoedelijk een nieuw regulatiesysteem dat van belang zal blijken 
in toekomstig biologisch en biomedisch onderzoek. Als dit waar blijkt te zijn, zal dit de 
ontwikkeling van een groot aantal potentiële geneesmiddelen mogelijk maken.
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ABBREvIATIONS
α alpha
AC adenylate cyclase
ACTH adrenocorticotropic hormone
AHA hemolytic anemia
ALT alanine aminotransferase
APC antigen presenting cells
Arg Arginine
Asn asparagine
AST aspartate aminotransferase
ATD autoimmune thyroid disease
ATP autoimmune thrombocytopenia
b beta
BUN blood urea nitrogen
CAM chorioallantoic membrane
cAMP cyclic adenosine monophostphate
CREAT creatinine
CREBP cAMP response element protein
CRH corticotropin releasing hormone
CTP C-terminal peptide
Cys cysteine
E.coli Escherichia coli
EGF epidermal growth factor
ERK extracellular signal-regulated kinase
FSH follicle-stimulating hormone
GH growth hormone
GM-CSF granulocyte macrophage cdolony stimulating factor
GnRH gonadotropin releasing hormone
GRH gonadotropin-releasing hormone
GTT glucose tolerance test
hCG human chorionic gonadotropin
His histidine
HKLM heat-killed Listeria monocytogenes
HLA human leukocyte antigens
hPL human placental lactogen
HPLC high performance liquid chromatography
ICAM intracellular adhesion molecule
ICU intensive care units
Abbreviations
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IL interleukin
INF-g interferon-gamma
L. monocytogenes Listeria monocytogenes
LH luteinizing hormone
LIF leukemia inhibitory factor
LLC lewis lung carcinoma
LLO listeriolysin O
LPS lipopolysaccharide
LQG leucine-glutamine-glycine
LQGV leucine-glutamine-glycine-valine
LRR leucine-rich repeat
Lys Lysine
MCP monocyte chemoattractant protein
MHC major histocompatibility complex
MIF macrophage migration inhibitory factor
MODS multiple organ dysfunction syndrome
mRNA messenger ribonucleic acid
MTR methionine-threonine-arginine
MTRV methionine-threonine-arginine-valine
NCR N-terminal cysteine-rich
NKT natural killer T cell
NMPF natural (immuno)modulatory pregnancy factor
NOD non-obese diabetic
PGE2 prostaglandin E2
Phe Phenylalanine
pI isoelectric point
PKA protein kinase A
PKC protein kinase C
RA rheumatoid arthritis
RER rough endoplasmatic reticulum
SCID severe combined immunodeficiency
Ser Serine
SIRS systemic inflammatory response syndrome
SLE systemic lupus erythematosus
Th T helper
Thr Threonine
TLR Toll-like receptor
TM Transmembrane
TNF-α tumor necrosis factor-alpha
Abbreviations
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Try Tryptophan
TSH thyroid-stimulating hormone
uNK uterine natural killer cell
VLPALP valine-leucine-proline-alanine-leucine-proline
VLPALPQ valine-leucine-proline-alanine-leucine-prolineglutamine
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